CA2628040A1 - Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof - Google Patents
Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof Download PDFInfo
- Publication number
- CA2628040A1 CA2628040A1 CA002628040A CA2628040A CA2628040A1 CA 2628040 A1 CA2628040 A1 CA 2628040A1 CA 002628040 A CA002628040 A CA 002628040A CA 2628040 A CA2628040 A CA 2628040A CA 2628040 A1 CA2628040 A1 CA 2628040A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- yloxy
- naphthalen
- hydroxy
- octenediamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives Chemical class 0.000 title claims abstract description 83
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 26
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 26
- 230000002401 inhibitory effect Effects 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title description 49
- 238000000034 method Methods 0.000 claims abstract description 223
- 150000001875 compounds Chemical class 0.000 claims description 423
- 150000001412 amines Chemical class 0.000 claims description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 8
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical group [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 230000010933 acylation Effects 0.000 claims description 7
- 238000005917 acylation reaction Methods 0.000 claims description 7
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- HDUMAEHTJLXNPY-DJKKODMXSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-(thiophen-2-ylmethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCC1=CC=CS1 HDUMAEHTJLXNPY-DJKKODMXSA-N 0.000 claims description 6
- XMFQQXGTUUFSCH-DHRITJCHSA-N (e)-n-(1-benzylpyrrolidin-3-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(C1)CCN1CC1=CC=CC=C1 XMFQQXGTUUFSCH-DHRITJCHSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 5
- LERXQMLCFARRIC-UFFVCSGVSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-(1-propan-2-ylpyrrolidin-3-yl)oct-2-enediamide Chemical compound C1N(C(C)C)CCC1NC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 LERXQMLCFARRIC-UFFVCSGVSA-N 0.000 claims description 5
- QYDMVJAUGRVBAV-SSDVNMTOSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-(2-piperidin-1-ylethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCCN1CCCCC1 QYDMVJAUGRVBAV-SSDVNMTOSA-N 0.000 claims description 5
- JFVDRPFRDGMNPX-UFFVCSGVSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-[3-(2-oxopyrrolidin-1-yl)propyl]oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCCCN1CCCC1=O JFVDRPFRDGMNPX-UFFVCSGVSA-N 0.000 claims description 5
- KYNZFXFAZXHSCE-VXLYETTFSA-N (e)-n'-hydroxy-n-(1-methoxypropan-2-yl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NC(C)COC)=C\CCCCC(=O)NO)=CC=CC2=C1 KYNZFXFAZXHSCE-VXLYETTFSA-N 0.000 claims description 5
- MJKWUXCIQUYXRT-GIJQJNRQSA-N (e)-n'-hydroxy-n-(2-methoxyethyl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCOC)=C\CCCCC(=O)NO)=CC=CC2=C1 MJKWUXCIQUYXRT-GIJQJNRQSA-N 0.000 claims description 5
- HOXGFNNYDIAJHI-ODCIPOBUSA-N (e)-n'-hydroxy-n-(2-morpholin-4-ylethyl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCCN1CCOCC1 HOXGFNNYDIAJHI-ODCIPOBUSA-N 0.000 claims description 5
- OMGXVMLJZNVWEK-DJKKODMXSA-N (e)-n'-hydroxy-n-(6-methoxypyridin-3-yl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=NC(OC)=CC=C1NC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 OMGXVMLJZNVWEK-DJKKODMXSA-N 0.000 claims description 5
- AHJMBYSCBHQGEN-LSFURLLWSA-N (e)-n'-hydroxy-n-[(4-methoxyphenyl)methyl]-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC(OC)=CC=C1CNC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 AHJMBYSCBHQGEN-LSFURLLWSA-N 0.000 claims description 5
- QCQOWAULLDMUBM-BHGWPJFGSA-N (e)-n-(1-cyclohexylpyrrolidin-3-yl)-n'-hydroxy-2-(naphthalen-2-yloxymethyl)oct-2-enediamide Chemical compound C=1C=C2C=CC=CC2=CC=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(C1)CCN1C1CCCCC1 QCQOWAULLDMUBM-BHGWPJFGSA-N 0.000 claims description 5
- DWUWNRYOCMZDCK-AUEPDCJTSA-N (e)-n-(1-cyclopentylpiperidin-4-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(CC1)CCN1C1CCCC1 DWUWNRYOCMZDCK-AUEPDCJTSA-N 0.000 claims description 5
- ZRMXVNQHSVWJKB-ODCIPOBUSA-N (e)-n-(1-cyclopropylpiperidin-4-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(CC1)CCN1C1CC1 ZRMXVNQHSVWJKB-ODCIPOBUSA-N 0.000 claims description 5
- PLCUEFKAXZAWRU-DNTJNYDQSA-N (e)-n-(1-cyclopropylpyrrolidin-3-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(C1)CCN1C1CC1 PLCUEFKAXZAWRU-DNTJNYDQSA-N 0.000 claims description 5
- FBMBRHBJRRMJMS-UFFVCSGVSA-N (e)-n-(1-ethylpiperidin-4-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1CN(CC)CCC1NC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 FBMBRHBJRRMJMS-UFFVCSGVSA-N 0.000 claims description 5
- JKQFTMSGBHBHQZ-UFFVCSGVSA-N (e)-n-(4-ethoxy-4-hydroxycyclohexa-1,5-dien-1-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC(OCC)(O)CC=C1NC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 JKQFTMSGBHBHQZ-UFFVCSGVSA-N 0.000 claims description 5
- DHFWZXUVQJZAMP-GIJQJNRQSA-N (e)-n-(furan-2-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC1=CC=CO1 DHFWZXUVQJZAMP-GIJQJNRQSA-N 0.000 claims description 5
- BXHBVPAEUJQWTL-DHRITJCHSA-N (e)-n-[1-(cyclohexylmethyl)pyrrolidin-3-yl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(C1)CCN1CC1CCCCC1 BXHBVPAEUJQWTL-DHRITJCHSA-N 0.000 claims description 5
- WYGLRWIQXUIFSA-YDZHTSKRSA-N (e)-n-[2-(cyclohexen-1-yl)ethyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCCC1=CCCCC1 WYGLRWIQXUIFSA-YDZHTSKRSA-N 0.000 claims description 5
- SKPWWXCTAJXHBE-CIAFOILYSA-N (e)-n-[3-(dimethylamino)-2,2-dimethylpropyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCC(C)(C)CN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 SKPWWXCTAJXHBE-CIAFOILYSA-N 0.000 claims description 5
- AUGCSOFQTDKPSO-RGVLZGJSSA-N (e)-n-[3-(dimethylamino)propyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 AUGCSOFQTDKPSO-RGVLZGJSSA-N 0.000 claims description 5
- NIFZMNPKVPWAMX-AUEPDCJTSA-N (e)-n-[[4-(dimethylamino)phenyl]methyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 NIFZMNPKVPWAMX-AUEPDCJTSA-N 0.000 claims description 5
- PUBJTMOEOWHHLN-RGVLZGJSSA-N (e)-n-cyclohexyl-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC1CCCCC1 PUBJTMOEOWHHLN-RGVLZGJSSA-N 0.000 claims description 5
- GIWTZPKFKWISHH-YIXHJXPBSA-N (e)-n-hydroxy-8-(4-methylpiperazin-1-yl)-7-(naphthalen-1-yloxymethyl)-8-oxooct-2-enamide Chemical compound C1CN(C)CCN1C(=O)C(CCC\C=C\C(=O)NO)COC1=CC=CC2=CC=CC=C12 GIWTZPKFKWISHH-YIXHJXPBSA-N 0.000 claims description 5
- IIFGBVMCTLXABQ-KGVSQERTSA-N (e)-n-hydroxy-8-morpholin-4-yl-7-(naphthalen-1-yloxymethyl)-8-oxooct-2-enamide Chemical compound C=1C=CC2=CC=CC=C2C=1OCC(CCC/C=C/C(=O)NO)C(=O)N1CCOCC1 IIFGBVMCTLXABQ-KGVSQERTSA-N 0.000 claims description 5
- LDJNXXPHZUQXET-UHFFFAOYSA-N FC1(CC=C(C=C1)NC(C(=CCCCCC(=O)NO)COC1=CC=CC2=CC=CC=C12)=O)OCC Chemical compound FC1(CC=C(C=C1)NC(C(=CCCCCC(=O)NO)COC1=CC=CC2=CC=CC=C12)=O)OCC LDJNXXPHZUQXET-UHFFFAOYSA-N 0.000 claims description 5
- 229910020667 PBr3 Inorganic materials 0.000 claims description 5
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 5
- 230000001093 anti-cancer Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 claims description 5
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
- VLERWGIRJCSZBV-ODCIPOBUSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-[[4-(trifluoromethoxy)phenyl]methyl]oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCC1=CC=C(OC(F)(F)F)C=C1 VLERWGIRJCSZBV-ODCIPOBUSA-N 0.000 claims description 4
- BTXIRHGRWJVJEZ-ZMOGYAJESA-N (e)-n-[1-(cyclohexanecarbonyl)pyrrolidin-3-yl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC(C1)CCN1C(=O)C1CCCCC1 BTXIRHGRWJVJEZ-ZMOGYAJESA-N 0.000 claims description 4
- BSCYXQIPEYZODK-UHFFFAOYSA-N 3-(diethylamino)propyl-(ethyliminomethylidene)azanium;chloride Chemical compound Cl.CCN=C=NCCCN(CC)CC BSCYXQIPEYZODK-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 4
- SPFCWPYSSCVUAF-ZVBGSRNCSA-N (e)-n'-hydroxy-n-(3-imidazol-1-ylpropyl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NCCCN1C=CN=C1 SPFCWPYSSCVUAF-ZVBGSRNCSA-N 0.000 claims description 3
- WJJUFDWLJQELQD-QGMBQPNBSA-N 3-[[(e)-8-(hydroxyamino)-2-(naphthalen-1-yloxymethyl)-8-oxooct-2-enoyl]amino]pyrrolidine-1-carboxylic acid Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC1CCN(C(O)=O)C1 WJJUFDWLJQELQD-QGMBQPNBSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000003235 pyrrolidines Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000006636 (C3-C8) cycloalkylcarbonyl group Chemical group 0.000 claims description 2
- OXXIMKIBPBGDBZ-QGMBQPNBSA-N (e)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)-n-pyrrolidin-3-yloct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC\C(=C/CCCCC(=O)NO)C(=O)NC1CCNC1 OXXIMKIBPBGDBZ-QGMBQPNBSA-N 0.000 claims description 2
- QKBPIIMDVOBGJW-KEBDBYFISA-N (e)-n'-hydroxy-n-methyl-n-(1-methylpyrrolidin-3-yl)-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C=1C=CC2=CC=CC=C2C=1OC/C(=C\CCCCC(=O)NO)C(=O)N(C)C1CCN(C)C1 QKBPIIMDVOBGJW-KEBDBYFISA-N 0.000 claims description 2
- CKTLNGMIRRQTRD-KEBDBYFISA-N (e)-n-(1-ethylpyrrolidin-3-yl)-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1N(CC)CCC1NC(=O)C(=C\CCCCC(=O)NO)\COC1=CC=CC2=CC=CC=C12 CKTLNGMIRRQTRD-KEBDBYFISA-N 0.000 claims description 2
- VEMWMZCBSGFTJY-VXLYETTFSA-N (e)-n-[2-(dimethylamino)ethyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 VEMWMZCBSGFTJY-VXLYETTFSA-N 0.000 claims description 2
- OGKNLQBPNNUKFC-RGVLZGJSSA-N (e)-n-[2-(dimethylamino)ethyl]-n'-hydroxy-n-methyl-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)N(C)CCN(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 OGKNLQBPNNUKFC-RGVLZGJSSA-N 0.000 claims description 2
- OSHBDRAUCLJVJY-FSJBWODESA-N (e)-n-[2-[di(propan-2-yl)amino]ethyl]-n'-hydroxy-2-(naphthalen-1-yloxymethyl)oct-2-enediamide Chemical compound C1=CC=C2C(OC/C(C(=O)NCCN(C(C)C)C(C)C)=C\CCCCC(=O)NO)=CC=CC2=C1 OSHBDRAUCLJVJY-FSJBWODESA-N 0.000 claims description 2
- OKAMTPRCXVGTND-UHFFFAOYSA-N 2-methoxyoxolane Chemical compound COC1CCCO1 OKAMTPRCXVGTND-UHFFFAOYSA-N 0.000 claims description 2
- CFVWNXQPGQOHRJ-UHFFFAOYSA-N 2-methylpropyl prop-2-enoate Chemical compound CC(C)COC(=O)C=C CFVWNXQPGQOHRJ-UHFFFAOYSA-N 0.000 claims description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 2
- FKMUKFBHNSAVFW-UHFFFAOYSA-N [6-(trifluoromethyl)benzotriazol-1-yl] methanesulfonate Chemical compound C1=C(C(F)(F)F)C=C2N(OS(=O)(=O)C)N=NC2=C1 FKMUKFBHNSAVFW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- XNZFUKOVJVOLPE-UHFFFAOYSA-N furan;pyridine Chemical group C=1C=COC=1.C1=CC=NC=C1 XNZFUKOVJVOLPE-UHFFFAOYSA-N 0.000 claims description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 150000003053 piperidines Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 1
- 239000012964 benzotriazole Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 4
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 151
- 239000007858 starting material Substances 0.000 description 147
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 111
- 239000002253 acid Substances 0.000 description 107
- 101150041968 CDC13 gene Proteins 0.000 description 105
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 105
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 81
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 69
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 48
- 150000004702 methyl esters Chemical class 0.000 description 48
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 47
- 238000005160 1H NMR spectroscopy Methods 0.000 description 35
- 238000000746 purification Methods 0.000 description 30
- 238000004128 high performance liquid chromatography Methods 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 238000010898 silica gel chromatography Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 15
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 11
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 11
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 11
- 229960000237 vorinostat Drugs 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 229940035423 ethyl ether Drugs 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- SYBUMHRMIXCULT-UHFFFAOYSA-N tert-butyl n-(1-cyclopropylpyrrolidin-3-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1C1CC1 SYBUMHRMIXCULT-UHFFFAOYSA-N 0.000 description 4
- SYXBLASQKPONBN-UHFFFAOYSA-N tert-butyl n-(1-propan-2-ylpiperidin-4-yl)carbamate Chemical compound CC(C)N1CCC(NC(=O)OC(C)(C)C)CC1 SYXBLASQKPONBN-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- FOMMHHOTNLKIKT-UHFFFAOYSA-N (3-aminopyrrolidin-1-yl)-cyclohexylmethanone Chemical compound C1C(N)CCN1C(=O)C1CCCCC1 FOMMHHOTNLKIKT-UHFFFAOYSA-N 0.000 description 3
- DPEPZAJVZHRORQ-UHFFFAOYSA-N 1-cyclohexylpyrrolidin-3-amine Chemical compound C1C(N)CCN1C1CCCCC1 DPEPZAJVZHRORQ-UHFFFAOYSA-N 0.000 description 3
- HJJXAKRPWXVQGP-UHFFFAOYSA-N 1-cyclopentylpiperidin-4-amine Chemical compound C1CC(N)CCN1C1CCCC1 HJJXAKRPWXVQGP-UHFFFAOYSA-N 0.000 description 3
- XQRNOQYMHPJDCY-UHFFFAOYSA-N 1-cyclopropylpiperidin-4-amine Chemical compound C1CC(N)CCN1C1CC1 XQRNOQYMHPJDCY-UHFFFAOYSA-N 0.000 description 3
- PISMTKYGUDKXTE-UHFFFAOYSA-N 1-cyclopropylpyrrolidin-3-amine Chemical compound C1C(N)CCN1C1CC1 PISMTKYGUDKXTE-UHFFFAOYSA-N 0.000 description 3
- UFETTXCVHFVMPU-UHFFFAOYSA-N 1-ethylpiperidin-4-amine Chemical compound CCN1CCC(N)CC1 UFETTXCVHFVMPU-UHFFFAOYSA-N 0.000 description 3
- GOLVGZOPWLLUSF-UHFFFAOYSA-N 1-ethylpyrrolidin-3-amine Chemical compound CCN1CCC(N)C1 GOLVGZOPWLLUSF-UHFFFAOYSA-N 0.000 description 3
- SYMMPPWYYXRLJX-UHFFFAOYSA-N 1-propan-2-ylpyrrolidin-3-amine Chemical compound CC(C)N1CCC(N)C1 SYMMPPWYYXRLJX-UHFFFAOYSA-N 0.000 description 3
- OQBSJVBSUDKKCY-UHFFFAOYSA-N 2-pyrrolidin-3-yloct-2-enediamide Chemical compound NC(=O)CCCCC=C(C(N)=O)C1CCNC1 OQBSJVBSUDKKCY-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000006197 histone deacetylation Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 3
- FXNPTFPQWVTMTN-SRZZPIQSSA-N (E)-1-(4-methylpiperazin-1-yl)-2-(naphthalen-1-yloxymethyl)oct-2-en-1-one Chemical compound CN1CCN(CC1)C(/C(=C/CCCCC)/COC1=CC=CC2=CC=CC=C12)=O FXNPTFPQWVTMTN-SRZZPIQSSA-N 0.000 description 2
- LIJLLDUDSVHFMZ-LDADJPATSA-N (E)-N,N-dimethyl-2-(naphthalen-1-yloxymethyl)oct-2-enamide Chemical compound CN(C(/C(=C/CCCCC)/COC1=CC=CC2=CC=CC=C12)=O)C LIJLLDUDSVHFMZ-LDADJPATSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 2
- ZRQQXFMGYSOKDF-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-amine Chemical compound CC(C)N1CCC(N)CC1 ZRQQXFMGYSOKDF-UHFFFAOYSA-N 0.000 description 2
- YSMWBHMJDOYACP-UHFFFAOYSA-N 2-(oxan-2-yloxy)oct-2-enediamide Chemical compound O1C(CCCC1)OC(C(=O)N)=CCCCCC(=O)N YSMWBHMJDOYACP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MKSTXMDSWOHKOR-UHFFFAOYSA-N 3-aminopyrrolidine-1-carboxylic acid Chemical compound NC1CCN(C(O)=O)C1 MKSTXMDSWOHKOR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 101000687448 Homo sapiens REST corepressor 1 Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100024864 REST corepressor 1 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- ATLBQTPBCVSZGU-UHFFFAOYSA-N methyl 6-hydroxyhex-2-enoate Chemical compound COC(=O)C=CCCCO ATLBQTPBCVSZGU-UHFFFAOYSA-N 0.000 description 2
- FDNFXHCDOASWAY-UHFFFAOYSA-N methyl 6-oxohexanoate Chemical compound COC(=O)CCCCC=O FDNFXHCDOASWAY-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WFKLUNLIZMWKNF-UHFFFAOYSA-N tert-butyl n-(1-benzylpiperidin-4-yl)carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 WFKLUNLIZMWKNF-UHFFFAOYSA-N 0.000 description 2
- OWXMMRQDSKAHST-UHFFFAOYSA-N tert-butyl n-(1-cyclohexylpyrrolidin-3-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1C1CCCCC1 OWXMMRQDSKAHST-UHFFFAOYSA-N 0.000 description 2
- XNNYFIMWBZGFIW-UHFFFAOYSA-N tert-butyl n-(1-cyclopentylpiperidin-4-yl)carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C1CCCC1 XNNYFIMWBZGFIW-UHFFFAOYSA-N 0.000 description 2
- QHPWESLNMUXZMX-UHFFFAOYSA-N tert-butyl n-(1-cyclopropylpiperidin-4-yl)carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1C1CC1 QHPWESLNMUXZMX-UHFFFAOYSA-N 0.000 description 2
- JUOXFFYHDMNFHE-UHFFFAOYSA-N tert-butyl n-(1-ethylpiperidin-4-yl)carbamate Chemical compound CCN1CCC(NC(=O)OC(C)(C)C)CC1 JUOXFFYHDMNFHE-UHFFFAOYSA-N 0.000 description 2
- WYPHJLKRZSTDMH-UHFFFAOYSA-N tert-butyl n-(1-ethylpyrrolidin-3-yl)carbamate Chemical compound CCN1CCC(NC(=O)OC(C)(C)C)C1 WYPHJLKRZSTDMH-UHFFFAOYSA-N 0.000 description 2
- IFWALANQXAWVQS-UHFFFAOYSA-N tert-butyl n-(1-methylpiperidin-4-yl)carbamate Chemical compound CN1CCC(NC(=O)OC(C)(C)C)CC1 IFWALANQXAWVQS-UHFFFAOYSA-N 0.000 description 2
- MMINECTYWKHJNS-UHFFFAOYSA-N tert-butyl n-[1-(cyclohexanecarbonyl)pyrrolidin-3-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1C(=O)C1CCCCC1 MMINECTYWKHJNS-UHFFFAOYSA-N 0.000 description 2
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- PGLBECGNJJOIMN-YBFXNURJSA-N (E)-N-(2-hydroxyethyl)-N-methyl-2-(naphthalen-1-yloxymethyl)oct-2-enamide Chemical compound OCCN(C(/C(=C/CCCCC)/COC1=CC=CC2=CC=CC=C12)=O)C PGLBECGNJJOIMN-YBFXNURJSA-N 0.000 description 1
- SGCDUQZMWQBVFU-LSHDLFTRSA-N (E)-N-(2-morpholin-4-ylethyl)-2-(naphthalen-1-yloxymethyl)oct-2-enamide Chemical compound O1CCN(CC1)CCNC(/C(=C/CCCCC)/COC1=CC=CC2=CC=CC=C12)=O SGCDUQZMWQBVFU-LSHDLFTRSA-N 0.000 description 1
- WXMIBRJGLKWZQH-HZHRSRAPSA-N (E)-N-[2-(diethylamino)ethyl]-N-methyl-2-(naphthalen-1-yloxymethyl)oct-2-enamide Chemical compound C(C)N(CCN(C(/C(=C/CCCCC)/COC1=CC=CC2=CC=CC=C12)=O)C)CC WXMIBRJGLKWZQH-HZHRSRAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- PVJMGFMLSTXKKY-WKULSOCRSA-N (e)-n-(1-benzylpyrrolidin-3-yl)-2-(naphthalen-1-yloxymethyl)-n'-(oxan-2-yloxy)oct-2-enediamide Chemical compound C1CCCOC1ONC(=O)CCCC\C=C(/COC=1C2=CC=CC=C2C=CC=1)C(=O)NC(C1)CCN1CC1=CC=CC=C1 PVJMGFMLSTXKKY-WKULSOCRSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HJORCZCMNWLHMB-UHFFFAOYSA-N 1-(3-aminopropyl)pyrrolidin-2-one Chemical compound NCCCN1CCCC1=O HJORCZCMNWLHMB-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- SBSSXCKDVHHANA-UHFFFAOYSA-N 1-(cyclohexylmethyl)pyrrolidin-3-amine Chemical compound C1C(N)CCN1CC1CCCCC1 SBSSXCKDVHHANA-UHFFFAOYSA-N 0.000 description 1
- YUBDLZGUSSWQSS-UHFFFAOYSA-N 1-benzylpiperidin-4-amine Chemical compound C1CC(N)CCN1CC1=CC=CC=C1 YUBDLZGUSSWQSS-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- NXMXETCTWNXSFG-UHFFFAOYSA-N 1-methoxypropan-2-amine Chemical compound COCC(C)N NXMXETCTWNXSFG-UHFFFAOYSA-N 0.000 description 1
- UNHOPMIDKWXFMF-UHFFFAOYSA-N 1-methylpyrrolidin-3-amine Chemical compound CN1CCC(N)C1 UNHOPMIDKWXFMF-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OKIDBHHMCXAYLN-UHFFFAOYSA-N 1-phenyl-n-(trifluoromethoxy)methanamine Chemical compound FC(F)(F)ONCC1=CC=CC=C1 OKIDBHHMCXAYLN-UHFFFAOYSA-N 0.000 description 1
- OFZVOZGWCBEPBB-UHFFFAOYSA-N 2,3,4,5-tetrabutylfuran Chemical compound CCCCC=1OC(CCCC)=C(CCCC)C=1CCCC OFZVOZGWCBEPBB-UHFFFAOYSA-N 0.000 description 1
- GOWUDHPKGOIDIX-UHFFFAOYSA-N 2-(4-methyl-1-piperazinyl)ethanamine Chemical compound CN1CCN(CCN)CC1 GOWUDHPKGOIDIX-UHFFFAOYSA-N 0.000 description 1
- IUDMXOOVKMKODN-UHFFFAOYSA-N 2-(cyclohexen-1-yl)ethanamine Chemical compound NCCC1=CCCCC1 IUDMXOOVKMKODN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- OBOSXEWFRARQPU-UHFFFAOYSA-N 2-n,2-n-dimethylpyridine-2,5-diamine Chemical compound CN(C)C1=CC=C(N)C=N1 OBOSXEWFRARQPU-UHFFFAOYSA-N 0.000 description 1
- AASLFZACKQKOAQ-UHFFFAOYSA-N 2-n-[2-(dimethylamino)ethyl]pyridine-2,5-diamine Chemical compound CN(C)CCNC1=CC=C(N)C=N1 AASLFZACKQKOAQ-UHFFFAOYSA-N 0.000 description 1
- CJNRGSHEMCMUOE-UHFFFAOYSA-N 2-piperidin-1-ylethanamine Chemical compound NCCN1CCCCC1 CJNRGSHEMCMUOE-UHFFFAOYSA-N 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- PDJZOFLRRJQYBF-UHFFFAOYSA-N 4-(aminomethyl)-n,n-dimethylaniline Chemical compound CN(C)C1=CC=C(CN)C=C1 PDJZOFLRRJQYBF-UHFFFAOYSA-N 0.000 description 1
- NKTAQFHZUKHHPT-UHFFFAOYSA-N 4-amino-1-ethoxycyclohexa-2,4-dien-1-ol Chemical compound CCOC1(O)CC=C(N)C=C1 NKTAQFHZUKHHPT-UHFFFAOYSA-N 0.000 description 1
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
- DPOILWCKMSWUOX-UHFFFAOYSA-N 4-ethoxy-4-fluorocyclohexa-1,5-dien-1-amine Chemical compound CCOC1(F)CC=C(N)C=C1 DPOILWCKMSWUOX-UHFFFAOYSA-N 0.000 description 1
- VUVSPPNEKMQHAB-UHFFFAOYSA-N 4-ethoxy-4-methoxycyclohexa-1,5-dien-1-amine Chemical compound CCOC1(OC)CC=C(N)C=C1 VUVSPPNEKMQHAB-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- RJWLLQWLBMJCFD-UHFFFAOYSA-N 4-methylpiperazin-1-amine Chemical compound CN1CCN(N)CC1 RJWLLQWLBMJCFD-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- NZTCEWZBMOTKCJ-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyridin-3-amine Chemical compound C1CN(C)CCN1C1=CC=C(N)C=N1 NZTCEWZBMOTKCJ-UHFFFAOYSA-N 0.000 description 1
- UUVDJIWRSIJEBS-UHFFFAOYSA-N 6-methoxypyridin-3-amine Chemical compound COC1=CC=C(N)C=N1 UUVDJIWRSIJEBS-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000005712 Baylis-Hillman reaction Methods 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- BPUQSVHKVSDVSQ-BHGWPJFGSA-N CN1CCN(CC1)C(/C(=C/CCCCC(=O)NOC1OCCCC1)/COC1=CC=CC2=CC=CC=C12)=O Chemical compound CN1CCN(CC1)C(/C(=C/CCCCC(=O)NOC1OCCCC1)/COC1=CC=CC2=CC=CC=C12)=O BPUQSVHKVSDVSQ-BHGWPJFGSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940122498 Gene expression inhibitor Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- KKKCRSKYYRFFLL-UHFFFAOYSA-N N-naphthalen-1-ylperoxyoct-2-enamide Chemical class CCCCCC=CC(=O)NOOC1=CC=CC2=CC=CC=C21 KKKCRSKYYRFFLL-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- UTVVREMVDJTZAC-UHFFFAOYSA-N furan-2-amine Chemical compound NC1=CC=CO1 UTVVREMVDJTZAC-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- VVNXEADCOVSAER-UHFFFAOYSA-N lithium sodium Chemical compound [Li].[Na] VVNXEADCOVSAER-UHFFFAOYSA-N 0.000 description 1
- WAZWGFFJLSIDMX-UHFFFAOYSA-M lithium;iodide;hydrate Chemical compound [Li+].O.[I-] WAZWGFFJLSIDMX-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VIPCJSCBXJTMQM-UHFFFAOYSA-N methyl 6-oxohex-2-enoate Chemical compound COC(=O)C=CCCC=O VIPCJSCBXJTMQM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 1
- ULDIVZQLPBUHAG-UHFFFAOYSA-N n',n',2,2-tetramethylpropane-1,3-diamine Chemical compound CN(C)CC(C)(C)CN ULDIVZQLPBUHAG-UHFFFAOYSA-N 0.000 description 1
- CURJNMSGPBXOGK-UHFFFAOYSA-N n',n'-di(propan-2-yl)ethane-1,2-diamine Chemical compound CC(C)N(C(C)C)CCN CURJNMSGPBXOGK-UHFFFAOYSA-N 0.000 description 1
- MKDYQLJYEBWUIG-UHFFFAOYSA-N n',n'-diethyl-n-methylethane-1,2-diamine Chemical compound CCN(CC)CCNC MKDYQLJYEBWUIG-UHFFFAOYSA-N 0.000 description 1
- UDGSVBYJWHOHNN-UHFFFAOYSA-N n',n'-diethylethane-1,2-diamine Chemical compound CCN(CC)CCN UDGSVBYJWHOHNN-UHFFFAOYSA-N 0.000 description 1
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- NFLXIAUKMQBTMN-UHFFFAOYSA-N n-benzylpyrrolidin-3-amine Chemical compound C=1C=CC=CC=1CNC1CCNC1 NFLXIAUKMQBTMN-UHFFFAOYSA-N 0.000 description 1
- 230000019569 negative regulation of cell differentiation Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- SSUCKKNRCOFUPT-UHFFFAOYSA-N o-[tert-butyl(dimethyl)silyl]hydroxylamine Chemical compound CC(C)(C)[Si](C)(C)ON SSUCKKNRCOFUPT-UHFFFAOYSA-N 0.000 description 1
- LVBXEMGDVWVTGY-UHFFFAOYSA-N oct-2-enal Chemical compound CCCCCC=CC=O LVBXEMGDVWVTGY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- PHOIDJGLYWEUEK-UHFFFAOYSA-N tert-butyl n-(1-benzylpyrrolidin-3-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CCN1CC1=CC=CC=C1 PHOIDJGLYWEUEK-UHFFFAOYSA-N 0.000 description 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
This invention discloses a novel alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide derivative of formula (1) useful for inhibiting the enzyme activity of histone deacetylase, which leads to effective suppression of the cancer cell proliferation, a method for preparing same and a pharmaceutical composition comprising same.
Description
ALKYLCARBAMOYL NAPHTHALENYLOXY -OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING
INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND
PREPARATION THEREOF
FIELD OF THE INVENTION
The present invention relates to a novel alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative, a method for preparing same and an anticancer composition comprising same.
BACKGROUND OF THE INVENTION
Histones associate with DNAs in the nuclei of eukaryotic cells as basic proteins and are subject to reversible acetylation at the amino group of the lysine residue. The reversible acetylation is involved in the formation of chromatin of a higher order structure, the cell division cycle and ultimately the gene expression, and can be regulated by the dynamic balance established between the opposing activities of histone acetyl transferases (HATs) and histone deacetylases (HDACs): means enzymes neutralize or restore the positive charges of lysine residues (e.g., 4 lysine residues in H4) by acetylation/deacetylation to regulate the gene transcriptional level.
HDACs play an important role in cell cancerization or differentiation and their expression is enhanced under conditions such as hypoxia, lowered glucose, and cell cancerization, to inhibit the expression of cell proliferation inhibitors. That is, histone deacetylation by HDAC causes cell proliferation, while hyperacetylation of histone facilitates the inhibition of cell proliferation and cell differentiation. Therefore, when HDACs are inhibited, cell proliferation and angiogenesis can be controlled.
Abnormal histone deacetylation has been reported to cause acute promyelocytic leukemica (APL) (Lin R. J. et. al. Oncogene 20: 7204, 2001;
Zelent A. et. al. Oncogene 20: 7186, 2001). Specifically, abnormality in the regulation of HDAC activity leads to oncoprotein's transcriptional suppression and the formation of abnormal chromatin structures, which after causes normal cells to become cancer. Accordingly, HDAC has been one of the targets for the study of anticancer drugs as well as gene expression inhibitor and there have been attempts to develope HDAC inhibitors as anticancer drugs.
Recent anticancer drug studies through chromatin modeling have shown that HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) or apicidin inhibit the proliferation of cancer cells and induce cell differentiation (Munster P. N. et al., Cancer research 61: 8492, 2001; Han J.
W. et. al. Cancer research 60: 6068, 2000).
Another HDAC inhibitor, n-butyrate was reported to be useful for the treatment of large intestine cancer. But it has to be used in such a high concentration in the order of milimolar (mM) that it disturbs the functions of other enzymes in cells, cytoskeleton, cell membrane, etc. Trichostatin A
(TSA) which enhances the differentiation and suppresses the proliferation of Friend murine erythroleukemia cells has been reported to inhibit HDAC
(Yoshida M. et al., Cancer research 47: 3688, 1987; Yoshida M. & Beppu T.
Exp Cell Res. 177: 122, 1988; Yoshida M. et al., J of Biol. Chem. 265: 17174, 1990).
Therefore, there has been a need for developing an improved HDAC
inhibitor. The present inventors have unexpectedly found that a novel alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative is an efficient inhibitor against cell proliferation which can be advantageously used for treating cancer.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a novel compound which efficiently inhibits the activity of histone deacetylases, thereby suppressing the proliferation of tumor cells, and a method for preparing same.
It is another object of the present invention to provide a pharmaceutical composition comprising the inventive compound as an active ingredient for preventing or treating cancers.
INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND
PREPARATION THEREOF
FIELD OF THE INVENTION
The present invention relates to a novel alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative, a method for preparing same and an anticancer composition comprising same.
BACKGROUND OF THE INVENTION
Histones associate with DNAs in the nuclei of eukaryotic cells as basic proteins and are subject to reversible acetylation at the amino group of the lysine residue. The reversible acetylation is involved in the formation of chromatin of a higher order structure, the cell division cycle and ultimately the gene expression, and can be regulated by the dynamic balance established between the opposing activities of histone acetyl transferases (HATs) and histone deacetylases (HDACs): means enzymes neutralize or restore the positive charges of lysine residues (e.g., 4 lysine residues in H4) by acetylation/deacetylation to regulate the gene transcriptional level.
HDACs play an important role in cell cancerization or differentiation and their expression is enhanced under conditions such as hypoxia, lowered glucose, and cell cancerization, to inhibit the expression of cell proliferation inhibitors. That is, histone deacetylation by HDAC causes cell proliferation, while hyperacetylation of histone facilitates the inhibition of cell proliferation and cell differentiation. Therefore, when HDACs are inhibited, cell proliferation and angiogenesis can be controlled.
Abnormal histone deacetylation has been reported to cause acute promyelocytic leukemica (APL) (Lin R. J. et. al. Oncogene 20: 7204, 2001;
Zelent A. et. al. Oncogene 20: 7186, 2001). Specifically, abnormality in the regulation of HDAC activity leads to oncoprotein's transcriptional suppression and the formation of abnormal chromatin structures, which after causes normal cells to become cancer. Accordingly, HDAC has been one of the targets for the study of anticancer drugs as well as gene expression inhibitor and there have been attempts to develope HDAC inhibitors as anticancer drugs.
Recent anticancer drug studies through chromatin modeling have shown that HDAC inhibitors such as suberoylanilide hydroxamic acid (SAHA) or apicidin inhibit the proliferation of cancer cells and induce cell differentiation (Munster P. N. et al., Cancer research 61: 8492, 2001; Han J.
W. et. al. Cancer research 60: 6068, 2000).
Another HDAC inhibitor, n-butyrate was reported to be useful for the treatment of large intestine cancer. But it has to be used in such a high concentration in the order of milimolar (mM) that it disturbs the functions of other enzymes in cells, cytoskeleton, cell membrane, etc. Trichostatin A
(TSA) which enhances the differentiation and suppresses the proliferation of Friend murine erythroleukemia cells has been reported to inhibit HDAC
(Yoshida M. et al., Cancer research 47: 3688, 1987; Yoshida M. & Beppu T.
Exp Cell Res. 177: 122, 1988; Yoshida M. et al., J of Biol. Chem. 265: 17174, 1990).
Therefore, there has been a need for developing an improved HDAC
inhibitor. The present inventors have unexpectedly found that a novel alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative is an efficient inhibitor against cell proliferation which can be advantageously used for treating cancer.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a novel compound which efficiently inhibits the activity of histone deacetylases, thereby suppressing the proliferation of tumor cells, and a method for preparing same.
It is another object of the present invention to provide a pharmaceutical composition comprising the inventive compound as an active ingredient for preventing or treating cancers.
It is still another object of the present invention to provide a pharmaceutical composition comprising the inventive compound as an active ingredient for inhibition of the histone deacetylase activity.
In accordance with one aspect of the present invention, there is provided an alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) or a pharmaceutically acceptable salt thereof:
CONHOH
~.~
~._.
RI--N
RI ~ (1) wherein:
R, is hydrogen or C1_3 alkyl;
R2 is C1_6 alkyl optionally having one or more substituents selected from the group consisting of diC1_3 alkylamino, oxopyrrolidinyl, pyrrolidinyl, piperidinyl, morpholinyl, C1_3 alkylpiperazinyl, cyano, hydroxy, imidazolyl, methoxy, tetrahydrofuran, C3_8 cycloalkenyl, and thiophenyl; C1_6 alkyl substituted with hydroxyphenyl, fluorophenyl, diC1_3 alkyl amino phenyl, methoxyphenyl and trifluoromethoxyphenyl; pyrrolidine substituted with C1_3 alkyl, C3_8 cycloalkyl, C3_8 cycloalkyl C1_3 alkyl, benzyl or C3_8 cycloalkylcarbonyl; piperidine substituted with C3_8 cycloalkyl or C1_6 alkyl;
furan; pyridine substituted with (diC1_3 alkyl amino) C1_3 alkyl amino, methoxy, diC1_3 alkyl amino, morpholino C1_3 alkylamino, or C1_3 alkylpiperazinyl; or C3_ g cycloalkyl; or R, and R2 may optionally form a morpholinyl, piperidinyl or piperazinyl ring together with the nitrogen atom to which they are bonded.
In accordance with another aspect of the present invention, there is provided a method for preparing the compound of formula (1).
In accordance with still another aspect of the present invention, there is provided an anti-cancer composition and an inhibitor of histone deacetylase activity comprising the compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
DETAILED DESCRIPTION OF THE INVENTION
Representative examples of preferred compounds as alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) include:
(E)-N8-hydroxy-N 1,N 1-dimethyl-2-((naphthalen-l-yloxy)methyl) octenediamide, (E)-N 1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(dimethylamino)ethyl)-N8 -hydroxy-N 1-methyl-2-((naphthalene-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N 1-(2-(diethylamino)ethyl)-N8-hydroxy-N 1-methyl-2-((naphthalene-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(2-(pyrrolidin-l-yl)ethyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(2-(piperidin-l-yl)ethyl)octenediamide, (E)-N8-hydroxy-N 1-(2-morpholinoethyl)-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N-hydroxy-8-(4-methylpiperazin-l-yl)-7-((naphthalen-l-yloxy) methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N 1-(2-(4-methylpiperazin-l-yl)ethyl)-2-((naphthalen -1-yloxy)methyl)octenediamide, (E)-N 1-(cyanomethyl)-N8-hydroxy-N 1-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(2-hydroxyethyl)-N 1-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-methyl-N 1-(1-methylpyrrolidin-3 -yl)-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N-hydroxy-8-morpholino-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N 1-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(6-(dimethylamino)pyridin-3 -yl)-N8-hydroxy-2-((naphthalen-1 -yloxy)methyl)octenediamide, (E)-N 1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(6-methoxypyridin-3-yl)-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N 1 -(3 -(1 H-imidazol-l-yl)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1 -(3 -(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(1-methoxypropan-2-yl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(4-methoxybenzyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(tetrahydrofuran -2-yl)methyl)-2-octenediamide, (E)-N 1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(3-(2-oxopyrrolidin-l-yl)propyl)-2-octenediamide, (E)-N 1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(2-methoxyethyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1-cyclohexyl-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(thiophen-2-ylmethyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(4-methoxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(4-1s (trifluoromethoxy)benzyl)-2-octenediamide, (E)-N 1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-2 5 ((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-3-(8-(hydroxyamino)-2-((naphthalen-l-yloxy)methyl)-8-oxo-2-octeneamido) pyrrolidin-1-carboxylic acid t-butylester, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(pyrrolidin-3-yl)2-octenediamide, (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, and (E)-N 1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide.
The inventive compound of formula (I) may be used in the form of a pharmaceutically acceptable addition salt formed with an inorganic acid or organic acid. Examples of the acid include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, acetic, glycolic, lactic, pyrubic, malonic, succinic, glutaric, fumaric, malic, mandelic, tartaric, citric, ascorbic, palmitic, maleic, hydroxy maleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, methanesulfonic, benzenesulfonic, and toluenesulfonic acid.
And the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) may be prepared by the method comprising the steps of 1) treating a compound of formula (2) with sulfuric acid, and then with pyridinium chlorochromate (PCC) to obtain a compound of formula (3);
2) allowing the compound of formula (3) to react with an alkyl acrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to obtain a compound of the formula (4);
3) subjecting the compound of formula (4) to a reaction with tribromophosphine (PBr3) to obtain a compound of formula (5);
4) bringing the compound of formula (5) to react with 1-naphthol to obtain a compound of formula (6);
5) hydrolyzing the compound of formula (6) in the presence of an inorganic or organic acid to obtain a compound of formula (7);
6) acylating the compound of formula (7) with an amine (RIR2NH or R2NH2) to obtain a compound of formula (8);
In accordance with one aspect of the present invention, there is provided an alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) or a pharmaceutically acceptable salt thereof:
CONHOH
~.~
~._.
RI--N
RI ~ (1) wherein:
R, is hydrogen or C1_3 alkyl;
R2 is C1_6 alkyl optionally having one or more substituents selected from the group consisting of diC1_3 alkylamino, oxopyrrolidinyl, pyrrolidinyl, piperidinyl, morpholinyl, C1_3 alkylpiperazinyl, cyano, hydroxy, imidazolyl, methoxy, tetrahydrofuran, C3_8 cycloalkenyl, and thiophenyl; C1_6 alkyl substituted with hydroxyphenyl, fluorophenyl, diC1_3 alkyl amino phenyl, methoxyphenyl and trifluoromethoxyphenyl; pyrrolidine substituted with C1_3 alkyl, C3_8 cycloalkyl, C3_8 cycloalkyl C1_3 alkyl, benzyl or C3_8 cycloalkylcarbonyl; piperidine substituted with C3_8 cycloalkyl or C1_6 alkyl;
furan; pyridine substituted with (diC1_3 alkyl amino) C1_3 alkyl amino, methoxy, diC1_3 alkyl amino, morpholino C1_3 alkylamino, or C1_3 alkylpiperazinyl; or C3_ g cycloalkyl; or R, and R2 may optionally form a morpholinyl, piperidinyl or piperazinyl ring together with the nitrogen atom to which they are bonded.
In accordance with another aspect of the present invention, there is provided a method for preparing the compound of formula (1).
In accordance with still another aspect of the present invention, there is provided an anti-cancer composition and an inhibitor of histone deacetylase activity comprising the compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
DETAILED DESCRIPTION OF THE INVENTION
Representative examples of preferred compounds as alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) include:
(E)-N8-hydroxy-N 1,N 1-dimethyl-2-((naphthalen-l-yloxy)methyl) octenediamide, (E)-N 1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(dimethylamino)ethyl)-N8 -hydroxy-N 1-methyl-2-((naphthalene-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N 1-(2-(diethylamino)ethyl)-N8-hydroxy-N 1-methyl-2-((naphthalene-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(2-(pyrrolidin-l-yl)ethyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(2-(piperidin-l-yl)ethyl)octenediamide, (E)-N8-hydroxy-N 1-(2-morpholinoethyl)-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N-hydroxy-8-(4-methylpiperazin-l-yl)-7-((naphthalen-l-yloxy) methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N 1-(2-(4-methylpiperazin-l-yl)ethyl)-2-((naphthalen -1-yloxy)methyl)octenediamide, (E)-N 1-(cyanomethyl)-N8-hydroxy-N 1-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(2-hydroxyethyl)-N 1-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-methyl-N 1-(1-methylpyrrolidin-3 -yl)-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N-hydroxy-8-morpholino-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N 1-(6-(4-methylpiperazin-l-yl)pyridin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(6-(dimethylamino)pyridin-3 -yl)-N8-hydroxy-2-((naphthalen-1 -yloxy)methyl)octenediamide, (E)-N 1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(6-methoxypyridin-3-yl)-2-((naphthalen-l-yloxy) methyl)octenediamide, (E)-N 1 -(3 -(1 H-imidazol-l-yl)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1 -(3 -(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N 1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N 1-(1-methoxypropan-2-yl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(4-methoxybenzyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(tetrahydrofuran -2-yl)methyl)-2-octenediamide, (E)-N 1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(3-(2-oxopyrrolidin-l-yl)propyl)-2-octenediamide, (E)-N 1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(2-methoxyethyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N 1-cyclohexyl-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(thiophen-2-ylmethyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(4-methoxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(4-1s (trifluoromethoxy)benzyl)-2-octenediamide, (E)-N 1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N 1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-2 5 ((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-3-(8-(hydroxyamino)-2-((naphthalen-l-yloxy)methyl)-8-oxo-2-octeneamido) pyrrolidin-1-carboxylic acid t-butylester, (E)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-N 1-(pyrrolidin-3-yl)2-octenediamide, (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide, (E)-N 1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, and (E)-N 1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide.
The inventive compound of formula (I) may be used in the form of a pharmaceutically acceptable addition salt formed with an inorganic acid or organic acid. Examples of the acid include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, acetic, glycolic, lactic, pyrubic, malonic, succinic, glutaric, fumaric, malic, mandelic, tartaric, citric, ascorbic, palmitic, maleic, hydroxy maleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, methanesulfonic, benzenesulfonic, and toluenesulfonic acid.
And the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) may be prepared by the method comprising the steps of 1) treating a compound of formula (2) with sulfuric acid, and then with pyridinium chlorochromate (PCC) to obtain a compound of formula (3);
2) allowing the compound of formula (3) to react with an alkyl acrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to obtain a compound of the formula (4);
3) subjecting the compound of formula (4) to a reaction with tribromophosphine (PBr3) to obtain a compound of formula (5);
4) bringing the compound of formula (5) to react with 1-naphthol to obtain a compound of formula (6);
5) hydrolyzing the compound of formula (6) in the presence of an inorganic or organic acid to obtain a compound of formula (7);
6) acylating the compound of formula (7) with an amine (RIR2NH or R2NH2) to obtain a compound of formula (8);
7) hydrolyzing the compound of formula (8) in the presence of an inorganic base to obtain a compound of formula (9);
8) acylating the compound of formula (9) with tetrahydropyranyloxyamine (NH2OTHP) to obtain a compound of formula (10); and 9) removing the tetrahydropyranyl group from the compound of formula (10) by trifluoroacetic acid (TFA) treatment.
.~-''~ CQNHOH
cr RI.."N
R2 ~ (1) 0 (2) 0 (3) YO~ (4) Me (5) ,~=" f Y020 (6) r..-h Me HO
0 (7) A C02Me R,-~
R2 0 (8) Rz 0 (9) CONHOT~~
~~- IN
.~-''~ CQNHOH
cr RI.."N
R2 ~ (1) 0 (2) 0 (3) YO~ (4) Me (5) ,~=" f Y020 (6) r..-h Me HO
0 (7) A C02Me R,-~
R2 0 (8) Rz 0 (9) CONHOT~~
~~- IN
(10) Wherein:
Rl and R2 have the same meanings as defined in formula (1) above, and Y is C1_4 alkyl.
The method described above may be represented by Reaction Scheme 1:
Reaction Scheme 1 /~/C0ZnO CoZn* co2ne 0 I)H2SO4 ~ ~~zt Bu PBr3 Br~
~0 H II)PCC 0 pqBCO Yp2 OH ~= YOZC
/
~I ~ I I COzMe COzMe C02Me KZCO_p TFq FM5,RlR2NH 0 0 0 _ Acetone - CHZCI2 R~ N
Y0zC ~ 0 R2 0 W2H CONHOTHP ~ ' ~ CONHOH
LIOH EDC,HCI, FOBT TFA ~ /
0 0 ~-~ 0 Rj- N Rl RI-N
Ry 0 R2 0 R 0 Wherein:
R, and R2 have the same meanings as defined in formula (1) above, and Y is C ) -4 alkyl.
In step 1) of Reaction Scheme 1, --caprolactone (formula 2) is dissolved in methanol and treated with concetrated sulfuric acid to form the 1, 6-hydroxy-hexanoic acid methylester of formula 3, which is then added to a pyridinium chlorochromate solution and reacted for 2 hrs to obtain 6-oxo-hexanoic acid methylester (formula 3).
Suitable for use in this step is a solvent such as dichloromethane, tetrahydrofuran, or dichloroethane.
In step 2), a hydroxy compound (formula 4) is obtained by the Baylis-Hillman reaction carried out between a 6-oxo-hexanoic acid methylester (formula 3) and a C1_4 alkylacrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) at 0-25 C for 5-7 days, above ethyl acrylate, isobutyl acrylate, or t-butyl acrylate may be used as the alkyl acrylate.
The reaction step 3) is carried out using a bromination agent in an organic solvent. Representative examples of the organic solvent include ethylether, dichloromethane and hydrofuran, and representative examples of the bromination agent include PBr3, CBr4 and N-bromo succinic acid (NBS).
In step 4), the bromo compound (formula 5) is reacted with 1 -naphthol to obtain an alcohol compound (formula 6) using acetone or acetonitrile as a solvent in the presence of potassium carbonate, sodium bicarbonate, or sodium carbonate.
The ester hydrolysis step 5) is carried out in the presence of an inorganic or organic acid in a solvent such as dichloromethane, tetrahydrofuran or N,N' -dimethylformamide. Representative examples of the inorganic acid include hydrochloric acid, sulfuric acid and phosphoric acid and representative examples of the organic acid include trifluoroacetic acid (TFA).
Acylation step 6) is carried out using N-Methanesulfonyloxy-6-trifluoromethylbenzotriazole (FMS), N-hydroxy-6-trifluorobenzotriazole (FOBT) or 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC - HC1) as an acylation agent in an aprotic solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran or dichloromethane.
The reaction in step 7) is preferably carried out using an aqueous alcohol or tetrahydrofuran solvent, and lithium hydroxide (LiOH - H2O) or sodium hydroxide as the inorganic base.
The acylation in step 8) is carried out in an organic solvent in the presence of N-hydroxy-6-trifluorobenzotriazole (FOBT) and 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl).
Representative examples of the organic solvent include N,N'-dimethylformamide, dimethylsulfoxide, tetrahydrofuran and dichloromethane.
Removing the tetrahydropyranyl group from the compound of formula (10) in step 9) is carried out in a solvent such as methanol, ethanol, tetrahydrofuran or dichloromethane.
The starting material (formula 2) for preparing the alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) is commercially available.
The inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) efficiently inhibits the activity of histone deacetylase, resulting in the efficient suppression of the cancer-cell proliferation.
Accordingly, the present invention also provides an inhibitor of histone deacetylase activity comprising the compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
Further, the present invention provides an anti-cancer composition comprising the compound of formula (1) as an active ingredient and a pharmaceutically acceptable carrier.
The inventive pharmaceutical composition comprises the compound of formula (1) as an active ingredient in an amount ranging from 0.1 to 75 wt%, preferably 1 to 50 wt%, based on the total weight of the composition.
The pharmaceutical composition may be formulated for oral or parenteral administration. The formulation for oral administration may take various forms such as tablet, pill, powder, sachet, soft and hard capsule, solution, suspension, emulsion, syrup, granule and the like, which may contain conventional additives such as a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), a lubricant (e.g., silica, talc, stearic acid or its zinc, magnesium or calcium salt, and/or polyethylene glycol). A tablet form may also comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxylmethyl cellulose and/or polyvinylpyrrolidone, and optionally a disintegrant such as starch, agar, alginic acid or its sodium salt, an effervescent mixture, an absorbent, a colorant, a flavor and a sweetener. For parenteral administration, sterile injectable formulations such as istonic solution and suspension may be preferred.
Rl and R2 have the same meanings as defined in formula (1) above, and Y is C1_4 alkyl.
The method described above may be represented by Reaction Scheme 1:
Reaction Scheme 1 /~/C0ZnO CoZn* co2ne 0 I)H2SO4 ~ ~~zt Bu PBr3 Br~
~0 H II)PCC 0 pqBCO Yp2 OH ~= YOZC
/
~I ~ I I COzMe COzMe C02Me KZCO_p TFq FM5,RlR2NH 0 0 0 _ Acetone - CHZCI2 R~ N
Y0zC ~ 0 R2 0 W2H CONHOTHP ~ ' ~ CONHOH
LIOH EDC,HCI, FOBT TFA ~ /
0 0 ~-~ 0 Rj- N Rl RI-N
Ry 0 R2 0 R 0 Wherein:
R, and R2 have the same meanings as defined in formula (1) above, and Y is C ) -4 alkyl.
In step 1) of Reaction Scheme 1, --caprolactone (formula 2) is dissolved in methanol and treated with concetrated sulfuric acid to form the 1, 6-hydroxy-hexanoic acid methylester of formula 3, which is then added to a pyridinium chlorochromate solution and reacted for 2 hrs to obtain 6-oxo-hexanoic acid methylester (formula 3).
Suitable for use in this step is a solvent such as dichloromethane, tetrahydrofuran, or dichloroethane.
In step 2), a hydroxy compound (formula 4) is obtained by the Baylis-Hillman reaction carried out between a 6-oxo-hexanoic acid methylester (formula 3) and a C1_4 alkylacrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) at 0-25 C for 5-7 days, above ethyl acrylate, isobutyl acrylate, or t-butyl acrylate may be used as the alkyl acrylate.
The reaction step 3) is carried out using a bromination agent in an organic solvent. Representative examples of the organic solvent include ethylether, dichloromethane and hydrofuran, and representative examples of the bromination agent include PBr3, CBr4 and N-bromo succinic acid (NBS).
In step 4), the bromo compound (formula 5) is reacted with 1 -naphthol to obtain an alcohol compound (formula 6) using acetone or acetonitrile as a solvent in the presence of potassium carbonate, sodium bicarbonate, or sodium carbonate.
The ester hydrolysis step 5) is carried out in the presence of an inorganic or organic acid in a solvent such as dichloromethane, tetrahydrofuran or N,N' -dimethylformamide. Representative examples of the inorganic acid include hydrochloric acid, sulfuric acid and phosphoric acid and representative examples of the organic acid include trifluoroacetic acid (TFA).
Acylation step 6) is carried out using N-Methanesulfonyloxy-6-trifluoromethylbenzotriazole (FMS), N-hydroxy-6-trifluorobenzotriazole (FOBT) or 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC - HC1) as an acylation agent in an aprotic solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran or dichloromethane.
The reaction in step 7) is preferably carried out using an aqueous alcohol or tetrahydrofuran solvent, and lithium hydroxide (LiOH - H2O) or sodium hydroxide as the inorganic base.
The acylation in step 8) is carried out in an organic solvent in the presence of N-hydroxy-6-trifluorobenzotriazole (FOBT) and 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl).
Representative examples of the organic solvent include N,N'-dimethylformamide, dimethylsulfoxide, tetrahydrofuran and dichloromethane.
Removing the tetrahydropyranyl group from the compound of formula (10) in step 9) is carried out in a solvent such as methanol, ethanol, tetrahydrofuran or dichloromethane.
The starting material (formula 2) for preparing the alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) is commercially available.
The inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) efficiently inhibits the activity of histone deacetylase, resulting in the efficient suppression of the cancer-cell proliferation.
Accordingly, the present invention also provides an inhibitor of histone deacetylase activity comprising the compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
Further, the present invention provides an anti-cancer composition comprising the compound of formula (1) as an active ingredient and a pharmaceutically acceptable carrier.
The inventive pharmaceutical composition comprises the compound of formula (1) as an active ingredient in an amount ranging from 0.1 to 75 wt%, preferably 1 to 50 wt%, based on the total weight of the composition.
The pharmaceutical composition may be formulated for oral or parenteral administration. The formulation for oral administration may take various forms such as tablet, pill, powder, sachet, soft and hard capsule, solution, suspension, emulsion, syrup, granule and the like, which may contain conventional additives such as a diluent (e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine), a lubricant (e.g., silica, talc, stearic acid or its zinc, magnesium or calcium salt, and/or polyethylene glycol). A tablet form may also comprise a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methyl cellulose, sodium carboxylmethyl cellulose and/or polyvinylpyrrolidone, and optionally a disintegrant such as starch, agar, alginic acid or its sodium salt, an effervescent mixture, an absorbent, a colorant, a flavor and a sweetener. For parenteral administration, sterile injectable formulations such as istonic solution and suspension may be preferred.
The composition may be steriled, additionally include preservatives, stabilizers, wetting agents, emulsifying agents, osmotic pressure-adjusting agents, buffering agents and the like, and may be formulated through a conventional mixing, granulating or coating procedures.
A typical daily dose of the compound of formula (1) ranges from about 2.5 to 100 mg/kg, preferably 5 to 60 mg/kg for mammals including a human subject, and can be orally or parenterally administered in a single dose or in divided doses.
The present invention is further described and illustrated in Examples provided below, which are, however, not intended to limit the scope of the present invention.
EXAMPLE
Preparation Example 1: 6-hydroxy-hexaenoic acid methyl ester c-Caprolactone (12.50 g, 109.51 mM) was dissolved in methanol (125 ml), a sulfuric acid solution (1 ml, 0.01 mM) was slowly added thereto, and the mixture was stirred at room temperature for 2 days. After the completion of the reaction, methanol was removed under a reduced pressure and ice water was poured thereinto. The resulting mixture was extracted with ethyl ether and the isolated organic layer was washed with saturated sodium bicarbonate and salt water in order. The resulting residue was subjected to column chromatography (ethyl acetic acid/n-hexane= 1/2) to obtain 10.18 g of the title compound (yield: 64%).
1H NMR (200 MHz, CDC13) 5 1.23 (m, 2H, CHZ), 1.33-1.42 (m, 4H, CH2CH2), 1.44-1.74 (t, 4H, CH2CH2), 3.66 (s, 3H, OCH3).
Preparation Example 2: 6-oxo-hexaenoic acid methyl ester (formula 3) Pyridinium chlorochromate (16.27 g, 75.48 mM) was dissolved in dichloromethane (140 ml), 6-hydroxy-hexaenoic acid methyl ester (10.03 g, 68.61 mM) obtained in Preparation Example 1 in dichloromethane (20 ml) was added dropwise thereto for 30 min, and the mixture was stirred at 25-30 C for 2 hrs. After the completion of the reaction, the reaction mixture was diluted with ethyl ether, and filtered. The filtrate was distilled under a reduced pressure, concentrated and subjected to column chromatography (ethyl acetic acid/n-hexane= 1/4), to obtain 5.77 g of the title compound (yield: 59%).
'H NMR (200 MHz, CDC13) 5 1.66 (m, 4H, CH2CH2), 2.33 (m, 2H, CH2), 2.46 (m, 2H, CH2), 3.66 (s, 3H, OCH3), 9.74 (S, 1H, CH).
Preparation Example 3: 3-hydroxy-2-methylene-dinonanoic acid 1-t-butyl ester 9-methylester (formula 4) 6-Oxo-hexaenoic acid methyl ester(20 g, 168.72 mM) obtained in Preparation Example 2 was dissolved in the mixture of water and dioxane (1:1) (100 mL), acrylic t-butyl ester (60.96 ml, 461.17 mM) was added thereto, and 1,4-diazabicyclo[2.2.2]octane (DABCO) (15.56 g, 138.72 mM) in the mixture of water and dioxane (1:1) (63 mL) were sequentially added thereto, and the mixture was stirred for 7 days. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl ether. The extract was washed with 2 N hydrochloric acid, saturated sodium bicarbonate and salt water in order, dried, concentrated under a reduced pressure and subjected to column chromatography (ethyl acetic acid/n-hexane= 1/9), to obtain 21.7 g of the title compound (yield: 57%).
'H NMR (200 MHz, CDC13) 6 1.46 (m, 2H, CHZ), 1.47 (S, 9H, 3CH3), 1.62 (m, 4H, CH2CH2), 2.96 (m, 4H, CH2CH2), 3.64 (s, 3H, OCH3), 5.67 (s, 1H, CH), 6.09 (s, 1H, CH).
Preparation Example 4: 2-bromomethyl-2-dioctene acid 1-t-butyl ester 8-methyl ester (formula 5) 3-Hydroxy-2-methylene-dinonanoic acid 1-t-butyl ester 9-methyl ester (10,40 g, 38.20 mM) obtained in Preparation Example 3 was dissolved in ethyl ether (100 ml) and cooled to 0 C . Then, PBr3 (3.93 ml, 42.02 mM) was slowly added thereto and stirred at room temperature for 1 hr. After the completion of the reaction, the reaction mixture was cooled to -10'C by pouring ice water, then extracted with ethyl ether. The extract was washed with salt water, dried over MgSO4 and filtered. The solvent was removed under a reduced pressure and subjected to silica gel column chromatography (ethyl acetic acid/n-hexane = 1/9), to obtain 6.30 g of the title compound (yield: 49%).
'H NMR (200 MHz, CDC13) 5 1.50 (s, 9H, CH3), 1.65 (m, 4H, CH2), 2.30 (m, 4H, CH2), 3.66 (s, 3H, OCH3), 4.27 (s, 2H, CHZ), 6.82 (m, 1H, CH).
Preparation Example 5: 2-(naphthalen-1-yloxymethyl)-2-dioctene acid 1-t-butyl ester 8-methylester (formula 6) 2-Bromomethyl-2-dioctene acid 1-t-butyl ester 8-methylester (11.2 g 33.41 mM) obtained in Preparation Example 4 was dissolved in acetone(50 ml), potassium carbonate (6.93 g 50.11 mM) and 1-naphthol(5.30 g 36.75 mM) were added thereto, and the mixture was boiled for 3 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 1/15) to obtain 11.5 g of the title compound as a white solid (yield: 86%).
'H NMR (200 MHz, CDC13) b 1.45 (s, 9H, CH3), 1.65 (m, 4H, CHZ), 2.30 (m, 4H, CH2), 3.62 (s, 3H, OCH3), 4.80 (s, 2H, CH2), 6.64 (m, 1H, ArH), 6.98 (m, 1 H, CH), 7.40 (m, 4H, ArH), 7.77 (m, 1 H, ArH), 8.19 (m, 1 H, ArH).
Preparation Example 6: 2-(naphthalen-1-yloxymethyl)-2-dioctene aicd 8-methylester (formula 7) 2-(Naphthalen-1-yloxymethyl)-2-dioctene acid 1-t-butyl ester 8-methylester (5.00 g, 12.55 mM) obtained in Preparation Example 5 was dissolved in dichloromethane (60 ml), trifluoroacetic acid (6.77 ml, 87.83 mM) was slowly added thereto at 0 C, and the mixture was reacted at room temperature for 7 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 1/4) to obtain 2.08 g of the title compound (yield: 48%).
'H NMR (200 MHz, CDC13) 5 1.46 (m, 2H, CH2), 1.59 (m, 2H, CH2), 2.26 (t, 2H, J = 7.1 Hz, CH2), 2.43 (q, 2H, J = 14.9, 7.5 Hz, CH2), 3.62 (s, 3H, OCH3), 4.94 (s, 2H, CH2), 6.89 (d, 1 H, J= 7.3 Hz, CH), 7.27-7.47 (m, 5H, ArH), 7.80 (dd, 1H, J = 7.3, 1.7 Hz, ArH), 8.20 (t, 1H, J= 7.1, 1.7 Hz, ArH).
The amine compound (R1R2NH or R2NH2) for preparing the compound of formula 8 is commercially available, or can be readily synthesized by the conventional method.
Substituted pyrrolidine and piperidine may be synthesized as described in the Reaction Scheme B.
Reaction Scheme B
NaOH(aq) Ph\_N~ t-Boc20 Ph 0~ Pd / C, H2 0~0 NHZ ~N~NH HN~NH
Method A: RCHO or RCOR
AcOH, NaCNBH3 0~\ 0 TFA
Method B RI or RBr, K2CO3 R-ND-NH
Ph / NaOH(aq) 0\\ ~ Pd / C, H2 O\\ ~
\--N' )-NHZ t-Boc2O Ph / \ I-O /~ J-0 v '-N, j-NH HN~ rNH
16 17 ~/ 18 Method A: RCHO or RCOR
AcOH, NaCNBH3 OO TFA Q /~
R-NrNHz 10 Method B: RI or RBr, K2C03 R-N, }-NH Method C : RCOCI, TEA ~~//
Wherein:
R is C1_3 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1_3 alkyl, benzyl, or C3_ 8 cycloalkyl carbonyl.
And procedures for preparation of the amine compounds are illustrated below.
Preparation Example I: t-butyl 1-benzylpiperidin-4-ylcarbamate (formula 12) 1-Benzylpiperidine-4-amine (3g, 15.8mml), the starting material, was dissolved in 1M aqueous sodium hydroxide solution (35.8 ml) and t-butanol (32 ml) in the 250 ml reaction vessel, t-butyl dicarbonate ((t-Boc)20; 3.79 g, 17.38 mmol) was added thereto while stirring, and the mixture was reacted for 12 hrs. After the completion of the reaction, the reaction mixture was extracted with ethyl ether 2 times. The extract was washed with 0.1N
hydrochloric acid solution and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 3.80 g of the title compound as a white solid (yield: 82.8%).
IH -NMR (200 MHz, CDC13) b 1.38 (s, 9H), 1.86-2.33 (m, 4H), 2.70 (m, 2H), 3.40 (m, 2H), 3.57 (br, 1H), 4.12 (s, 2H), 7.43 (m, 3H), 7.55 (m, 2H).
LC/MS (M+H): 291.
Preparation Example II: t-butyl piperidin-4-ylcarbamate (formula 13) t-Butyl-l-benzylpiperidin-4-ylcarbamate (3.80 g, 13.1 mmol) obtained in Preparation Example I was dissolved in 26 ml of methanol in the 100 ml reaction vessel, catalytic quantities of 10% active palladium/carbon was added thereto, and reacted under the hydrogen for 12 hrs. After the completion of the reaction, the reduction mixture was filtered through a cellite pad to remove palladium/carbon and the solvent was removed under a reduced pressure. Then, the mixture was subjected to silica gel column chromatography to obtain 2.64 g of the title compound (yield: 99%).
'H-NMR (200 MHz, CD3OD) b 1.36 (s, 9H), 1.84-2.36 (m, 4H), 2.74 (m, 2H), 3.42 (m, 2H), 3.60 (br, 1 H).
LC/MS (M+H): 201.
Preparation Example III: t-butyl 1 -R-piperidin-4-ylcarbam ate (formula 14) (111-1) t-butyl 1-isopropylpiperidin-4-ylcarbamate (14a) Method A: t-butyl piperidin-4-ylcarbamate (3 g, 15 mmol) obtained in Preparation Example II was dissolved in methanol (30m1) in the 100 ml reaction vessel, acetone (7.70 ml, 105 mmol) and acetic acid (0.45 ml, 7.5 mmol) were added thereto while stirring, 4 portions of NaCNBH3 (1.88 mg, 30 mmol) were added dropwise and reacted for 18 hrs. After the completion of the reaction, ice water was poured thereinto and then the mixture was stirred and extracted with ethyl ether. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 2.644 g of title compound as a white solid (yield: 73.3 %).
'H -NMR (200 MHz, CDC13) S 1.36 (d, J = 7.0 Hz, 6H), 1.44 (s, 9H), 2.00 (m, 2H), 2.17 (m, 2H), 2.94 (m, 2H), 3.3 8(m, 3H), 3.69 (m, 1 H), 4.92 (br, 1 H).
LC/MS (M+H): 243.
(111-2) t-butyl 1-cyclopropylpiperidin-4-ylcarbamate (14b) The procedure of Preparation Example (III-1) was repeated except for using bromocyclopropane instead of acetone as the amine substituent to obtain 0.72 g of the title compound as pale yellow oil (yield: 60%).
'H -NMR (200 MHz, CDC13) S 0.44 (m, 4H), 1.31 (m, 2H), 1.47 (s, 9H), 1.58 (m, 1 H), 1.90 (m, 2H), 2.29 (m, 2H), 2.94 (m, 2H), 3.49 (br, 1 H), 4.42 (br, 1 H).
LC/MS (M+H): 241.
(111-3) t-butyl 1-cyclopentylpiperidin-4-ylcarbamate (14c) The procedure of Preparation Example (111-1) was repeated except for using bromocyclophentane instead of acetone as the amine substituent to obtain 1.16 g of the title compound as pale yellow oil (yield: 86%).
'H-NMR (200 MHz, CDC13) S 1.45 (s, 9H), 1.50-1.80 (m, 8H), 1.81-2.18 (m, 6H), 2.50 (m, 1H), 2.94 (m, 2H), 3.48 (br, 1H), 4.41 (br, 1H).
LC/MS (M+H): 269.
(111-4) t-butyl 1-methylpiperidin-4-ylcarbamate (14d) The procedure of Preparation Example (111-1) was repeated except for using iodomethane instead of acetone as the amine substituent to obtain 1.43 g of the title compound as pale yellow oil (yield: 79.4%).
'H-NMR (200 MHz, CDC13) 8 1.44 (s, 9H), 1.45 (m, 2H), 1.92 (m, 2H), 2.07 (m, 2H), 2.27 (s, 3H), 2.74 (m, 2H), 3.44 (br, 1H), 4.43 (br, 1H).
LC/MS (M+H): 215.
(111-5) t-butyl 1-ethylpiperidin-4-ylcarbamate (14e) Method B: t-butyl piperidin-4-ylcarbamate (1.5 g, 7.49 mmol) obtained in Preparation Example II was dissolved in N,N-dimethylformamide (19 ml) in the 25 ml reaction vessel, K2CO3 (2.07 g, 14.98 mmol, 2 eq.) and iodoethane (0.60 ml, 7.49 mmol, 1 eq.) were added thereto while stirring, heated from 0 C to room temperature and kept for 4 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with ethyl ester. The organic layer was washed with saturated sodium bicarbonate and salt water in order, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.34 g of the title compound as pale yellow oil (yield: 78%).
'H-NMR (200 MHz, CDC13) b 1.10 (t, J = 7.4 Hz, 3H), 1.43 (m, 2H), 1.47 (s, 9H), 1.99 (m, 4H), 2.40 (q, J = 7.2 Hz, 2H), 2.85 (m, 2H), 3.47 (br, 1H), 4.43 (br, 1 H).
LC/MS (M+H): 229.
Preparation Example IV: 1-R-piperidin-4-amine (formula 15) (IV-1) 1- isopropylpiperidin-4-amine (15a) The compound (14a) obtained in Preparation Example (III-1) (1.5 g, 7.49 mmol) was dissolved in methanol (20 ml) in the 250 ml reaction vessel, trifluoro acetic acid (4.06 ml, 54.5 mmol, 5 eq.) was added dropwise thereto while stirring, and kept for 18 hrs. After the completion of the reaction, the mixture was concentrated under a reduced pressure, and then subjected to azeotropic distillation with CHC13 3 times. The reaction mixture was basified with aqueous KOH solution (20 ml) and extracted with CHC13 3 times. The extract was washed with salt water, dried, filtered and distilled under a reduced pressure, to obtain 1.23 g of the title compound as yellow oil (yield: 79.3%).
'H-NMR (200 MHz, CDC13) 8 1.02 (d, J = 6.6 Hz, 6H), 1.38 (m, 2H), 1.56 (br, 2H), 1.80 (d, J = 11.8 Hz, 2H), 2.17 (m, 2H), 2.71 (m, 2H), 2.80 (m, 2H).
LC/MS (M+H): 143.
(IV-2) 1-cyclopropylpiperidin-4-amine (15b) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-2) as the starting material, to obtain 286 mg of the title compound as pale yellow oil (yield:
75%).
'H-NMR (200 MHz, CDC13) b 0.44 (m, 4H), 1.33 (m, 2H), 1.52 (m, 1H), 1.76 (m, 2H), 2.20 (m, 2H), 2.66 (m, 1 H), 3.00 (m, 2H).
LC/MS (M+H): 141.
(IV-3) 1-cyclopentylpiperidin-4-amine (15c) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-3) as the starting material, to obtain 689 mg of the title compound as pale yellow oil (yield:
95%).
'H-NMR (200 MHz, CDC13) S 1.50-1.80 (m, 8H), 1.81-2.18 (m, 6H), 2.50 (m, 2H), 2.74 (m, 2H).
LC/MS (M+H): 169.
(IV-4) 1-methylpiperidin-4-amine (15d) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-4) as the starting material, to obtain 820 mg of the title compound as pale yellow oil (yield:
86%).
'H-NMR (200 MHz, CDC13) 8 1.37 (m, 2H), 1.78 (m, 2H), 1.99 (m, 2H), 2.27 (s, 3H), 2.70 (m, 1H), 2.81 (m, 2H).
LC/MS (M+H): 115.
(IV-5) 1-ethylpiperidin-4-amine (15e) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-5) as the starting material, to obtain 672 mg of the title compound as pale yellow oil (yield:
89%).
'H-NMR (200 MHz, CDC13) 6 1.08 (t, J= 7.2 Hz, 3H), 1.37 (m, 2H), 1.81-2.08 (m, 4H), 2.37 (q, J = 7.2 Hz, 2H), 2.65 (m, 1H), 2.87 (m, 2H).
LC/MS (M+H): 129.
Preparation Example V: t-butyl 1-benzylpyrrolidin-3-ylcarbamate (formula 17) The starting material (10 g, 57 mmol) was dissolved in 3M aqueous sodium hydroxide solution (21 ml) and t-butanol (114 ml) in the 500 ml reaction vessel, t-butyl dicarbonate ((t-Boc)20; 13.07 g, 59.9 mmol) was added thereto while stirring, kept for 12 hrs. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate 2 times. The extract was washed with 0.1N hydrochloric acid solution and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 15.25 g of the title compound as a white solid (yield: 97%).
'H-NMR (200 MHz, CDC13) 8 1.43 (s, 9H), 2.27 (m, 2H), 2.57 (m, 3H), 2.75 (m, 1H), 3.59 (s, 2H), 4.16 (br, 1H), 4.85 (br, 1H), 7.30 (m, 5H).
LC/MS (M+H): 277.
Preparation Example VI: t-butyl pyrrolidin-3-ylcarbamate (formula 18) The starting material (15.75 g, 57.0 mmol) was dissolved in methanol and tetrabutylfuran (4:1) (114 ml) in the 100 ml reaction vessel, catalytic quantities of 10% active palladium/carbon was added thereto, and reacted under the hydrogen for 12 hrs. After the completion of the reaction, the reduction mixture was filtered through a cellite pad to remove palladium/carbon and the solvent was removed therefrom under a reduced pressure. Then, the mixture was subjected to silica gel column chromatography to obtain 9.51 g of the title compound (yield: 99%).
'H-NMR (200 MHz, CDC13) S 1.41 (s, 9H), 2.26 (m, 2H), 2.55 (m, 3H), 2.74 (m, 1H), 4.84 (br, 1 H).
LC/MS (M+H): 187.
Preparation Example VII: t-butyl 1-R-pyrrolidin-3-ylcarbamate (formula 19) (VII-1) t-butyl 1-cyclopropylpyrrolidin-3-ylcarbamate (19a) Method A: t-butyl pyrrolidin-3-ylcarbamate(1.24 g, 6.7 mmol) was dissolved in methanol (14 ml) in the 250 ml reaction vessel, acetone (3.44 ml, 46.9 mmol) and acetic acid (0.19 ml, 3.35 mmol) were added thereto while stirring, and 4 portions of NaCNBH3 (842 mg, 13.4 mmol) were added thereto dropwise and kept for 18 hrs. After the completion of the reaction, ice water was poured thereinto and then the mixture was stirred and extracted with ethyl acetate. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 897 g of title compound as a white solid (yield: 58 %).
'H-NMR (200 MHz, CDC13) S 1.40 (d, J = 6.6 Hz, 6Hz), 1.44 (s, 9H), 2.12 (m, 1H), 2.48 (m, 1H), 3.27 (m, 1H), 3.39 (m, 3H), 3.57 (m, 1H), 4.38 (m, I H), 5.41 (m, 1H).
LC/MS (M+H): 229.
(VII-2) t-butyl 1-cyclopropylpyrrolidin-3-ylcarbamate (19b) The procedure of Preparation Example (VII-1)was repeated except for using bromocyclopropane instead of acetone as the amine substituent to obtain 7.17 g of the title compound as pale yellow oil (yield: 59%).
'H-NMR (200 MHz, CDC13) 8 0.40 (m, 4H), 1.44 (s, 9H), 1.60 (m, 2H), 2.19 (m, 1 H), 2.57 (m, 2H), 2.81 (m, 2H), 4.14 (br, 1 H), 4.80 (br, 1 H).
LC/MS (M+H): 227.
(VII-3) t-butyl 1-cyclohexylpyrrolidin-3-ylcarbamate (19c) The procedure of Preparation Example (VII-1)was repeated except for using cyclohexanone instead of acetone as the amine substituent to obtain 1.10 g of the title compound as pale yellow oil (yield: 77%).
'H-NMR (200 MHz, CDC13) 8 1.23 (m, 2H), 1.41 (m, 2H), 1.46 (s, 9H), 1.78 (m, 2H), 1.89 (m, 2H), 2.06 (m, 3H), 2.44 (m, 1 H), 2.76 (m, 1 H), 3.04 (m, 1 H), 3.24 (m, 2H), 3.49 (m, 1 H), 4.34 (m, 1 H), 5.33 (m, 1H).
LC/MS (M+H): 269.
(VII-4) t-butyl 1-ethylpyrrolidin-3-ylcarbamate (19d) Method B: The starting material (1.5 g, 8.05 mmol) was dissolved in N,N-dimethylformamide (20 ml) at 0 C in the 100 ml reaction vessel, K2CO3 (2.23 g, 16.1 mmol, 2 eq.) and iodoethane (0.64 ml, 8.05 mmol, 1 eq.) were added thereto while stirring, heated from 0 C to room temperature, and kept for 12 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with ethyl ester.
The extract was washed with saturated sodium bicarbonate and salt water in order. The resulting organic layer was washed with saturated sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.13 g of the title compound as pale yellow oil (yield: 66%).
'H-NMR (200 MHz, CDC13) S 1.10 (t, J= 7.4 Hz, 3H), 1.44 (s, 9H), 1.69 (m, 1 H), 2.27 (m, 2H), 2.48 (q, J= 7.0 Hz, 2H), 2.57 (m, 1 H), 2.81 (m, 1 H), 4.16 (br, 1H), 4.86 (br, 1H).
LC/MS (M+H): 215.
(VII-5) t-butyl 1-(cyclohexanecarbonyl)pyrrolidin-3-ylcarbamate (19e) Method C: The starting material (1 g, 5.4 mmol) was dissolved in dichloromethane (14 ml) at 0 C in the 50 ml reaction vessel, triethyl amine(0.83 ml, 5.94 mmol, 1.1 eq.) and cyclohexylcarbonyl chloride (0.79 ml, 5.94 mmol, 1.1 were added thereto while stirring, heated from 0 C to room temperature, and kept for 4 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with dichloromethane. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was washed with saturated sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.57 g of the title compound as pale yellow oil (yield: 98%).
'H-NMR (200 MHz, CDC13) 8 1.26 (m, 4H), 1.46 (s, 9H), 1.79 (m, 6H), 1.98 (m, 1 H), 2.08-2.49 (m, 2H), 3.39 (m, 1 H), 3.59 (m, 2H), 3.73 (m, 1H), 4.22 (m, 1H), 4.63 (m, 1 H).
LC/MS (M+H): 297.
Preparation Example VIII: 1-R- pyrrolidine-3-amine (formula 20) (VIII-1) 1- isopropyl pyrrolidine-3-amine (20a) The compound (14a) obtained in Preparation Example (VII-1) (0.90 g, 3.9 mmol) was dissolved in dichloromethane (10 ml) in the 50 ml reaction vessel, trifluoro acetic acid (1.45 ml, 1.95 mmol, 5 eq.) was slowly added thereto dropwise while stirring, followed by reacting for 18 hrs. After the completion of the reaction, the mixture was distilled and concentrated under a reduced pressure, and then subjected to azeotropic distillation with CHC13 3 times. The reaction mixture was basified with aqueous 2N potassium hydroxide solution (20 ml) and extracted with CHC13 3 times. The extract was washed with salt water, dried, filtered and distilled under a reduced pressure, to obtain 433 mg of the title compound as yellow oil (yield: 86%).
'H-NMR (200 MHz, CDC13) 8 1.38 (d, J = 6.6 Hz, 6Hz), 2.11 (m, 1H), 2.47 (m, 1 H), 3.15 (m, 1 H), 3.29 (m, 4H), 3.5 7(m, 1 H).
LC/MS (M+H): 129.
(VIII-2) 1-cyclopropyl pyrrolidine-3-amine (20b) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-2) as the starting material, to obtain 477 mg of the title compound as pale yellow oil (yield: 79%).
'H-NMR (200 MHz, CDC13) S 0.41 (m, 4H), 1.55 (m, 2H), 2.16 (m, 1H), 2.40 (m, 1 H), 2.68 (m, 1 H), 2.80 (m, 1 H), 2.93 (m, 1 H), 3.47 (m, 1 H).
LC/MS(M+H): 127.
(VIII-3) 1-cyclohexyl pyrrolidine-3-amine (20c) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-3) as the starting material, to obtain 513 mg of the title compound as pale yellow oil (yield: 74%).
'H-NMR (200 MHz, CDC13) S 1.19 (m, 4H), 1.39-1.62 (m, 4H), 1.72 (m, 1H), 1.93 (m, 3H), 2.14 (m, 1H), 2.31 (m, 1H), 2.58-2.78 (m, 2H), 2.85 (m, 1H), 3.47 (m, 1 H).
LC/MS (M+H): 169.
(VIII-4) 1-ethyl pyrrolidine-3-amine (20d) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-4) as the starting material, to obtain 477 mg of the title compound as pale yellow oil (yield: 79%).
'H-NMR (200 MHz, CDC13) S 1.13 (t, J = 7.2 Hz, 3H), 1.51 (m, 2H), 2.31 (m, 2H), 2.47 (m, 3H), 2.73 (m, 1H), 3.54 (m, 1H).
LC/MS(M+H): 115.
(VIII-5) (3-amino pyrrolidin-1-yl)(cyclohexyl)methanone (20e) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-5) as the starting material, to obtain 1.51 g of the title compound as pale yellow oil (yield: 99%).
'H-NMR (200 MHz, CDC13) S 1.26 (m, 4H), 1.79 (m, 6H), 1.98 (m, 1H), 2.08-2.49 (m, 2H), 3.39 (m, 1H), 3.59 (m, 2H), 3.73 (m, 1H).
LC/MS (M+H): 197.
Example 1: (E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy) methyl)octenediamide (formula 1) (1-1):(E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester (formula 8) 2-(Naphthalen-1-yloxymethyl)-2-dioctene acid 8-methylester (423 mg, 1.24 mM) obtained in Preparation Example 6 was dissolved in dimethylformamide (4 ml) and cooled to 0 C, followed by adding triethylamine (520 0, 3.72 mM) and N-Methanesulfonyloxy-6-trifluorobenzotriazole (418 mg, 1.49 mM), and stirring at 0 C for 30 min. A
dimethylaminehydrochloride (111 mg, 1.36 mM) was slowly added thereto, and stirred at room temperature for 1 hr. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The extract was successively washed with 1 N hydrochloric acid, sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, and filtered. The solvent was removed under a reduced pressure and resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 2/1), to obtain 437 mg of the title compound (yield:
95%).
'H NMR (300 MHz, CDC13) 8 1.46 (m, 2H, CH2), 1.59 (m, 2H, CHZ), 2.43 (q, 4H, J = 14.9, 7.5 Hz, CH2), 3.02 (s, 6H, N(CH3)2), 3.63 (s, 3H, OCH3), 4.95 (s, 2H, CHz), 5.84 (t, 1 H, J = 14.8, 6.5 Hz, CH), 6.85 (d, 1H, J= 7.4 Hz, ArH), 7.36-7.47 (m, 4H, ArH), 7.79 (t, 1H, J= 9.0, 1.4 Hz, ArH), 8.10 (t, 1H, J
8.8, 7.5 Hz, ArH).
(1-2):(E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid (formula 9) (E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester (437 mg, 1.18 mM) obtained in Example (1-1) was dissolved in 30% aqueous ethanol solution (4 ml), whereto a monohydrated sodium lithium (248 mg, 5.90 mM) and tetrahydrofuran (4 ml) were added.
The reaction mixture was stirred at room temperature for 10 min and at 50 C
for 3 hrs. After the completion of the reaction, the reaction mixture was cooled to room temperature by pouring ice water and the solvent was removed under a reduced pressure. The reaction solution was cooled to 5 C
and 2 N hydrochloric acid was added thereto to adjust its pH to 4. The resulting mixture was filtered and dried over anhydrous magnesium sulfate, to obtain 413 mg of the title compound as a white solid (yield: 99%).
(1-3):(E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy)methyl) octenediamide (formula 1) (E)-8-(dimethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid (413 mg, 1.16 mM) obtained in Example (1-2) was dissolved in dimethylformamide (4 ml) and cooled to 0 C , whereto triethylamine (240 L, 1.74 mM) and N-methanesulfonyloxy-6-trifluorobenzotriazole (391 mg, 1.39 mM) were added, followed by stirring for 20 min. And then, N-t-butyldimethylsilyloxyamine (256 mg, 1.74 mM) was added thereto and stirred at room temperature for 1 hr. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The extract was successively washed with sodium bicarbonate, dried over anhydrous sodium sulfate, and filtered. The solvent was removed and resulting residue was subjected to silica gel column chromatography, to obtain 280 mg of the title compound as a white solid (yield: 65%).
'H NMR (300 MHz, MeOH-d4) S 1.46 (m, 2H, CH2)01.59 (m, 2H, CHZ), 2.43 (q, 4H, J = 14.9, 7.4 Hz, CHZ), 3.02 (s, 6H, N(CH3)2), 4.94 (s, 2H, CH2), 5.84 (t, 1H, J = 14.8, 6.5 Hz, CH), 6.85 (d, 1H, J = 7.4 Hz, ArH), 7.36-7.47 (m, 4H, ArH), 7.79 (d, 1 H, J = 7.4 Hz, ArH), 8.10 (d, 1 H, J= 7.4 Hz, ArH).
Example 2:(E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (2-1):(E)-8-(2-(dimethylamino)ethylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(dimethylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 428 mg of the title compound (yield: 86%).
'H NMR (300 MHz, CDC13) S 1.51 (m, 2H, CHZ), 1.63 (m, 2H, CH2)02.03 (s, 6H, N(CH3)2), 2.23 (m, 4H, CH2CH2), 2.38 (m, 2H, CH2), 2.37 (q, 1H, J =
11.1, 5.7 Hz, CH2), 3.62 (s, 3H, OCH3), 4.92 (s, 2H, CHZ), 6.85 (t, 1H, J =
A typical daily dose of the compound of formula (1) ranges from about 2.5 to 100 mg/kg, preferably 5 to 60 mg/kg for mammals including a human subject, and can be orally or parenterally administered in a single dose or in divided doses.
The present invention is further described and illustrated in Examples provided below, which are, however, not intended to limit the scope of the present invention.
EXAMPLE
Preparation Example 1: 6-hydroxy-hexaenoic acid methyl ester c-Caprolactone (12.50 g, 109.51 mM) was dissolved in methanol (125 ml), a sulfuric acid solution (1 ml, 0.01 mM) was slowly added thereto, and the mixture was stirred at room temperature for 2 days. After the completion of the reaction, methanol was removed under a reduced pressure and ice water was poured thereinto. The resulting mixture was extracted with ethyl ether and the isolated organic layer was washed with saturated sodium bicarbonate and salt water in order. The resulting residue was subjected to column chromatography (ethyl acetic acid/n-hexane= 1/2) to obtain 10.18 g of the title compound (yield: 64%).
1H NMR (200 MHz, CDC13) 5 1.23 (m, 2H, CHZ), 1.33-1.42 (m, 4H, CH2CH2), 1.44-1.74 (t, 4H, CH2CH2), 3.66 (s, 3H, OCH3).
Preparation Example 2: 6-oxo-hexaenoic acid methyl ester (formula 3) Pyridinium chlorochromate (16.27 g, 75.48 mM) was dissolved in dichloromethane (140 ml), 6-hydroxy-hexaenoic acid methyl ester (10.03 g, 68.61 mM) obtained in Preparation Example 1 in dichloromethane (20 ml) was added dropwise thereto for 30 min, and the mixture was stirred at 25-30 C for 2 hrs. After the completion of the reaction, the reaction mixture was diluted with ethyl ether, and filtered. The filtrate was distilled under a reduced pressure, concentrated and subjected to column chromatography (ethyl acetic acid/n-hexane= 1/4), to obtain 5.77 g of the title compound (yield: 59%).
'H NMR (200 MHz, CDC13) 5 1.66 (m, 4H, CH2CH2), 2.33 (m, 2H, CH2), 2.46 (m, 2H, CH2), 3.66 (s, 3H, OCH3), 9.74 (S, 1H, CH).
Preparation Example 3: 3-hydroxy-2-methylene-dinonanoic acid 1-t-butyl ester 9-methylester (formula 4) 6-Oxo-hexaenoic acid methyl ester(20 g, 168.72 mM) obtained in Preparation Example 2 was dissolved in the mixture of water and dioxane (1:1) (100 mL), acrylic t-butyl ester (60.96 ml, 461.17 mM) was added thereto, and 1,4-diazabicyclo[2.2.2]octane (DABCO) (15.56 g, 138.72 mM) in the mixture of water and dioxane (1:1) (63 mL) were sequentially added thereto, and the mixture was stirred for 7 days. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl ether. The extract was washed with 2 N hydrochloric acid, saturated sodium bicarbonate and salt water in order, dried, concentrated under a reduced pressure and subjected to column chromatography (ethyl acetic acid/n-hexane= 1/9), to obtain 21.7 g of the title compound (yield: 57%).
'H NMR (200 MHz, CDC13) 6 1.46 (m, 2H, CHZ), 1.47 (S, 9H, 3CH3), 1.62 (m, 4H, CH2CH2), 2.96 (m, 4H, CH2CH2), 3.64 (s, 3H, OCH3), 5.67 (s, 1H, CH), 6.09 (s, 1H, CH).
Preparation Example 4: 2-bromomethyl-2-dioctene acid 1-t-butyl ester 8-methyl ester (formula 5) 3-Hydroxy-2-methylene-dinonanoic acid 1-t-butyl ester 9-methyl ester (10,40 g, 38.20 mM) obtained in Preparation Example 3 was dissolved in ethyl ether (100 ml) and cooled to 0 C . Then, PBr3 (3.93 ml, 42.02 mM) was slowly added thereto and stirred at room temperature for 1 hr. After the completion of the reaction, the reaction mixture was cooled to -10'C by pouring ice water, then extracted with ethyl ether. The extract was washed with salt water, dried over MgSO4 and filtered. The solvent was removed under a reduced pressure and subjected to silica gel column chromatography (ethyl acetic acid/n-hexane = 1/9), to obtain 6.30 g of the title compound (yield: 49%).
'H NMR (200 MHz, CDC13) 5 1.50 (s, 9H, CH3), 1.65 (m, 4H, CH2), 2.30 (m, 4H, CH2), 3.66 (s, 3H, OCH3), 4.27 (s, 2H, CHZ), 6.82 (m, 1H, CH).
Preparation Example 5: 2-(naphthalen-1-yloxymethyl)-2-dioctene acid 1-t-butyl ester 8-methylester (formula 6) 2-Bromomethyl-2-dioctene acid 1-t-butyl ester 8-methylester (11.2 g 33.41 mM) obtained in Preparation Example 4 was dissolved in acetone(50 ml), potassium carbonate (6.93 g 50.11 mM) and 1-naphthol(5.30 g 36.75 mM) were added thereto, and the mixture was boiled for 3 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 1/15) to obtain 11.5 g of the title compound as a white solid (yield: 86%).
'H NMR (200 MHz, CDC13) b 1.45 (s, 9H, CH3), 1.65 (m, 4H, CHZ), 2.30 (m, 4H, CH2), 3.62 (s, 3H, OCH3), 4.80 (s, 2H, CH2), 6.64 (m, 1H, ArH), 6.98 (m, 1 H, CH), 7.40 (m, 4H, ArH), 7.77 (m, 1 H, ArH), 8.19 (m, 1 H, ArH).
Preparation Example 6: 2-(naphthalen-1-yloxymethyl)-2-dioctene aicd 8-methylester (formula 7) 2-(Naphthalen-1-yloxymethyl)-2-dioctene acid 1-t-butyl ester 8-methylester (5.00 g, 12.55 mM) obtained in Preparation Example 5 was dissolved in dichloromethane (60 ml), trifluoroacetic acid (6.77 ml, 87.83 mM) was slowly added thereto at 0 C, and the mixture was reacted at room temperature for 7 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 1/4) to obtain 2.08 g of the title compound (yield: 48%).
'H NMR (200 MHz, CDC13) 5 1.46 (m, 2H, CH2), 1.59 (m, 2H, CH2), 2.26 (t, 2H, J = 7.1 Hz, CH2), 2.43 (q, 2H, J = 14.9, 7.5 Hz, CH2), 3.62 (s, 3H, OCH3), 4.94 (s, 2H, CH2), 6.89 (d, 1 H, J= 7.3 Hz, CH), 7.27-7.47 (m, 5H, ArH), 7.80 (dd, 1H, J = 7.3, 1.7 Hz, ArH), 8.20 (t, 1H, J= 7.1, 1.7 Hz, ArH).
The amine compound (R1R2NH or R2NH2) for preparing the compound of formula 8 is commercially available, or can be readily synthesized by the conventional method.
Substituted pyrrolidine and piperidine may be synthesized as described in the Reaction Scheme B.
Reaction Scheme B
NaOH(aq) Ph\_N~ t-Boc20 Ph 0~ Pd / C, H2 0~0 NHZ ~N~NH HN~NH
Method A: RCHO or RCOR
AcOH, NaCNBH3 0~\ 0 TFA
Method B RI or RBr, K2CO3 R-ND-NH
Ph / NaOH(aq) 0\\ ~ Pd / C, H2 O\\ ~
\--N' )-NHZ t-Boc2O Ph / \ I-O /~ J-0 v '-N, j-NH HN~ rNH
16 17 ~/ 18 Method A: RCHO or RCOR
AcOH, NaCNBH3 OO TFA Q /~
R-NrNHz 10 Method B: RI or RBr, K2C03 R-N, }-NH Method C : RCOCI, TEA ~~//
Wherein:
R is C1_3 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1_3 alkyl, benzyl, or C3_ 8 cycloalkyl carbonyl.
And procedures for preparation of the amine compounds are illustrated below.
Preparation Example I: t-butyl 1-benzylpiperidin-4-ylcarbamate (formula 12) 1-Benzylpiperidine-4-amine (3g, 15.8mml), the starting material, was dissolved in 1M aqueous sodium hydroxide solution (35.8 ml) and t-butanol (32 ml) in the 250 ml reaction vessel, t-butyl dicarbonate ((t-Boc)20; 3.79 g, 17.38 mmol) was added thereto while stirring, and the mixture was reacted for 12 hrs. After the completion of the reaction, the reaction mixture was extracted with ethyl ether 2 times. The extract was washed with 0.1N
hydrochloric acid solution and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 3.80 g of the title compound as a white solid (yield: 82.8%).
IH -NMR (200 MHz, CDC13) b 1.38 (s, 9H), 1.86-2.33 (m, 4H), 2.70 (m, 2H), 3.40 (m, 2H), 3.57 (br, 1H), 4.12 (s, 2H), 7.43 (m, 3H), 7.55 (m, 2H).
LC/MS (M+H): 291.
Preparation Example II: t-butyl piperidin-4-ylcarbamate (formula 13) t-Butyl-l-benzylpiperidin-4-ylcarbamate (3.80 g, 13.1 mmol) obtained in Preparation Example I was dissolved in 26 ml of methanol in the 100 ml reaction vessel, catalytic quantities of 10% active palladium/carbon was added thereto, and reacted under the hydrogen for 12 hrs. After the completion of the reaction, the reduction mixture was filtered through a cellite pad to remove palladium/carbon and the solvent was removed under a reduced pressure. Then, the mixture was subjected to silica gel column chromatography to obtain 2.64 g of the title compound (yield: 99%).
'H-NMR (200 MHz, CD3OD) b 1.36 (s, 9H), 1.84-2.36 (m, 4H), 2.74 (m, 2H), 3.42 (m, 2H), 3.60 (br, 1 H).
LC/MS (M+H): 201.
Preparation Example III: t-butyl 1 -R-piperidin-4-ylcarbam ate (formula 14) (111-1) t-butyl 1-isopropylpiperidin-4-ylcarbamate (14a) Method A: t-butyl piperidin-4-ylcarbamate (3 g, 15 mmol) obtained in Preparation Example II was dissolved in methanol (30m1) in the 100 ml reaction vessel, acetone (7.70 ml, 105 mmol) and acetic acid (0.45 ml, 7.5 mmol) were added thereto while stirring, 4 portions of NaCNBH3 (1.88 mg, 30 mmol) were added dropwise and reacted for 18 hrs. After the completion of the reaction, ice water was poured thereinto and then the mixture was stirred and extracted with ethyl ether. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 2.644 g of title compound as a white solid (yield: 73.3 %).
'H -NMR (200 MHz, CDC13) S 1.36 (d, J = 7.0 Hz, 6H), 1.44 (s, 9H), 2.00 (m, 2H), 2.17 (m, 2H), 2.94 (m, 2H), 3.3 8(m, 3H), 3.69 (m, 1 H), 4.92 (br, 1 H).
LC/MS (M+H): 243.
(111-2) t-butyl 1-cyclopropylpiperidin-4-ylcarbamate (14b) The procedure of Preparation Example (III-1) was repeated except for using bromocyclopropane instead of acetone as the amine substituent to obtain 0.72 g of the title compound as pale yellow oil (yield: 60%).
'H -NMR (200 MHz, CDC13) S 0.44 (m, 4H), 1.31 (m, 2H), 1.47 (s, 9H), 1.58 (m, 1 H), 1.90 (m, 2H), 2.29 (m, 2H), 2.94 (m, 2H), 3.49 (br, 1 H), 4.42 (br, 1 H).
LC/MS (M+H): 241.
(111-3) t-butyl 1-cyclopentylpiperidin-4-ylcarbamate (14c) The procedure of Preparation Example (111-1) was repeated except for using bromocyclophentane instead of acetone as the amine substituent to obtain 1.16 g of the title compound as pale yellow oil (yield: 86%).
'H-NMR (200 MHz, CDC13) S 1.45 (s, 9H), 1.50-1.80 (m, 8H), 1.81-2.18 (m, 6H), 2.50 (m, 1H), 2.94 (m, 2H), 3.48 (br, 1H), 4.41 (br, 1H).
LC/MS (M+H): 269.
(111-4) t-butyl 1-methylpiperidin-4-ylcarbamate (14d) The procedure of Preparation Example (111-1) was repeated except for using iodomethane instead of acetone as the amine substituent to obtain 1.43 g of the title compound as pale yellow oil (yield: 79.4%).
'H-NMR (200 MHz, CDC13) 8 1.44 (s, 9H), 1.45 (m, 2H), 1.92 (m, 2H), 2.07 (m, 2H), 2.27 (s, 3H), 2.74 (m, 2H), 3.44 (br, 1H), 4.43 (br, 1H).
LC/MS (M+H): 215.
(111-5) t-butyl 1-ethylpiperidin-4-ylcarbamate (14e) Method B: t-butyl piperidin-4-ylcarbamate (1.5 g, 7.49 mmol) obtained in Preparation Example II was dissolved in N,N-dimethylformamide (19 ml) in the 25 ml reaction vessel, K2CO3 (2.07 g, 14.98 mmol, 2 eq.) and iodoethane (0.60 ml, 7.49 mmol, 1 eq.) were added thereto while stirring, heated from 0 C to room temperature and kept for 4 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with ethyl ester. The organic layer was washed with saturated sodium bicarbonate and salt water in order, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.34 g of the title compound as pale yellow oil (yield: 78%).
'H-NMR (200 MHz, CDC13) b 1.10 (t, J = 7.4 Hz, 3H), 1.43 (m, 2H), 1.47 (s, 9H), 1.99 (m, 4H), 2.40 (q, J = 7.2 Hz, 2H), 2.85 (m, 2H), 3.47 (br, 1H), 4.43 (br, 1 H).
LC/MS (M+H): 229.
Preparation Example IV: 1-R-piperidin-4-amine (formula 15) (IV-1) 1- isopropylpiperidin-4-amine (15a) The compound (14a) obtained in Preparation Example (III-1) (1.5 g, 7.49 mmol) was dissolved in methanol (20 ml) in the 250 ml reaction vessel, trifluoro acetic acid (4.06 ml, 54.5 mmol, 5 eq.) was added dropwise thereto while stirring, and kept for 18 hrs. After the completion of the reaction, the mixture was concentrated under a reduced pressure, and then subjected to azeotropic distillation with CHC13 3 times. The reaction mixture was basified with aqueous KOH solution (20 ml) and extracted with CHC13 3 times. The extract was washed with salt water, dried, filtered and distilled under a reduced pressure, to obtain 1.23 g of the title compound as yellow oil (yield: 79.3%).
'H-NMR (200 MHz, CDC13) 8 1.02 (d, J = 6.6 Hz, 6H), 1.38 (m, 2H), 1.56 (br, 2H), 1.80 (d, J = 11.8 Hz, 2H), 2.17 (m, 2H), 2.71 (m, 2H), 2.80 (m, 2H).
LC/MS (M+H): 143.
(IV-2) 1-cyclopropylpiperidin-4-amine (15b) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-2) as the starting material, to obtain 286 mg of the title compound as pale yellow oil (yield:
75%).
'H-NMR (200 MHz, CDC13) b 0.44 (m, 4H), 1.33 (m, 2H), 1.52 (m, 1H), 1.76 (m, 2H), 2.20 (m, 2H), 2.66 (m, 1 H), 3.00 (m, 2H).
LC/MS (M+H): 141.
(IV-3) 1-cyclopentylpiperidin-4-amine (15c) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-3) as the starting material, to obtain 689 mg of the title compound as pale yellow oil (yield:
95%).
'H-NMR (200 MHz, CDC13) S 1.50-1.80 (m, 8H), 1.81-2.18 (m, 6H), 2.50 (m, 2H), 2.74 (m, 2H).
LC/MS (M+H): 169.
(IV-4) 1-methylpiperidin-4-amine (15d) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-4) as the starting material, to obtain 820 mg of the title compound as pale yellow oil (yield:
86%).
'H-NMR (200 MHz, CDC13) 8 1.37 (m, 2H), 1.78 (m, 2H), 1.99 (m, 2H), 2.27 (s, 3H), 2.70 (m, 1H), 2.81 (m, 2H).
LC/MS (M+H): 115.
(IV-5) 1-ethylpiperidin-4-amine (15e) The procedure of Preparation Example (IV-1) was repeated except for using the compound obtained in Preparation Example (111-5) as the starting material, to obtain 672 mg of the title compound as pale yellow oil (yield:
89%).
'H-NMR (200 MHz, CDC13) 6 1.08 (t, J= 7.2 Hz, 3H), 1.37 (m, 2H), 1.81-2.08 (m, 4H), 2.37 (q, J = 7.2 Hz, 2H), 2.65 (m, 1H), 2.87 (m, 2H).
LC/MS (M+H): 129.
Preparation Example V: t-butyl 1-benzylpyrrolidin-3-ylcarbamate (formula 17) The starting material (10 g, 57 mmol) was dissolved in 3M aqueous sodium hydroxide solution (21 ml) and t-butanol (114 ml) in the 500 ml reaction vessel, t-butyl dicarbonate ((t-Boc)20; 13.07 g, 59.9 mmol) was added thereto while stirring, kept for 12 hrs. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate 2 times. The extract was washed with 0.1N hydrochloric acid solution and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 15.25 g of the title compound as a white solid (yield: 97%).
'H-NMR (200 MHz, CDC13) 8 1.43 (s, 9H), 2.27 (m, 2H), 2.57 (m, 3H), 2.75 (m, 1H), 3.59 (s, 2H), 4.16 (br, 1H), 4.85 (br, 1H), 7.30 (m, 5H).
LC/MS (M+H): 277.
Preparation Example VI: t-butyl pyrrolidin-3-ylcarbamate (formula 18) The starting material (15.75 g, 57.0 mmol) was dissolved in methanol and tetrabutylfuran (4:1) (114 ml) in the 100 ml reaction vessel, catalytic quantities of 10% active palladium/carbon was added thereto, and reacted under the hydrogen for 12 hrs. After the completion of the reaction, the reduction mixture was filtered through a cellite pad to remove palladium/carbon and the solvent was removed therefrom under a reduced pressure. Then, the mixture was subjected to silica gel column chromatography to obtain 9.51 g of the title compound (yield: 99%).
'H-NMR (200 MHz, CDC13) S 1.41 (s, 9H), 2.26 (m, 2H), 2.55 (m, 3H), 2.74 (m, 1H), 4.84 (br, 1 H).
LC/MS (M+H): 187.
Preparation Example VII: t-butyl 1-R-pyrrolidin-3-ylcarbamate (formula 19) (VII-1) t-butyl 1-cyclopropylpyrrolidin-3-ylcarbamate (19a) Method A: t-butyl pyrrolidin-3-ylcarbamate(1.24 g, 6.7 mmol) was dissolved in methanol (14 ml) in the 250 ml reaction vessel, acetone (3.44 ml, 46.9 mmol) and acetic acid (0.19 ml, 3.35 mmol) were added thereto while stirring, and 4 portions of NaCNBH3 (842 mg, 13.4 mmol) were added thereto dropwise and kept for 18 hrs. After the completion of the reaction, ice water was poured thereinto and then the mixture was stirred and extracted with ethyl acetate. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was dried over anhydrous sodium sulfate, filtered, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 897 g of title compound as a white solid (yield: 58 %).
'H-NMR (200 MHz, CDC13) S 1.40 (d, J = 6.6 Hz, 6Hz), 1.44 (s, 9H), 2.12 (m, 1H), 2.48 (m, 1H), 3.27 (m, 1H), 3.39 (m, 3H), 3.57 (m, 1H), 4.38 (m, I H), 5.41 (m, 1H).
LC/MS (M+H): 229.
(VII-2) t-butyl 1-cyclopropylpyrrolidin-3-ylcarbamate (19b) The procedure of Preparation Example (VII-1)was repeated except for using bromocyclopropane instead of acetone as the amine substituent to obtain 7.17 g of the title compound as pale yellow oil (yield: 59%).
'H-NMR (200 MHz, CDC13) 8 0.40 (m, 4H), 1.44 (s, 9H), 1.60 (m, 2H), 2.19 (m, 1 H), 2.57 (m, 2H), 2.81 (m, 2H), 4.14 (br, 1 H), 4.80 (br, 1 H).
LC/MS (M+H): 227.
(VII-3) t-butyl 1-cyclohexylpyrrolidin-3-ylcarbamate (19c) The procedure of Preparation Example (VII-1)was repeated except for using cyclohexanone instead of acetone as the amine substituent to obtain 1.10 g of the title compound as pale yellow oil (yield: 77%).
'H-NMR (200 MHz, CDC13) 8 1.23 (m, 2H), 1.41 (m, 2H), 1.46 (s, 9H), 1.78 (m, 2H), 1.89 (m, 2H), 2.06 (m, 3H), 2.44 (m, 1 H), 2.76 (m, 1 H), 3.04 (m, 1 H), 3.24 (m, 2H), 3.49 (m, 1 H), 4.34 (m, 1 H), 5.33 (m, 1H).
LC/MS (M+H): 269.
(VII-4) t-butyl 1-ethylpyrrolidin-3-ylcarbamate (19d) Method B: The starting material (1.5 g, 8.05 mmol) was dissolved in N,N-dimethylformamide (20 ml) at 0 C in the 100 ml reaction vessel, K2CO3 (2.23 g, 16.1 mmol, 2 eq.) and iodoethane (0.64 ml, 8.05 mmol, 1 eq.) were added thereto while stirring, heated from 0 C to room temperature, and kept for 12 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with ethyl ester.
The extract was washed with saturated sodium bicarbonate and salt water in order. The resulting organic layer was washed with saturated sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.13 g of the title compound as pale yellow oil (yield: 66%).
'H-NMR (200 MHz, CDC13) S 1.10 (t, J= 7.4 Hz, 3H), 1.44 (s, 9H), 1.69 (m, 1 H), 2.27 (m, 2H), 2.48 (q, J= 7.0 Hz, 2H), 2.57 (m, 1 H), 2.81 (m, 1 H), 4.16 (br, 1H), 4.86 (br, 1H).
LC/MS (M+H): 215.
(VII-5) t-butyl 1-(cyclohexanecarbonyl)pyrrolidin-3-ylcarbamate (19e) Method C: The starting material (1 g, 5.4 mmol) was dissolved in dichloromethane (14 ml) at 0 C in the 50 ml reaction vessel, triethyl amine(0.83 ml, 5.94 mmol, 1.1 eq.) and cyclohexylcarbonyl chloride (0.79 ml, 5.94 mmol, 1.1 were added thereto while stirring, heated from 0 C to room temperature, and kept for 4 hrs. After the completion of the reaction, the solvent was distilled under a reduced pressure and the remaining was extracted with dichloromethane. The extract was washed with sodium bicarbonate and salt water in order. The resulting organic layer was washed with saturated sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, concentrated under a reduced pressure and then subjected to silica gel column chromatography to obtain 1.57 g of the title compound as pale yellow oil (yield: 98%).
'H-NMR (200 MHz, CDC13) 8 1.26 (m, 4H), 1.46 (s, 9H), 1.79 (m, 6H), 1.98 (m, 1 H), 2.08-2.49 (m, 2H), 3.39 (m, 1 H), 3.59 (m, 2H), 3.73 (m, 1H), 4.22 (m, 1H), 4.63 (m, 1 H).
LC/MS (M+H): 297.
Preparation Example VIII: 1-R- pyrrolidine-3-amine (formula 20) (VIII-1) 1- isopropyl pyrrolidine-3-amine (20a) The compound (14a) obtained in Preparation Example (VII-1) (0.90 g, 3.9 mmol) was dissolved in dichloromethane (10 ml) in the 50 ml reaction vessel, trifluoro acetic acid (1.45 ml, 1.95 mmol, 5 eq.) was slowly added thereto dropwise while stirring, followed by reacting for 18 hrs. After the completion of the reaction, the mixture was distilled and concentrated under a reduced pressure, and then subjected to azeotropic distillation with CHC13 3 times. The reaction mixture was basified with aqueous 2N potassium hydroxide solution (20 ml) and extracted with CHC13 3 times. The extract was washed with salt water, dried, filtered and distilled under a reduced pressure, to obtain 433 mg of the title compound as yellow oil (yield: 86%).
'H-NMR (200 MHz, CDC13) 8 1.38 (d, J = 6.6 Hz, 6Hz), 2.11 (m, 1H), 2.47 (m, 1 H), 3.15 (m, 1 H), 3.29 (m, 4H), 3.5 7(m, 1 H).
LC/MS (M+H): 129.
(VIII-2) 1-cyclopropyl pyrrolidine-3-amine (20b) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-2) as the starting material, to obtain 477 mg of the title compound as pale yellow oil (yield: 79%).
'H-NMR (200 MHz, CDC13) S 0.41 (m, 4H), 1.55 (m, 2H), 2.16 (m, 1H), 2.40 (m, 1 H), 2.68 (m, 1 H), 2.80 (m, 1 H), 2.93 (m, 1 H), 3.47 (m, 1 H).
LC/MS(M+H): 127.
(VIII-3) 1-cyclohexyl pyrrolidine-3-amine (20c) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-3) as the starting material, to obtain 513 mg of the title compound as pale yellow oil (yield: 74%).
'H-NMR (200 MHz, CDC13) S 1.19 (m, 4H), 1.39-1.62 (m, 4H), 1.72 (m, 1H), 1.93 (m, 3H), 2.14 (m, 1H), 2.31 (m, 1H), 2.58-2.78 (m, 2H), 2.85 (m, 1H), 3.47 (m, 1 H).
LC/MS (M+H): 169.
(VIII-4) 1-ethyl pyrrolidine-3-amine (20d) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-4) as the starting material, to obtain 477 mg of the title compound as pale yellow oil (yield: 79%).
'H-NMR (200 MHz, CDC13) S 1.13 (t, J = 7.2 Hz, 3H), 1.51 (m, 2H), 2.31 (m, 2H), 2.47 (m, 3H), 2.73 (m, 1H), 3.54 (m, 1H).
LC/MS(M+H): 115.
(VIII-5) (3-amino pyrrolidin-1-yl)(cyclohexyl)methanone (20e) The procedure of Preparation Example (VIII-1) was repeated except for using the compound obtained in Preparation Example (VII-5) as the starting material, to obtain 1.51 g of the title compound as pale yellow oil (yield: 99%).
'H-NMR (200 MHz, CDC13) S 1.26 (m, 4H), 1.79 (m, 6H), 1.98 (m, 1H), 2.08-2.49 (m, 2H), 3.39 (m, 1H), 3.59 (m, 2H), 3.73 (m, 1H).
LC/MS (M+H): 197.
Example 1: (E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy) methyl)octenediamide (formula 1) (1-1):(E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester (formula 8) 2-(Naphthalen-1-yloxymethyl)-2-dioctene acid 8-methylester (423 mg, 1.24 mM) obtained in Preparation Example 6 was dissolved in dimethylformamide (4 ml) and cooled to 0 C, followed by adding triethylamine (520 0, 3.72 mM) and N-Methanesulfonyloxy-6-trifluorobenzotriazole (418 mg, 1.49 mM), and stirring at 0 C for 30 min. A
dimethylaminehydrochloride (111 mg, 1.36 mM) was slowly added thereto, and stirred at room temperature for 1 hr. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The extract was successively washed with 1 N hydrochloric acid, sodium bicarbonate and salt water, dried over anhydrous magnesium sulfate, and filtered. The solvent was removed under a reduced pressure and resulting residue was subjected to silica gel column chromatography (ethyl acetic acid/n-hexane= 2/1), to obtain 437 mg of the title compound (yield:
95%).
'H NMR (300 MHz, CDC13) 8 1.46 (m, 2H, CH2), 1.59 (m, 2H, CHZ), 2.43 (q, 4H, J = 14.9, 7.5 Hz, CH2), 3.02 (s, 6H, N(CH3)2), 3.63 (s, 3H, OCH3), 4.95 (s, 2H, CHz), 5.84 (t, 1 H, J = 14.8, 6.5 Hz, CH), 6.85 (d, 1H, J= 7.4 Hz, ArH), 7.36-7.47 (m, 4H, ArH), 7.79 (t, 1H, J= 9.0, 1.4 Hz, ArH), 8.10 (t, 1H, J
8.8, 7.5 Hz, ArH).
(1-2):(E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid (formula 9) (E)-8-(dimethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester (437 mg, 1.18 mM) obtained in Example (1-1) was dissolved in 30% aqueous ethanol solution (4 ml), whereto a monohydrated sodium lithium (248 mg, 5.90 mM) and tetrahydrofuran (4 ml) were added.
The reaction mixture was stirred at room temperature for 10 min and at 50 C
for 3 hrs. After the completion of the reaction, the reaction mixture was cooled to room temperature by pouring ice water and the solvent was removed under a reduced pressure. The reaction solution was cooled to 5 C
and 2 N hydrochloric acid was added thereto to adjust its pH to 4. The resulting mixture was filtered and dried over anhydrous magnesium sulfate, to obtain 413 mg of the title compound as a white solid (yield: 99%).
(1-3):(E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy)methyl) octenediamide (formula 1) (E)-8-(dimethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid (413 mg, 1.16 mM) obtained in Example (1-2) was dissolved in dimethylformamide (4 ml) and cooled to 0 C , whereto triethylamine (240 L, 1.74 mM) and N-methanesulfonyloxy-6-trifluorobenzotriazole (391 mg, 1.39 mM) were added, followed by stirring for 20 min. And then, N-t-butyldimethylsilyloxyamine (256 mg, 1.74 mM) was added thereto and stirred at room temperature for 1 hr. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The extract was successively washed with sodium bicarbonate, dried over anhydrous sodium sulfate, and filtered. The solvent was removed and resulting residue was subjected to silica gel column chromatography, to obtain 280 mg of the title compound as a white solid (yield: 65%).
'H NMR (300 MHz, MeOH-d4) S 1.46 (m, 2H, CH2)01.59 (m, 2H, CHZ), 2.43 (q, 4H, J = 14.9, 7.4 Hz, CHZ), 3.02 (s, 6H, N(CH3)2), 4.94 (s, 2H, CH2), 5.84 (t, 1H, J = 14.8, 6.5 Hz, CH), 6.85 (d, 1H, J = 7.4 Hz, ArH), 7.36-7.47 (m, 4H, ArH), 7.79 (d, 1 H, J = 7.4 Hz, ArH), 8.10 (d, 1 H, J= 7.4 Hz, ArH).
Example 2:(E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (2-1):(E)-8-(2-(dimethylamino)ethylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(dimethylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 428 mg of the title compound (yield: 86%).
'H NMR (300 MHz, CDC13) S 1.51 (m, 2H, CHZ), 1.63 (m, 2H, CH2)02.03 (s, 6H, N(CH3)2), 2.23 (m, 4H, CH2CH2), 2.38 (m, 2H, CH2), 2.37 (q, 1H, J =
11.1, 5.7 Hz, CH2), 3.62 (s, 3H, OCH3), 4.92 (s, 2H, CHZ), 6.85 (t, 1H, J =
15.3, 7.6 Hz, CH), 6.91 (d, 1H, J = 7.0 Hz, ArH), 7.44 (m, 4H, ArH), 7.78 (dd, 1H, J = 6.8, 1.8 Hz, ArH), 8.20 (t, 1H, J = 9.3, 7.5 Hz, ArH).
(2-2): (E)-8-(2-(dimethylamino)ethylamino)-7-((naphthalen=l-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (2-1) as the starting material, to obtain 335 mg of the title compound (yield: 81 %).
'H NMR (300 MHz, MeOH-d4) 6 1.52 (m, 2H, CH2), 1.64 (m, 2H, CH2), 2.20 (m, 2H, CH2), 2.27 (s, 6H, N(CH3)2), 2.38 (m, 2H, CH2), 2.55 (m, 2H, CH2), 3.42 (m, 2H, CH2), 4.97 (s, 2H, CH2), 6.67 (s, 1 H, CH), 6.99 (t, 1 H, J =
7.0, 1.8 Hz, ArH), 7.41 (m, 4H, ArH), 7.77 (d, 1 H, J = 7.0, 1.8 Hz, ArH), 8.14 (d, 1 H, J = 7.2 Hz, ArH).
(2-3):(E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (2-2) as the starting material, to obtain 134 mg of the title compound (yield: 88%).
~H NMR (200 MHz, MeOH-d4) S 1.58 (m, 4H, CH2CH2), 2.40 (m, 2H, CH2), 2.82 (s, 6H, N(CH3)2), 3.30 (m, 4H, CH2CH2), 3.62 (m, 2H, CH2), 5.01 (s, 2H, CHZ), 6.70 (t, 1 H, J = 15.2, 7.4 Hz, CH), 7.04 (d, 1 H, J = 1.2 Hz, ArH), 7.44 (m, 4H, ArH), 7.81 (m, 1 H, ArH), 8.19 (m, ArH).
Example 3: (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (3-1):(E)-8-((2-(dimethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (2-(dimethylamino)ethyl)(methyl)amine instead of dimethylaminehydrochloride as the amine to obtain 351 mg of the title compound (yield: 77%).
'H NMR (200 MHz, CDC13) S 1.6 (m, 4H, CH2CH2), 2.2 (m, 8H, CH2CH2CH2CH2), 3.05 (s, 3H, NCH3), 3.55 (m, 2H, CH2), 3.70 (s, 3H, OCH3), 5.00 (s, 2H, Ph CH2), 5.80 (s, 1 H, CH), 6.89 (d, 1 H, J = 1.4 Hz, ArH), 7.48 (m, 4H, ArH), 7.80 (dd, 1H, J = 6.0, 2.0 Hz, ArH), 8.20 (m, 1H, ArH).
(3-2): (E)- 8-((2-(dimethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (3-1) as the starting material, to obtain 224 mg of the title compound (yield: 92%).
'H NMR (200 MHz, MeOH-d4) 8 1.6 (m, 4H, CH2CH2), 2.4 (m, 6H, CH2CH2CH2), 2.50 (m, 4H, CH2CH2), 2.80 (m, 2H, CH2), 3.01 (s, 3H, NCH3), 3.29 (m, 1 H, CH), 3.65 (m, 1 H, CH), 4.95 (s, 2H, PhCH2), 6.00 (m, 1 H, CH), 7.00 (t, 1 H, J= 16.6, 9.4 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (m, 1 H, ArH), 8.18 (m, 1 H, ArH).
(3-3): (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (3-2) as the starting material, to obtain 155 mg of the title compound (yield: 68%).
1 H NMR (200 MHz, MeOH-d4) S 1.48 (m, 2H, CHZ), 1.58 (m, 2H, CHZ), 2.4 (m, 6H, CH2CH2CH2), 2.49 (m, 4H, CH2CH2), 2.81 (m, 2H, CH2), 3.02 (s, 3H, NCH3), 3.28 (m, 1H, CH), 3.64 (m, 1H, CH), 4.95 (s, 2H, PhCH2), 6.02 (m, 1 H, CH), 7.00 (d, 1 H, J = 8.2 Hz, ArH), 7.44 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.17 (m, 1 H, ArH).
Example 4: (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-2 0 1-yloxy)methyl)octenediamide (4-1):(E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(diethylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 164 mg of the title compound (yield: 37%).
'H NMR (200 MHz, CDC13) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.14 (t, 2H, J = 14,2, 7.4 Hz, CHZ), 2.40 (m, 2H, CH2), 3.14 (rim, 6H, CH2CH2CH2CH2), 3.50 (s, 2H, CH2), 3.86 (s, 3H, OCH3), 5.02 (s, 2H, CH2), 6.73 (t, 1 H, J = 14.6, 7.2 Hz, CH), 7.01 (d, 1 H, J = 7.4 Hz, ArH), 7.40 (m, 4H, ArH), 7.76 (d, 1 H, J = 7.4 Hz, ArH), 8.18 (dd, 1 H, J = 7.4, 2.8 Hz, ArH).
(4-2):(E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (4-1) as the starting material, to obtain 130 mg of the title compound (yield: 81 %).
'H NMR (200 MHz, MeOH-d4) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.12 (m, 2H, JCHZ), 2.36 (m, 2H, CH2), 3.14 (m, 6H, CH2CH2CH2), 3.50 (s, 2H, CH2), 5.01 (s, 2H, CH2), 6.72 (d, 1H, J = 7.4 Hz, CH), 7.02 (d, 1 H, J = 7.4 Hz, ArH), 7.40 (m, 4H, ArH), 7.80 (dd, 1 H, J = 7.6, 1.8 Hz, ArH), 8.16 (d, 1 H, J = 7.2 Hz, ArH).
(4-3): (E)-N1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide (E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid (311 mg, 0.71 mM) obtained in Example (4-2) was dissolved in dimethylformamide (3 ml), whereto triethylamine (150 0, 1.07 mM) was added, followed by cooling to 0 C . N-hydroxy-6-trifluoro-6-trifluorobenzotriazole (159 mg, 0.78 mM), 1-(3-diethylaminopropyl)-3-ethylcarbodiimidhydrochloride (177 mg, 0.92 mM) and tetrahydropyranyl oxyamine (125 mg, 1.07 mM) were added thereto, and the mixture was stirred at room temperature for 18 hrs. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and salt water in order, dried over anhydrous magnesium sulfate, and concentrated under a reduced pressure. The resulting residue was subjected to silica gel column chromatography, to obtain 320 mg of the title compound (yield: 87%).
'H NMR (200 MHz, MeOH-d4) S 0.80 (m, 6H, CH2CH2CH2), 1.80 (m, 12H, CH2CH2CH2CH2), 2.10 (s, 1H, CH2), 2.35 (m, 6H, CH3CH3), 2.58 (m, 2H, CH2), 3.40 (m, 2H, CH2), 3.60 (m, 1 H, CH), 3.94 (m, 1 H, CH), 4.96 (s, 2H, CH2), 6.80 (d, 1H, J = 7.4 Hz, CH), 6.98 (d, 1H, J = 6.8 Hz, ArH), 7.42 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.21 (dd, 1 H, J = 12.6, 6.4 Hz, ArH).
(4-4):(E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide (E)-N 1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide (320 mg, 0.62 mM) obtained in Example (4-4) was dissolved in dichloromethane (10 ml), whereto trifluoroacetic acid (0.46 ml, 6.20 mM) was added slowly at 0 C, followed by reacting at room temperature for 18 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (methylalcohol/dichloromethane= 1/9) to obtain 261 mg of the title compound (yield: 95%).
'H NMR (200 MHz, MeOH-d4) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.14 (t, 2H, J = 13,8, 7.0 Hz, CHZ), 2.40 (q, 2H, J = 14.4, 7.0 Hz, CH2), 3.12 (m, 6H, CHZCH2CH2), 3.51 (s, 2H, CHZ), 5.02 (s, 2H, CHZ), 6.73 (t, 1 H, J = 14.8, 7.4 Hz, CH), 7.02 (d, 1 H, J = 6.4 Hz, ArH), 7.41 (m, 4H, ArH), 7.80 (dd, 1 H, J = 5.6, 2.0 Hz, ArH), 8.18 (dd, 1 H, J = 7.0, 3.8 Hz, ArH).
Example 5: (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (5-1):(E)-8-((2-(diethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (2-(diethylamino)ethyl)(methyl)amine instead of dimethylaminehydrochloride as the amine to obtain 483 mg of the title compound (yield: 71 %).
'H NMR (300 MHz, CDC13) S 1.11 (m, 6H, CH2CH2CH2), 1.40 (m, 2H, CH2), 1.65 (m, 2H, CHz), 2.28 (m, 8H, CH2 CH2CH3CH3), 2.90 (s, 2H, CH2), 3.00 (s, 3H, NCH3), 3.57 (s, 2H, CH2), 3.66 (s, 3H, OCH3), 4.93 (s, 2H, CHZ), 6.85 (d, 1 H, J= 7.8 Hz, CH), 6.99 (m, 1 H, ArH), 7.41 (m, 4H, ArH), 7.75 (m, 1 H, ArH), 8.14 (m, 1 H, NH), 8.17 (m, 1 H, ArH).
(5-2): (E)-8-((2-(diethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (5-1) as the starting material, to obtain 300 mg of the title compound (yield: 65%).
'H NMR (300 MHz, MeOH-d4) S 1.05 (m, 6H, CH2CHZCH2), 1.38 (m, 2H, CH2), 1.50 (m, 2H, CH2), 2.17 (m, 4H, CH2CH2), 2.99 (m, 6H, CH3CH3), 3.16 (s, 3H, NCH3), 3.60 (m, 2H, CH2), 4.87 (s, 2H, CH2), 5.86 (d, 1H, J =
7.4 Hz, CH), 6.82 (d, 1H, J = 7.4 Hz, ArH), 7.28 (m, 4H, ArH), 7.64 (t, 1 H, J
= 9.4, 6.1 Hz, ArH), 7.92 (d, 1 H, J= 9.7 Hz, ArH).
(5-3): (E)-N1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (5-2) as the starting material, to obtain 320 mg of the title compound (yield: 87%).
'H NMR (300 MHz, MeOH-d4) 8 1.00 (m, 6H, CH2CH2CH2), 1.54 (m, 4H, CH2CH2), 1.73 (m, 8H, CH2CH2CH2CH2), 2.14 (d, 2H, J = 7.0 Hz, CH2), 2.36 (d, 2H, J = 7.4 Hz, CH2), 2.58 (d, 2H, J = 6.8 Hz, CH2), 3.07 (m, 6H, CH3CH3), 3.32 (s, 3H, NCH3), 3.55 (m, 2H, CH2)03.98 (m, 1H, CH), 5.05 (s, 2H, CH2), 5.94 (m, 1 H, CH), 7.01 (d, 1 H, J = 7.4 Hz, ArH), 7.48 (m, 4H, ArH), 7.82 (t, 1H, J = 9.1, 2.0 Hz, ArH), 8.11 (dd, 1H, J = 7.4, 2.3 Hz, ArH).
(5-4): (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediam ide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (5-3) as the starting material, to obtain 285 mg of the title compound (yield: 93%).
1H NMR (300 MHz, MeOH-d4) S 1.10 (m, 6H, CHZCH2CH2), 1.13 (m, 2H, CH2), 1.58 (m, 2H, CHZ), 2.02 (t, 2H, J = 14.1, 7.0 Hz, CHZ), 2.28 (d, 2H, J =
7.2 Hz, CH2), 3.07 (m, 6H, CH3CH3), 3.21 (s, 3H, NCH3), 3.64 (m, 2H, CHZ), 4.96 (s, 2H, CH2), 5.93 (s, 1 H, CH), 6.90 (d, 1 H, J= 7.2 Hz, ArH), 7.36 (m, 4H, ArH), 7.71 (dd, 1 H, J = 8.0, 3.7 Hz, ArH), 7.98 (d, 1 H, J = 9.4 Hz, ArH);
MS (LC, 70 eV) m/z 456 (M+1), 382.
Example 6: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide (6-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(pyrrolidin-l-yl) thylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(pyrrolidin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 74 mg of the title compound (yield: 29%).
1H NMR (200 MHz, CDC13) 8 1.50 (d, 2H, J = 7.4 Hz, CHZ), 1.62 (d, 2H, J
7.4 Hz, CHZ), 1.89 (m, 4H, CH2), 2.09 (m, 2H, CH2), 2.35 (m, 2H, CH2), 3.13 (m, 5H, CHCH2CH2), 3.32 (s, 1H, CH), 3.58 (t, 2H, J = 12.1, 6.1 Hz, CH2), 3.96 (s, 3H, OCH3), 4.96 (s, 2H, CHZ), 6.80 (d, 1H, J = 7.4 Hz, CH), 6.98 (d, 1 H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.21 (m, 1 H, ArH).
(6-2): (E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(pyrrolidin-1-yl) thylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (6-1) as the starting material, to obtain 69 mg of the title compound (yield: 96%).
'H NMR (200 MHz, MeOH-d4) 8 1.50 (d, 2H, J= 7.2 Hz, CH2), 1.60 (d, 2H, J = 7.2 Hz, CH2), 1.88 (m, 4H, CH2), 2.08 (m, 2H, CH2), 2.34 (m, 2H, CH2), 3.14 (m, 5H, CHCH2CH2), 3.34 (s, 1H, CH), 3.58 (t, 2H, J = 12.1, 6.1 Hz, CH2), 4.96 (s, 2H, CH2), 6.80 (d, 1 H, J = 7.0 Hz, CH), 6.98 (d, 1 H, J = 7.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.21 (m, 1H, ArH).
(6-3):(E)-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (6-2) was repeated except for using the compound obtained in Example (4-3) as the starting material, to obtain 87 mg of the title compound (yield: 85%).
'H NMR (200 MHz, MeOH-d4) 8 1.50 (m, 8H, CH2CH2CH2CH2), 1.80 (m, 4H, CH2CH2), 2.01 (m, 2H, CH2), 2.40 (m, 4H, CH2CH2), 2.59 (m, 5H, CHCH2CH2), 2.78 (m, 2H, CH2), 3.50 (m, 3H, CHCH2), 3.90 (s, 1H, CH), 4.96 (s, 2H, CHZ), 6.80 (d, 1H, J = 7.2 Hz, CH), 6.98 (d, 1H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.21 (m, 1 H, ArH).
(6-4): (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (6-3) as the starting material, to obtain 72 mg of the title compound (yield: 84%).
'H NMR (300 MHz, MeOH-d4) S 1.51 (d, 2H, J = 7.0 Hz, CH2), 1.62 (d, 2H, J= 7.9 Hz, CH2), 1.89 (m, 4H, CH2CH2), 2.09 (m, 2H, CH2), 2.35 (m, 2H, CH2), 3.13 (m, 5H, CHCH2CH2), 3.32 (s, 1H, CH), 3.58 (t, 2H, J= 12.1, 6.1 Hz, CH2), 5.01 (s, 2H, CH2), 6.70 (s, 1 H, CH), 7.00 (d, 1 H, J = 7.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (t, 1H, J = 8.4, 1.8 Hz, ArH), 8.12 (t, 1H, J = 9.4, 7.5 Hz, ArH); MS (LC, 70 eV) m/z 440 (M+1), 425, 328, 313, 242, 210, 192.
Example 7: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide (7-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(piperidin-l-yl) thylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(piperidin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 290 mg of the title compound (yield: 94%).
'H NMR (200 MHz, CDC13) 8 1.10 (m, 2H, CH2), 1.21 (m, 2H, CHZ), 1.60 (m, 4H, CHZ), 2.01 (m, 2H, CH2), 2.21 (m, 5H, CHCH2CH2), 2.38 (m, 5H, CHCH2CH2), 3.41 (t, 2H, J= 11.4, 5.8 Hz, CH), 3.65 (s, 3H, OCH2), 4.95 (s, 2H, CHZ), 6.81 (d, 1 H, J = 7.8 Hz, CH), 6.95 (d, 1 H, J = 7.0 Hz, ArH), 7.10 (brs, 1H, NH), 7.45 (m, 4H, ArH), 7.80 (q, 1H, J = 5.8, 2.4 Hz, ArH), 8.21 (dd, 1H, J= 7.0, 3.4 Hz, ArH).
(7-2): (E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(piperidin-1-yl) thylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (7-1) as the starting material, to obtain 256 mg of the title compound (yield: 94%).
'H NMR (300 MHz, MeOH-d4) 8 1.44 (m, 4H, CH2CH2), 1.64 (m, 2H, CH2), 2.12 (m, 2H, CHZ), 2.26 (m, 2H, CH2)03.08 (m, IOH, CH2CH2CH2CH2CH2), 3.51 (d, 2H, J = 6.0 Hz, CH), 4.91 (s, 2H, CH2), 6.61 (s, 1 H, CH), 6.91 (d, 1 H, J = 6.2 Hz, ArH), 7.31 (m, 4H, ArH), 7.68 (dd, 1H, J = 6.8, 3.4 Hz, ArH), 8.00 (dd, 1H, J = 7.0, 3.4 Hz, ArH).
(7-3): (E)-2-((naphthalen-1-yloxy)methyl)-Nl-(2-(piperidin-1-yl)ethyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (7-2) as the starting material, to obtain 288 mg of the title compound (yield: 91 %).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 2H, CH2), 1.45 (m, 4H, CH2CH2), 1.60 (m, 8H, CH2CH2CH2CH2), 2.09 (s, 2H, CH2), 2.29 (m, lOH, CH2CH2CH2CH2CH2), 3.21 (m, 2H, CHZ), 3.47 (m, 2H, CHZ), 3.89 (t, 1 H, J=
7.2 Hz, CH), 4.90 (s, 2H, CH2), 6.50 (s, 1 H, CH), 6.90 (d, 1 H, J= 7.2 Hz, ArH), 7.33 (m, 4H, ArH), 7.70 (t, 1H, J = 9.0, 1.4 Hz, ArH), 8.02 (d, 1H, J
8.2 Hz, ArH).
(7-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (7-3) as the starting material, to obtain 213 mg of the title compound (yield: 94%).
'H NMR (300 MHz, MeOH-d4) S 1.41 (m, 4H, CH2CH2), 1.65 (m, 4H, CH2CH2), 2.10 (t, 2H, J = 14.3, 7.0 Hz, CH2), 2.41 (d, 2H, J = 7.2 Hz, CHz), 2.89 (m, 2H, CH2), 3.22 (t, 2H, J = 11.8, 5.9 Hz, CH), 3.32 (m, 2H, CH2), 3.52 (d, 2H, J = 11.8 Hz, CH2), 3.65 (t, J 11.8, 5.8 Hz, 2H, CHZ), 5.04 (s, 2H, CH2), 6.70 (s, 1H, CH), 7.05 (t, 1H, J 7.3, 1.0 Hz, ArH), 7.45 (m, 4H, ArH), 7.83 (d, 1 H, J = 7.2 Hz, ArH), 8.13 (d, 1 H, J = 7.2 Hz, ArH).
Example 8: (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-l-yloxy)methyl)octenediamide (8-1):(E)-8-(2-morpholinoethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-morpholinoethylamine instead of dimethylaminehydrochloride as the amine to obtain 266 mg of the title compound (yield: 91 %).
'H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CHZ), 1.64 (m, 2H, CH2), 2.20 (m, 4H, CH2CH2), 2.25 (m, 4H, CH2CH2), 2.40 (m, 2H, CH2), 3.07 (t, 2H, J =
8.6, 4.2 Hz, CH), 3.42 (t, 2H, J = 10.6, 5.4 Hz, CH2), 3.61 (s, 3H, OCH3), 4.89 (s, 2H, CH2), 6.90 (s, 1H, CH), 6.94 (d, 1H, J = 7.8 Hz, ArH), 7.45 (m, 4H, ArH), 7.82 (dd, 1H, J = 7.8, 2.4 Hz, ArH), 8.19 (dd, 1H, J = 7.8, 2.8 Hz, ArH).
(8-2): (E)-8-(2-morpholinoethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (8-1) as the starting material, to obtain 250 mg of the title compound (yield: 96%).
1 H NMR (300 MHz, MeOH-d4) S 1.50 (m, 2H, CH2), 1.62 (m, 2H, CHZ), 2.24 (m, 4H, CH2CH2), 2.38 (m, 4H, CH2CH2), 2.58 (m, 2H, CH2), 3.32 (q, 2H, J
= 3.1, 1.5 Hz, CH), 3.43 (m, 4H, CH2CH2), 4.96 (s, 2H, CHZ), 6.71 (s, 1H, CH), 7.01 (d, 1 H, J = 7.3 Hz, ArH), 7.43 (m, 4H, ArH), 7.80 (t, 1 H, J= 7.1, 5.5 Hz, ArH), 8.19 (d, 1H, J = 7.6 Hz, ArH); MS (LC, 70 eV) m/z 416 (M+1), 403, 346, 313, 298, 204, 102.
(8-3): (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-1-yloxy) ethyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (8-2) as the starting material, to obtain 155 mg of the title compound (yield: 90%).
'H NMR (300 MHz, MeOH-d4) 8 1.48 (m, 2H, CHZ), 1.59 (m, 2H, CH2), 2.25 (m, 4H, CH2CH2), 2.38 (m, 4H, CH2CH2), 2.56 (m, 2H, CHZ), 3.30 (d, 2H, J
= 7.5 Hz, CH), 3.42 (m, 4H, CH2CH2), 5.01 (s, 2H, CH2), 6.78 (s, 1H, CH), 7.00 (d, 1 H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.78 (d, 1 H, J= 7.4 Hz, ArH), 8.14 (d, 1H, J = 7.6 Hz, ArH); MS (LC, 70 eV) m/z 416 (M+1), 403, 346, 313, 298, 204, 102.
Example 9: (E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide (9-1): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methylpiperazin-1-ylamine instead of dimethylaminehydrochloride as the amine to obtain 175 mg of the title compound (yield: 41 %).
'H NMR (300 MHz, CDC13) 6 1.46 (m, 2H, CH2), 1.53 (m, 2H, CH2), 2.17 (m, 4H, CH2CH2), 2.34 (m, 8H, CH2CH2CH2CH2CH2CH2), 3.64 (s, 3H, NCH3), 3.75 (s, 3H, OCH3), 4.98 (s, 2H, CH2), 5.78 (t, 1H, J = 15.0, 7.5 Hz, CH), 6.84 (d, 1 H, J = 7.5 Hz, ArH), 7.44 (m, 4H, ArH), 7.79 (t, 1 H, J = 8.7, 1.2 Hz, ArH), 8.13 (d, 1 H, J= 7.8 Hz, ArH).
(9-2): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (9-1) as the starting material, to obtain 168 mg of the title compound (yield: 100%).
'H NMR (300 MHz, MeOH-d4) 6 1.55 (m, 2H, CH2), 1.68 (m, 2H, CHZ), 2.32 (m, 11H, CHCH2CH2CH2CH2CH2CH2), 3.31 (m, 1H, CH), 3.66 (s, 3H, NCH3), 5.09 (s, 2H, CH2), 5.92 (s, 1 H, CH), 6.97 (dd, 1 H, J = 6.5, 6.5 Hz, ArH), 7.46 (m, 4H, ArH), 7.81 (d, 1 H, J = 7.8 Hz, ArH), 8.16 (d, 1 H, J = 7.8 Hz, ArH).
(9-3): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-N-(tetrahydro-2H-pyran-2-yloxy)-6-octeneamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (9-2) as the starting material, to obtain 317 mg of the title compound (yield: 83%).
'H NMR (300 MHz, MeOH-d4) 8 1.54 (m, 4H, CH2CH2), 1.72 (m, 4H, CH2CH2), 2.17 (m, 8H, CH2CH2CH2CH2), 2.37 (m, 6H, CH2CH2CH2), 3.32 (q, 2H, J = 3.2, 1.6 Hz, CH2), 3.57 (s, 3H, NCH3), 3,92 (m, 1 H, CH), 5.08 (s, 2H, CH2), 5.86 (s, 1 H, CH), 6.96 (d, 1 H, J = 7.3 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (d, 1 H, J = 7.3 Hz, ArH), 8.14 (d, 1 H, J = 7.3 Hz, ArH). .
(9-4):(E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy) methyl)-8-oxoocteneamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (9-3) as the starting material, to obtain 287 mg of the title compound (yield: 92%).
'H NMR (300 MHz, MeOH-d4) 6 1.52 (m, 2H, CH2), 1.57 (m, 2H, CHZ), 2.13 (t, 2H, J = 14.3, 7.1 Hz, CH2), 2.37 (q, 2H, J = 14.4, 7.1 Hz, CH2), 2.61 (m, 4H, CH2CH2), 3.32 (m, 2H, CH2), 3.76 (m, 2H, CH2), 3.80 (s, 3H, NCH3), 5.10 (s, 2H, CH2), 5.96 (s, 1 H, CH), 6.97 (d, 1 H, J = 7.3 Hz, ArH), 7.47 (m, 4H, ArH), 7.83 (t, 1 H, J = 9.1, 4.0 Hz, ArH), 8.13 (t, 1 H, J= 9.2, 5.1 Hz, ArH); MS (LC, 70 eV) m/z 426 (M+1), 407, 325, 293, 281, 265, 149, 102.
Example 10: (E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy)methyl)octenediamide (10-1): (E)-8-(2-(4-methylpiperazin-l-yl)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(4-methylpiperazin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 225 mg of the title compound (yield: 48%).
'H NMR (300 MHz, CDC13) 6 1.53 (m, 2H, CH2), 1.66 (m, 4H, CH2CH2), 1.92 (m, 4H, CH2CH2), 2.31 (m, 8H, CH2CH2CH2CH2), 2.42 (s, 3H, NCH3), 3.40 (q, 2H, J = 10.5, 5.4 Hz, CHZ), 3.63 (s, 3H, OCH3), 4.87 (s, 2H, CH2), 6.95 (dd, 1 H, J = 15.6, 7.8 Hz, CH), 7.05 (s, 1 H, ArH), 7.45 (m, 4H, ArH), 7.80 (dd, 1 H, J= 6.9, 1.8 Hz, ArH), 8.19 (t, 1 H, J = 9.6, 7.8 Hz, ArH).
(10-2):(E)-8-(2-(4-methylpiperazin-1-yl)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (10-1) as the starting material, to obtain 157 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) S 1.24 (s, 1H, CH), 1.54 (m, 4H, CHZCH2), 2.20 (m, 4H, CH2CH2), 2.29 (m, 4H, CH2CH2), 2.51 (m, 4H, CH2CH2), 3.05 (m, 1H, CH), 3.24 (s, 3H, NCH3), 3.34 (m, 2H, CH2), 4.94 (s, 2H, CH2), 6.69 (s, 1 H, CH), 7.01 (dd, 1 H, J = 7.2, 1.0 Hz, ArH), 7.42 (m, 4H, ArH), 7.75 (d, 1H, J = 7.2 Hz, ArH), 8.08 (d, 1H, J = 1.7 Hz, ArH).
(10-3):(E)-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (10-2) as the starting material, to obtain 137 mg of the title compound (yield: 54%).
1H NMR (300 MHz, MeOH-d4) S 1.54 (m, 4H, CH2CH2), 1.64 (m, 6H, CHCH2CH2), 2.11 (m, 5H, CHCH2CH2), 2.41 (m, 8H, CH2CH2CH2CH2), 3.27 (s, 3H, NCH3), 3.34 (m, 3H, CHCH2), 3.50 (m, 2H, CH2), 3.85 (t, 1H, J
= 7.2, 1.8 Hz, CH), 4.96 (s, 2H, CHz), 6.70 (s, 1 H, CH), 7.01 (d, 1 H, J =
7.2 Hz, ArH), 7.43 (m, 4H, ArH), 7.79 (dd, 1 H, J = 6.6, 1.7 Hz, ArH), 8.10 (t, 1 H, J= 8.9, 7.2 Hz, ArH).
(10-4):(E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (10-3) as the starting material, to obtain 118 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) S 1.53 (d, 2H, J = 7.7 Hz, CHZ), 1.65 (d, 2H, J = 7.0 Hz, CH2), 2.10 (t, 2H, J = 14.3, 7.0 Hz, CH2), 2.39 (t, 2H, J = 14.2, 7.3 Hz, CHZ), 2.72 (d, 2H, J = 8.2 Hz, CHZ), 2.95 (d, 2H, J = 5.4 Hz, CHZ), 3.12 (m, 6H, CH2CH2CH2), 3.32 (s, 3H, NCH3), 3.56 (t, 2H, J = 11.2, 5.6 Hz, CH2), 5.02 (s, 2H, CH2), 6.75 (t, 1 H, J = 15.0, 7.2 Hz, CH), 7.05 (d, 1 H, J
=
7.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (d, 1 H, J = 7.5 Hz, ArH), 8.14 (d, 1 H, J = 8.5 Hz, ArH).
Example 11: (E)-N1-(cyanomethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (11-1):(E)-8-((cyanomethyl)(cyanomethyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using cyanomethylamineas instead of dimethylaminehydrochloride the amine to obtain 299 mg of the title compound (yield: 76%).
'H NMR (200 MHz, CDC13) S 1.35 (m, 2H, CH2), 1.60 (m, 2H, CH2), 2.31 (m, 4H, CH2CH2), 3.11 (s, 3H, NCH3), 3.67 (s, 3H, OCH3), 4.38 (s, 2H, CH2), 4.97 (s, 2H, CHZ), 5.98 (s, 1 H, CH), 6.85 (d, 1 H, J = 4.6 Hz, ArH), 7.37 (t, 1H, J = 10.6, 5.2 Hz, ArH), 7.47 (m, 3H, ArH), 7.79 (dd, 1H, J = 6.2, 1.4 Hz, ArH), 8.06 (d, 1 H, J = 4.6 Hz, ArH).
(11-2):(E)-8-((cyanomethyl)(cyanomethyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (11-1) as the starting material, to obtain 250 mg of the title compound (yield: 84%).
1H NMR (300 MHz, MeOH-d4) S 1.37 (m, 2H, CH2), 1.61 (m, 2H, CHZ), 2.31 (m, 4H, CH2CH2), 3.31 (s, 3H, NCH3), 4.16 (d, 2H, J = 8.5 Hz, CH2), 5.01 (s, 2H, CH2), 6.21 (m, 1 H, CH), 6.98 (d, 1H, J = 7.0 Hz, ArH), 7.44 (m, 4H, ArH), 7.81 (t, 1 H, J = 8.8, 2.8 Hz, ArH), 8.13 (d, 1 H, J = 13.6 Hz, ArH).
(11-3):(E)-N1-(cyanomethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (11-2) as the starting material, to obtain 222 mg of the title compound (yield: 64%).
'H NMR (300 MHz, MeOH-d4) S 1.48 (m, 4H, CH2CH2), 1.71 (m, 4H, CH2CH2), 1.92 (m, 4H, CH2CH2), 2.32 (m, 4H, CH2CH2), 3.21 (s, 3H, NCH3), 3.73 (t, 1H, J = 7.2 Hz, CH2), 4.39 (s, 2H, CH2), 5.06 (s, 2H, CH2), 6.18 (m, 1 H, CH), 7.20 (d, 1 H, J = 7.0 Hz, ArH), 7.64 (m, 4H, ArH), 8.09 (dd, 1 H, J
14.8, 7.2 Hz, ArH), 8.13 (m, 1H, ArH).
(11-4):(E)-N1-(cyanomethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (11-3) as the starting material, to obtain 170 mg of the title compound (yield: 75%).
'H NMR (300 MHz, MeOH-d4) S 1.34 (d, 2H, J = 7.7 Hz, CHZ), 1.50 (d, 2H, J = 6.7 Hz, CH2), 1.89 (d, 2H, J = 7.2 Hz, CH2), 2.25 (q, 2H, J = 16.2, 7.9 Hz, CH2), 3.20 (s, 3H, NCH3), 3.91 (d, 2H, J = 7.6 Hz, CH2), 4.98 (s, 2H, CH2), 5.98 (d, 1 H, J = 14.7 Hz, CH), 6.86 (d, 1 H, J= 6.7 Hz, ArH), 7.3 5(m, 4H, ArH), 7. 5 6(t, 1 H, J = 9.1, 3.4 Hz, ArH), 7.9 8(m, 1 H, ArH).
Example 12: (E)-N8-hydroxy-N1-(2-hydroxyethyl)-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (12-1):(E)-8-((2-hydroxyethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-2 0 hydroxyethylamine instead of dimethylaminehydrochloride as the amine to obtain 366 mg of the title compound (yield: 93%).
'H NMR (300 MHz, CDC13) S 1.51 (m, 2H, CH2), 1.68 (m, 2H, CH2), 2.29 (m, 4H, CH2CH2), 3.08 (s, 3H, NCH3), 3.66 (m, 4H, CH2CH2), 3.81 (S, 3H, OCH3), 4.96 (s, 2H, CH2), 6.86 (d, 1 H, J = 7.0 Hz, CH), 7.26 (s, 1 H, ArH), 7.44 (m, 4H, ArH), 7.77 (d, 1 H, J = 7.2 Hz, ArH), 8.15 (d, 1 H, J = 7.2 Hz, ArH).
(12-2): (E)-8-((2-hydroxyethyl)(methyl)amino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (12-1) as the starting material, to obtain 320 mg of the title compound (yield: 88%).
'H NMR (300- MHz, MeOH-d4) S 1.30 (m, 4H, CH2CH2), 2.08 (m, 4H, CH2CH2), 3.07 (s, 3H, NCH3), 3.09 (m, 4H, CH2CH2), 4.74 (s, 2H, CHZ), 6.77 (t, 1H, J = 7.2, 1.2 Hz, CH), 6.95 (s, 1H, ArH), 7.20 (m, 4H, ArH), 7.56 (t, 1 H, J = 7.0, 1.9 Hz, ArH), 7.90 (d, 1 H, J = 7.2 Hz, ArH).
(12-3):(E)-N8-hydroxy-N1-(2-hydroxyethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (12-2) as the starting material, to obtain 262 mg of the title compound (yield: 90%).
ls 'H NMR (300 MHz, MeOH-d4) 8 1.32 (m, 4H, CH2CH2), 2.06 (m, 4H, CH2CH2), 3.08 (s, 3H, NCH3), 3.13 (m, 4H, CH2CH2), 4.92 (s, 2H, CH2), 6.78 (t, 1H, J= 7.4, 1.8 Hz, CH), 6.92 (s, 1H, ArH), 7.28 (m, 4H, ArH), 7.56 (d, 1H, J = 7.4 Hz, ArH), 7.88 (d, 1H, J = 7.4 Hz, ArH); MS (LC, 70 eV) m/z 448 (M+l), 305, 204.
Example 13: (E)-N8-hydroxy-Nl-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (13-1):(E)-8-(methyl(1-methylpyrrolidin-3-yl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-methylpyrrolidin-3-ylamine instead of dimethylaminehydrochlori.de as the amine to obtain 355 mg of the title compound (yield: 91%).
'H NMR (200 MHz, CDC13) S 1.42 (m, 4H, CHZCHZ), 1.80 (m, 4H, CHZCH2), 2.20 (m, 4H, CH2CH2), 2.98 (s, 3H, NCH3), 3.61 (s, 3H, NCH3), 3.80 (s, 3H, OCH3), 4.82 (s, 2H, CH2), 4.96 (s, 2H, CH2), 5.81 (m, 1H, CH), 6.82 (m, 1H, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.15 (m, 1H, ArH).
(13-2):(E)-8-(methyl(1-methylpyrrolidin-3-yl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (13-1) as the starting material, to obtain 320 mg of the title compound (yield: 86%).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 4H, CH2CH2), 1.76 (m, 4H, CH2CH2), 2.22 (m, 4H, CH2CH2), 2.88 (s, 3H, NCH3), 3.58 (s, 3H, NCH3), 4.80 (s, 2H, CHZ), 4.99 (s, 2H, CH2), 5.84 (m, 1 H, CH), 6.80 (m, 1 H, ArH), 7.44 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.12 (m, 1 H, ArH).
(13-3):(E)-N8-hydroxy-Nl-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (13-2) as the starting material, to obtain 188 mg of the title compound (yield: 41 %).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 4H, CHZCH2), 1.80 (m, 4H, CH2CH2), 2.20 (m, 4H, CH2CH2), 2.98 (s, 3H, NCH3), 3.60 (s, 3H, NCH3), 3.80 (s, 3H, OCH2), 5.00 (s, 2H, CH2), 4.96 (s, 2H, CH2), 5.82 (m, 1 H, CH), 6.84 (m, 1 H, ArH), 7.44 (m, 4H, ArH), 7.78 (m, 1 H, ArH), 8.14 (m, 1H, ArH).
Example 14: (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (14-1):(E)-7-(3-(dimethylamino)propylcarbamoyl)-8-(naphthalen-l-yloxy)octane acid methylester The procedure of Example (1-1) was repeated except for using 3-(dimethylamino)propylamine instead of dimethylaminehydrochloride as the amine to obtain 467 mg of the title compound (yield: 73%).
'H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CH2), 1.64 (m, 4H, CH2CH2), 2.01 (s, 6H, N(CH3)2), 2.25 (m, 6H, CH2CH2CH2), 3.40 (m, 2H, CH2), 3.60 (s, 3H, OCH3), 4.96 (s, 2H, CH2), 6.81 (t, 1H, J = 15.4, 7.8 Hz, CH), 6.94 (t, 1H, J = 7.4, 6.2 Hz, ArH), 7.43 (m, 4H, ArH), 7.79 (m, 1 H, ArH), 8.19 (dd, 1 H, J
= 6.8, 3.6 Hz, ArH).
(14-2):(E)-7-(3-(dimethylamino)propylcarbamoyl)-8-(naphthalen-l-yloxy)octane acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (14-1) as the starting material, to obtain 154 mg of the title compound (yield: 83%).
'H NMR (300 MHz, MeOH-d4) S 1.30 (m, 2H, CHZ), 1.64 (d, 2H, J = 6.9 Hz, CH2), 1.94 (m, 2H, CH2), 2.27 (t, 2H, J = 14.2, 7.0 Hz, CHZ), 2.39 (d, 2H, J=
7.2 Hz, CH2), 2.74 (s, 6H, N(CH3)2), 3.03 (t, 2H, J = 15.0, 7.2 Hz, CH2), 3.33 (m, 2H, CH2), 5.05 (s, 2H, CH2), 6.66 (s, 1 H, CH), 7.03 (dd, 1 H, J = 7.2, 1.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.80 (d, 1 H, J = 6.9 Hz, ArH), 8.14 (d, 1 H, J
7.0 Hz, ArH).
(14-3):(E)-N1-(3-(dimethylamino)propyl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (14-2) as the starting material, to obtain 160 mg of the title compound (yield: 89%).
'H NMR (200 MHz, MeOH-d4) S 1.59 (m, 13H, CH2CH2CH2CH2CH2CH2CH2), 1.90 (s, 6H, N(CH3)2), 2.23 (m, 6H, CH2CHZCH2), 3.41 (q, 2H, J = 11.8, 6.2 Hz, CH2), 3.61 (m, 1 H, CH), 3.91 (m, 1 H, CH), 4.87 (s, 2H, CH2), 6.82 (d, 1 H, J = 7.4 Hz, CH), 6.89 (d, 1 H, J =
6.8 Hz, ArH), 7.44 (m, 4H, ArH), 7.79 (dd, 1 H, J = 5.2, 3.2 Hz, ArH), 8.16 (t, 1 H, J= 9.4, 6.4 Hz, ArH).
(14-4):(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (14-3) as the starting material, to obtain 142 mg of the title compound (yield: 92%).
1 H NMR (300 MHz, MeOH-d4) 6 1.52 (t, 2H, J = 7.5, 4.1 Hz, CH2), 1.64 (d, 2H, J = 7.1 Hz, CHZ), 1.92 (t, 2H, J= 13.8, 7.5 Hz, CH2), 2.10 (t, 1 H, J=
14.2, 7.0 Hz, CH2), 2.37 (d, 2H, J = 7.2 Hz, CH2), 2.72 (s, 6H, N(CH3)2), 3.01 (t, 2H, J = 14.8, 7.3 Hz, CHz), 3.35 (m, 3H, CHCHZ), 5.03 (s, 2H, CH2), 6.62 (t, 1 H, J = 15.0, 7.5 Hz, CH), 7.02 (d, 1 H, J = 7.1 Hz, ArH), 7.46 (m, 4H, ArH), 7.80 (dd, 1 H, J= 6.2, 1.9 Hz, ArH), 8.14 (t, 1 H, J = 8.9, 6.9 Hz, ArH); MS
(LC, 70 eV) m/z 429 (M+1), 413, 301, 256, 224.
Example 15: (E)-N-hydroxy-8-morpholino-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide (15-1): (E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctene acid methylester The procedure of Example (1-1) was repeated except for using morpholinoamine instead of dimethylaminehydrochloride as the amine to obtain 416 mg of the title compound (yield: 67%).
1H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CHZ), 1.63 (m, 2H, CH2), 2.25 (m, 4H, CH2CH2), 3.60 (m, 8H, CH2CH2CH2CH2), 3.71 (s, 3H, OCH3), 5.01 (s, 2H, CH2), 5.82 (t, 1 H, J= 15.0, 7.8 Hz, CH), 6.84 (dd, 1 H, J 7.2, 1.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.79 (m, 1 H, ArH), 8.13 (dd, 1 H, J= 4.0, 3.2 Hz, ArH).
(15-2): (E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (15-1) as the starting material, to obtain 85 mg of the title compound (yield: 89%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H, CH2), 1.63 (m, 2H, CH2), 2.24 (m, 4H, CH2CH2), 3.58 (m, 8H, CH2CH2CH2CH2), 5.02 (s, 2H, CHZ), 5.86 (t, 1 H, J = 15.2, 7.6 Hz, CH), 6.82 (dd, 1 H, J = 7.4, 1.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (d, 1 H, J= 7.4 Hz, ArH), 8.13 (t, 1 H, J = 7.4, 3.4 Hz, ArH).
(15-3):(E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxo-N-(tetrahydro-2H-pyran-2-yloxy)octeneamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (15-2) as the starting material, to obtain 92 mg of the title compound (yield: 88%).
'H NMR (200 MHz, MeOH-d4) 6 1.54 (m, 5H, CH CH2CH2), 1.68 (m, 4H, CH2CH2), 2.18 (m, 2H, CH2), 2.40 (m, 2H, CH2), 3.25 (m, 5H, CHCH2CH2), 3.59 (m, 6H, CH2CH2CH2), 3.99 (m, 1H, CH), 5.08 (s, 2H, CHZ), 5.90 (t, 1H, J= 15.0, 7.6 Hz, CH), 6.97 (t, 1 H, J= 7.0, 5.8 Hz, ArH), 7.48 (m, 4H, ArH), 7.91 (dd, 1 H, J = 12.6, 3.0 Hz, ArH), 8.13 (t, 1 H, J = 7.0, 4.0 Hz, ArH).
(15-4): (E)-N-hydroxy-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (15-3) as the starting material, to obtain 64 mg of the title compound (yield: 72%).
1 H NMR (300 MHz, MeOH-d4) 6 1.53 (s, 2H, CH2), 1.68 (m, 2H, CHZ), 2.13 (t, 2H, J = 14.1, 7.0 Hz, CHZ), 2.35 (q, 2H, J = 14.6, 7.3 Hz, CHZ), 3.33 (m, 2H, CH2), 3.53 (m, 6H, CH2CH2CH2), 5.06 (s, 2H, ArH), 5.86 (t, 1H, J = 14.9, 7.4 Hz, CH), 6.97 (t, 1 H, J = 7.2, 2.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (dd, 1 H, J = 5.6, 2.6 Hz, ArH), 8.13 (dd, 1 H, J = 6.2, 2.6 Hz, ArH); MS (LC, 70 eV) m/z 413 (M+1), 380, 309, 293, 265, 236, 149, 121.
Example 16: (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3-1o yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (16-1): (E)-8-(6-(4-methylpiperazin-1-yl)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(4-methylpiperazin-1-yl)pyridin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 216 mg of the title compound (yield: 37%).
'H NMR (300 MHz, MeOH-d4) 8 1.47 (m, 2H), 1.67 (, 2H), 1.88 (m, 2H), 2.37 (t, 2H), 2.93 (s, 3H), 3.34 (m, 4H), 3.61 (s, 3H), 3.79 (br, 4H), 4.34 (t, 1 H), 4.5 8(d, 1 H), 6.91 (d, 1 H), 7.42 (m, 3H), 7.51 (d, 1 H), 7. 8 6(m, 1 H), 7.91 (m, 2H), 8.06 (s, 1 H), 8.11 (m, 1 H), 8.39 (s, 1 H); MS (LC, 70 eV) m/z 517 (M+1).
(16-2):(E)-8-(6-(4-methylpiperazin-1-yl)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (16-1) as the starting material, to obtain 249 mg of the title compound (yield: 94%).
1H NMR (300 MHz, MeOH-d4) 6 1.45 (m, 2H), 1,67 (m, 2H), 2.30 (t, 2H), 2.94 (s, 3H), 3.33 (m, 4H), 3.83 (br, 4H), 4.45 (t, 1H), 4.56 (d) 1H), 7.03 (d, 1 H), 7.41 (m, 4H), 7.76 (m, 2H), 7.92 (d, 1 H), 8.12 (m, 2H), 8.49 (s, 1 H);
MS
(LC, 70 eV) m/z 503 (M+l).
(16-3): (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (16-2) as the starting material, to obtain 132 mg of the title compound (yield: 72%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H), 1,67 (m, 2H), 2.11 (t, 2H), 2.94 (s, 3H), 3.33 (m, 4H), 3.83 (br, 4H), 4.45 (t, 1H), 4.56 (d, 1H), 7.03 (d, 1H), 7.41 (m, 4H), 7.76 (m, 2H), 7.92 (d, 1 H), 8.12 (m, 2H), 8.49 (s, 1 H);
MS
(LC, 70 eV) m/z 518 (M+1).
Example 17: (E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (17-1):(E)-7-(6-(2-morpholinoethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(2-morpholinoethylamino)pyridin-3-yl instead of dimethylaminehydrochloride amine as the amine to obtain 350 mg of the title compound (yield: 64%).
'H NMR (300 MHz, MeOH-d4) 6 1.45 (m, 2H), 1.63 (m, 2H), 1.91 (m, 2H), 2.29 (t, 2H), 2.88 (m, 6H), 3.52 (t, 2H), 3.69 (s, 3H), 3.81 (m, 4H), 4.34 (t, 1 H), 4.78 (d, 1 H), 6.60 (d, 1 H), 7.42 (m, 6H), 7.66 (d, 1 H), 7.74 (m, 1 H), 8.12 (m, 1H), 8.24 (s, 1 H); MS (LC, 70 eV) m/z 547 (M+1).
(17-2):(E)-7-(6-(2-morpholinoethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (17-1) as the starting material, to obtain 207 mg of the title compound (yield: 87%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H), 1.63 (m, 2H), 1.91 (m, 2H), 2.29 (t, 2H), 2.88 (m, 6H), 3.52 (t, 2H), 3.81 (m, 4H), 4.34 (t, 1H), 4.78 (d, 1 H), 6.60 (d, 1 H), 7.42 (m, 6H), 7.66 (d, 1 H), 7.74 (m, 1 H), 8.12 (m, 1 H), 8.24 (s, 1H); MS (LC, 70 eV) m/z 533 (M+1).
(17-3):(E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (17-2) as the starting material, to obtain 171 mg of the title compound (yield: 48%).
'H NMR (300 MHz, DMSO-d6) 8 1.39 (m, 2H), 1.54 (m, 2H), 1.78 (m, 2H), 1.96 (t, 2H), 3.35 (m, 6H), 3.69 (m, 2H), 3.85 (m, 4H), 4.38 (t,1H), 4.52 (d, 1 H), 6.87 (d, 1 H), 7.45 (m, 6H), 7.82 (m, 2H), 8.03 (m, 1 H), 8.3 8(s, 1 H), 10.07 (s, 1H), 10.39 (s, 1H); MS (LC, 70 eV) m/z 548 (M+l ).
Example 18: (E)-N1-(6-(dimethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (18-1):(E)-7-(6-(dimethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-l-yloxy)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using not dimethylaminehydrochloride but 6-(dimethylamino)pyridin-3-ylamine as the amine to obtain 256 mg of the title compound (yield: 63%).
'H NMR (300 MHz, CDC13) S 1.64 (m, 4H), 2.36 (m, 4H), 3.07 (s, 6H), 3.68 (s, 3H), 5.06 (s, 2H), 6.52 (d, 1H), 6.98 (m, 2H), 7.44 (t, 1H), 7.53 (m, 3H), 7.87 (m, 2H), 8.11 (d, 1H), 8.27 (m, 1H); MS (LC, 70 eV) m/z 462 (M+1).
(18-2):(E)-7-(6-(dimethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (18-1) as the starting material, to obtain 190 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) 8 1.61 (m, 4H), 2.28 (t, 2H), 2.44 (q, 2H), 3.08 (s, 6H), 5.12 (s, 2H), 6.71 (m, 2H), 7.05 (d, 1H), 7.44 (m, 4H), 7.79 (m, 2H), 8.23 (m, 2H); MS (LC, 70 eV) m/z 448 (M+1).
(18-3):(E)-Nl-(6-(dimethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (18-2) as the starting material, to obtain 90 mg of the title compound (yield: 46%).
'H NMR (300 MHz, MeOH-d4) S 1.66 (m, 4H), 2.11 (t, 2H), 2.43 (q, 2H), 3.06 (s, 6H), 5.10 (s, 2H), 6.68 (m, 2H), 7.07 (d, 1H), 7.44 (m, 4H), 7.78 (m, 2H), 8.20 (m, 2H); MS (LC, 70 eV) m/z 463 (M+1).
Example 19: (E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (19-1):(E)-8-(6-(2-(dimethylamino)ethylamino)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(2-(dimethylamino)ethylamino)pyridin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 307 mg of the title compound (yield: 31 %).
'H NMR (300 MHz, CDC13) 8 1.65 (m, 4H), 2.08 (m, 2H), 2.31 (s, 6H), 2.38 (m, 2H), 2.59 (t, 2H), 3.35 (q, 2H), 3.67 (s, 3H), 5.06 (s, 2H), 6.44 (d, 1H), 7.03 (m, 2H), 7.45 (t, 1 H), 7.53 (m, 3H), 7.75 (dd, IH), 7.85 (dd, 1H), 8.06 (d, 1H), 8.24 (m, 2H); MS (LC, 70 eV) m/z 505 (M+1).
(19-2):(E)-8-(6-(2-(dimethylamino)ethylamino)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (19-1) as the starting material, to obtain 226 mg of the title compound (yield: 75%).
'H NMR (300 MHz, MeOH-d4) S 1.64 (m, 4H), 2.27 (t, 2H), 2.47 (m, 2H), 2.91 (s, 6H), 3.28 (q, 2H), 3.65 (t, 2H), 5.11 (s, 2H), 6.66 (d, 1 H), 6.72 (t, 1 H), 7.08 (d, 1 H), 7.44 (m, 4H), 7.67 (dd, 1 H), 7.78 (dd, 1 H), 8.15 (dd, 1 H), 8.29 (m, 1H); MS (LC, 70 eV) m/z 491 (M+1).
(19-3):(E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (19-2) as the starting material, to obtain 11 mg of the title compound (yield: 5%).
'H NMR (300 MHz, MeOH-d4) 8 1.64 (m, 4H), 2.11 (t, 2H), 2.50 (s, 6H), 2.52 (m, 2H), 2.83 (t, 2H), 4.11 (t, 2H), 5.13 (s, 2H), 6.78 (m, 1H), 7.06 (d, 1 H), 7.45 (m, 4H), 7.5 8(dd, 1 H), 7.78 (dd, 1 H), 8.06 (dd, 1 H), 8.13 (d, 1 H), 8.74 (d, 1 H); MS (LC, 70 eV) m/z 506 (M+1).
Example 20: (E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (20-1):7-(6-methoxy-pyridin-3-ylcarbamoyl)-8-(naphthalen-1-ylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (6-methoxypyridin-3-yl)amine instead of dimethylaminehydrochloride as the amine to obtain 1.67 mg of the title compound (yield: 42%).
1H NMR (300 MHz, CDC13) S 1.54-1.73 (m, 4H), 2.29-2.37 (m, 4H), 3.63 (S, 3H), 3.85 (S, 3H), 6.65 (m, 1H), 6.82-6.98 (m, 2H), 7.39-7.52 (m, 4H), 7.81-7.91 (m, 3H), 8.10 (m, 1H), 9.29 (S, 1H).
(20-2):7-(6-methoxy-pyridin-3-ylcarbamoyl)-8-(naphthalen-1-ylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (20-1) as the starting material, to obtain 670 mg of the title compound (yield: 40%).
(20-3):(E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (20-2) as the starting material, to obtain 482 mg of the title compound (yield: 69%).
1H NMR (300 MHz, MeOH-d4) S 1.45-1.59 (m, 4H), 1.97 (m, 2H), 2.40 (m, 2H), 3.80 (S, 3H), 4.17 (S, 2H), 6.15 (S, 1H), 6.55 (m, 2H), 6.78 (d, J = 9.0 Hz, 1 H), 7.13 (d, J = 7.7 Hz, 1 H), 7.24-7.41 (m, 3 H), 7.74 (d, J = 8.8 Hz, 1 H), 7.91 (m, 1H), 8.10 (S, 1H), 8.38 (S, 1H), 9.84 (S, 1H), 10.37 (S, 1H).
Example 21: (E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yl)methyl)octenediamide (21-1):(E)-8-(3-(1H-imidazol-1-yl)propylamino)-7-((naphthalen-l-yl)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(1 H-imidazol-1-yl)propylamine instead of dimethylaminehydrochloride as the amine to obtain 449 mg of the title compound (yield: 77%).
'H NMR (300 MHz, CDC13) 6 1.53-1.84 (m, 4H), 2.05 (m, 2H), 2.39 (m, 4H), 3.42 (q, J = 6.3Hz, 2H), 3.72 (s, 3H), 3.98 (t, J=7.OHz, 2H), 5.02 (s, 2H), 6.72 (t, J = 6.0 Hz, 1H), 6.88-7.07 (m, 4H), 7.36-7.65(m, 4H), 7.90(d, J = 6.7 Hz, 1 H), 8.22 (d, J = 7.3 Hz, 1 H).
LC/MS (M+H): 450.23.
(21-2):(E)-8-(3-(1H-imidazol-1-yl)propylamino)-7-((naphthalen-l-yl)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (21-1) as the starting material, to obtain 350 mg of the title compound (yield: 85%).
(21-3):(E)-N1-(3-(1H-imidazol-l-yl)propyl)-2-((naphthalen-l-yl)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (21-2) as the starting material, to obtain 220 mg of the title compound (yield: 63%).
'H NMR (200 MHz, CDC13) 6 1.40-1.75 (m, 11H), 1.81 (t, J= 6.4 Hz, 2H), 1.96 (m, 2H), 2.15 (m, 2H), 3.19 (q, J = 6.1 Hz, 2H), 3.38 (d, J = 11.8 Hz, 1 H), 3.76 (t, J = 6.9 Hz, 3H), 4.74 (s, 2H), 6.46 (m, 1 H), 6.67 (m, 2H), 6.83 (m, 2H) 7.32 (m, 5H), 7.65 (d, J = 6.5 Hz, 1H), 7.96 (d, J= 7.7 Hz, 1H), 9.33 (br, 1H).
LC/MS (M+H): 535.28.
(21-4):(E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (21-3) as the starting material, to obtain 63 mg of the title compound (yield: 37%).
HPLC purification: 46mg (purity : 97%) 'H NMR (300 MHz, MeOH-d4) S 1.52 (m, 2H), 1.68 (m, 2H), 2.03 (t, J
6.6Hz, 2H), 2.11 (t, J = 6.6 Hz, 2H), 2.3 5(q, J = 7.2Hz, 2H), 5.04 (s, 2H), 6.57 (t, J = 6.3 Hz, 2H), 7.01 (d, J = 7.2 Hz, 1 H), 7.18 (s, 1 H), 7.26 (s, 1 H), 7.43 (m, 4H), 7.78 (d, J = 7.8Hz, 1 H), 8.09 (s, 1 H), 8.13 (d, J =5.1 Hz, 1 H).
LC/MS (M+H): 451.23.
Example 22: (E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (22-1):(E)-8-(4-hydroxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-2 0 8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-hydroxyphenetylamine instead of dimethylaminehydrochloride as the amine to obtain 461 mg of the title compound (yield: 95%).
'H NMR (300 MHz, CDC13) S 1.50-1.80 (m, 4H), 2.38 (m, 4H), 2.82 (t, J
6.9Hz, 2H), 3.63 (m, 2H), 3.72 (s, 3H), 4.92 (s, 2H), 6.44 (br, 1H), 6.53-6.59 (t, J 5.4 Hz, 1H), 6.66 (d, J 8.4 Hz, 2H), 6.95 (m, 4H), 7.37 (m, 4H), 7.90 (d, J 9.1 Hz, 1 H), 8.12 (d, J 9.7 Hz, 1 H).
LC/MS (M+H): 412.20.
(22-2):(E)-8-(4-hydroxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (22-1) as the starting material, to obtain 439 mg of the title compound (yield: 92%).
'H NMR (300 MHz, MeOH-d4) 8 1.52 (m, 2H, CH2), 1.64 (m, 2H, CH2), 2.20 (m, 2H, CH2), 2.27 (s, 6H, N(CH3)2), 2.38 (m, 2H, CH2), 2.55 (m, 2H, CH2), 3.42 (m, 2H, CH2), 4.97 (s, 2H, CH2), 6.67 (s, 1 H, CH), 6.99 (t, 1 H, J= 7.0, 1.8 Hz, ArH), 7.41 (m, 4H, ArH), 7.77 (d, 1 H, J= 7.0, 1.8 Hz, ArH), 8.14 (d, 1 H, J = 7.2 Hz, ArH).
(22-3):(E)-N1-(4-hydroxyphenetyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (22-2) as the starting material, to obtain 394 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 1.42-1.85 (m, 12H), 2.04 (m, 2H), 2.22 (m, 2H), 2.71 (t, J = 6.4 Hz, 2H), 3.50 (m, 3H), 3.92 (m, 1H), 4.79 (s, 2H), 4.92 (m, 1 H), 6.3 8(t, J = 5.4 Hz, 1 H), 6.67 (m, 3H), 6.86 (m, 3H) 7.18 (br, 1 H), 7.44 (m, 4H), 7.77 (m, 1 H), 8.00 (m, 1 H), 8.93 (br, 1 H).
LC/MS (M+H): 497.26.
(22-4):(E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (22-3) as the starting material, to obtain 121 mg of the title compound (yield: 78%).
HPLC purification: 61mg (purity: 95%) 'H NMR (200 MHz, MeOH-d4) S 1.48-1.72 (m, 4H), 2.08 (t, J = 7.2Hz, 2H), 2.34 (q, J = 6.8 Hz, 2H), 2.73 (t, J = 7.2Hz, 2H), 3.45 (t, 7.0 Hz, 2H), 4.98 (s, 2H), 6.53 (t, J = 7.4 Hz, 1H), 6.63 (d, J = 7.8 Hz, 211), 6.97 (d, J = 8. 2Hz, 3H), 7.43 (m, 4H), 7.78 (d, J = 7.0 Hz, 1H), 8.10 (d, J = 9.2 Hz, 1H).
LC/MS (M+H): 413.20.
Example 23: (E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (23-1):(E)-8-(3-(dimethylamino)-2,2-dimethylpropylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(dimethylamino)-2,2-dimethylpropylamine instead of dimethylaminehydrochloride as the amine to obtain 454 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 0.87 (s, 6H), 1.45-1.73 (m, 4H), 1.85 (s, 6H), 2.11 (s, 2H), 2.27 (m, 2H), 3.25 (d, J = 4.4 Hz, 2H), 3.60 (s, 3H), 4.87 (s, 2H), 6.92 (m, 2H), 7.42 (m, 4H), 7.72 (d, J = 7.4 Hz, 1 H), 8.19 (d, J = 9.0 Hz, 1 H).
LC/MS (M+H): 405.27.
(23-2):(E)-8-(3-(dimethylamino)-2,2-dimethylpropylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (23-1) as the starting material, to obtain 339 mg of the title compound (yield: 93%).
'H NMR (200 MHz, MeOH-d4) S 1.6 (m, 4H, CH2CH2), 2.4 (m, 6H, CH2CH2CH2), 2.50 (m, 414, CH2CH2), 2.80 (m, 2H, CH2), 3.01 (s, 3H, NCH3), 3.29 (m, IH, CH), 3.65 (m, 1 H, CH), 4.95 (s, 2H, PhCH2), 6.00 (m, 1 H, CH), 7.00 (t, 1 H, J= 16.6, 9.4 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (m, 1 H, ArH), 8.18 (m, 1 H, ArH).
(23-3):(E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (23-2) as the starting material, to obtain 304 mg of the title compound (yield: 52%).
'H NMR (200 MHz, CDC13) 6 0.88 (s, 6H), 1.49-1.82 (m, 10H), 1.86 (s, 6H), 2.02 (m, 2H), 2.13 (s, 2H), 2.31 (q, J = 7.4 Hz, 2H), 3.27 (d, J = 4.6 Hz, 2H), 3.58 (m, 1H), 3.93 (m, 1H), 4.88 (s, 2H), 4.90 (m, 1H), 6.95 (t, J= 7.4 Hz, 2H), 7.45 (m, 4H), 7.78 (d, J= 6.0 Hz, 1H), 8.21 (d, J = 7.0 Hz, 1H), 8.48 (br, 1 H), 8.62 (br, 1 H).
LC/MS (M+H): 490.32.
(23-4):(E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (23-3) as the starting material, to obtain 144 mg of the title compound (yield: 74%).
HPLC purification: 101 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 0.98(s, 6H), 1.54 (m, 2H), 1.6 6(m, 2H), 2.12 (t, J= 7.4 Hz, 2H), 2.40 (s, 6H), 2.46 (m, 4H), 3.26 (s, 2H), 5.04 (s, 2H), 6.71 (t, J = 8.2 Hz, 1 H), 7.04 (m, 1 H), 7.45 (m, 4H), 7.80 (d, J = 7.8 Hz, 1 H), 8.13 (d, J = 8.6 Hz, 1H.
LC/MS (M+H): 406.26.
Example 24: (E)-Nl-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (24-1):(E)-8-(2-(diisopropylamino)ethylamino)-8-oxo-7-((naphthalen-l-yloxy)methyl)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(diisopropylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 420 mg of the title compound (yield: 89%).
'H NMR (200 MHz, CDC13) 8 0.87 (d, J = 7.0 Hz, 12H), 1.51 (m, 2H), 1.64 (m, 2H), 2.26 (m, 4H), 2.57 (t, J = 6.0 Hz, 2H), 2.86 (m, 2H), 3.31 (q, J =
5.6 Hz, 2H), 3.61 (s, 3H), 4.90 (s, 1H), 6.90 (m, 3H), 7.44 (m, 4H), 7.77 (d, J
7.2 Hz, 1 H), 8.17 (d, J= 7.0 Hz, 1 H).
LC/MS (M+H): 419.28.
(24-2):(E)-8-(2-(diisopropylamino)ethylamino)-8-oxo-7-((naphthalen-l-yloxy)methyl)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (24-1) as the starting material, to obtain 420 mg of the title compound (yield: 78%).
(24-3):(E)-N1-(2-(diisopropylamino)ethyl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (24-2) as the starting material, to obtain 319 mg of the title compound (yield: 50%).
'H NMR (200 MHz, CDC13) 8 0.95 (br, 9H), 1.50-1.95 (m, lOH), 2.10 (m, 2H), 2.31 (q, J = 6.8 Hz, 2H), 2.67 (m, 2H), 2.96 (s, 2H), 3.46 (m, 2H), 3.57 (m, 2H), 3.97 (m, 1 H), 4.93 (s, 2H), 4.94 (m, 1 H), 6.87 (m, 3H), 7.49 (m, 4H), 7.78 (d, J= 6.8 Hz, 1H), 8.15 (d, J= 8.6 Hz, 1H).
LC/MS (M+H): 504.34.
(24-4):(E)-N1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (24-3) as the starting material, to obtain 145 mg of the title compound (yield: 85%).
HPLC purification: 59 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 1.32 (t, J = 6.2 Hz, 9H), 1.46-1.78 (m, 4H), 2.10 (t, J 7.0 Hz, 2H), 2.41 (q, J 6.8 Hz, 2H), 3.23 (t, J 6.2 Hz, 2H), 3.63 (t, J 7.0 Hz, 1 H), 3.74 (m, 2H), 5.05 (s, 2H), 6.76 (t, J 6.6 Hz, 1 H), 7.02 (d, J 7.0 Hz, 1 H), 7.45 (m, 4H), 7.80 (d, J = 7.6 Hz, 1 H), 8.12 (d, J
7.8 Hz, 1 H).
LC/MS (M+H): 420.28.
Example 25: (E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (25-1):(E)-8-(1-methoxypropan-2-ylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-methoxypropan-2-ylamine instead of dimethylaminehydrochloride as the amine to obtain 413 mg of the title compound (yield: 83%).
'H NMR (200 MHz, CDC13) 8 1.15 (d, J = 6.8 Hz, 3H), 1.50 (m, 2H), 1.63 (m, 2H), 2.29 (m, 4H), 3.15 (s, 3H), 3.31 (d, J = 4.0 Hz, 2H), 3.62 (s, 3H), 4.24 (m, 1 H), 4.93 (s, 2H), 6.64 (d, J = 7.8 Hz, 1 H), 6.84 (t, J= 7.8 Hz, 1 H), 6.91 (d, J = 7.2 Hz, 1 H), 7.46 (m, 4H), 7.83 (m, 1H), 8.19 (m, 1 H).
LC/MS (M+H): 414.22.
(25-2):(E)-8-(1-methoxypropan-2-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (25-1) as the starting material, to obtain 346 mg of the title compound (yield: 81 %).
(25-3):(E)-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (25-2) as the starting material, to obtain 289 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 1.17 (d, J = 6.8 Hz, 3H), 1.41-1.89 (m, lOH), 2.09 (m, 2H), 2.31 (q, J = 7.0 Hz, 2H), 3.17 (s, 3H), 3.57 (m, 1H), 3.93 (m, 1 H), 4.24 (m, 1 H), 4.93 (m, 1 H), 6.69 (d, J = 7.8 Hz, 1 H), 6.84 (t, J =
6.6 Hz, 1 H), 6.91 (d, J = 7.8 Hz, 1 H), 7.41 (m, 4H), 7.8 0(d, J = 7.8 Hz, 1 H), 8.19 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 499.27.
(25-4):(E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-l-2 0 yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (25-3) as the starting material, to obtain 125 mg of the title compound (yield: 88%).
HPLC purification: 63mg (purity: 97%) 'H NMR (200 MHz, DMSO-d4) 6 1.07 (d, J = 7.0 Hz, 3H), 1.45 (m, 2H), 1.51 (m, 2H), 1.96 (t, J = 7.0 Hz, 2H), 2.29 (m, 2H), 3.24 (s, 3H), 3.36 (s, 2H), 4.09 (m, 1 H), 4.96 (s, 2H), 6.51 (t, J = 7.8 Hz, 1 H), 7.07 (d, J = 6.8 Hz, 1H), 7.47 (m, 4H), 7.86 (m, 2H), 8.06 (d, J = 9.0 Hz, 1H), 8.70 (br, 4H), 10.35 (br, 1 H).
LC/MS (M+H): 415.22.
Example 26: (E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (26-1):(E)-8-(4-methoxybenzylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methoxybenzylamine instead of dimethylaminehydrochloride as the amine to obtain 461 mg of the title compound (yield: 98%).
'H NMR (200 MHz, CDC13) S 1.49 (m, 2H), 1.59 (m, 2H), 2.29 (m, 4H), 3.62 (s, 3H), 3.77 (s, 3H), 4.44 (d, J = 5.8 Hz, 2H), 4.94 (s, 2H), 6.75 (m, 3H), 6.88 (d, J= 7.4 Hz, 2H), 7.15 (d, J= 8.6 Hz, 2H), 7.44 (m, 4H), 7.78 (d, J= 7.4 Hz, 1 H), 7.99 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 462.22.
(26-2):(E)-8-(4-methoxybenzylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (26-1) as the starting material, to obtain 454 mg of the title compound (yield: 86%).
(26-3):(E)-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy)methyl)-N8-2 5 (tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (26-2) as the starting material, to obtain 378 mg of the title compound (yield: 85%).
'H NMR (200 MHz, CDC13) S 1.52-1.95 (m, 10H), 2.07 (m, 2H), 2.29 (q, J
7.2 Hz, 2H), 3.75 (s, 3H), 3.91 (m, 1H), 4.43 (d, J = 5.8 Hz, 2H), 4.90 (m, 1H), 4.92 (s, 2H), 6.79 (m, 3H), 6.87 (d, J= 7.6 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.47 (m, 4H), 7.77 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 8.65 (br, 1H).
LC/MS (M+H): 547.27.
(26-4):(E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (26-3) as the starting material, to obtain 142 mg of the title compound (yield: 80%).
HPLC purification: 81mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) 8 1.52 (m, 2H), 1.58 (m, 2H), 2.08 (t, J = 7.4 Hz, 2H), 2.34 (q, J = 7.6 Hz, 2H), 3.37 (s, 3H), 3.74 (s, 1H), 5.03 (s, 2H), 6.59 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 8.2 Hz, 2H), 6.96 (d, J = 6.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.42 (m, 4H), 7.77 (d, J = 7.8 Hz, 1H),8.06(d,J=
7.4 Hz, 1 H).
LC/MS (M+H): 463.22.
Example 27: (E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (27-1):(E)-8-(4-fluorophenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-fluorophenetylamine instead of dimethylaminehydrochloride as the amine to obtain 463 mg of the title compound (yield: 93%).
'H NMR (200 MHz, CDC13) S 1.52 (m, 2H), 1.62 (m, 2H), 2.28 (m, 4H), 2.76 (t, J= 6.8 Hz, 2H), 3.54 (q, J = 5.6 Hz, 2H), 3.61 (s, 3H), 4.82 (s, 2H), 6.66 (br, 1H), 6.70 (m, 2H), 6.86 (m, 2H), 6.96 (m, 2H), 7.48 (m, 4H), 7.80 (d, J
7.4 Hz, 1H), 7.99 (d, J = 7.0 Hz, 1 H).
LC/MS (M+H): 464.21.
(27-2):(E)-8-(4-fluorophenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (27-1) as the starting material, to obtain 434 mg of the title compound (yield: 86%).
(27-3):(E)-N1-(4-fluorophenetylamino)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (27-2) as the starting material, to obtain 362 mg of the title compound (yield: 651 %).
'H NMR (200 MHz, CDC13) 6 1.48-1.89 (m, 10H), 2.16 (m, 2H), 2.28 (q, J
7.2 Hz, 2H), 2.75 (t, J = 6.8 Hz, 2H), 3.53 (q, J= 5.8 Hz, 2H), 3.60 (m, 1H), 3.91 (m, 1 H), 4.81 (s, 2H), 4.90 (m, 1 H), 6.49 (m, 1 H), 6.70 (m, 2H), 6.85 (m, 2H), 6.96 (m, 2H), 7.42 (m, 4H), 7.81 (d, J = 7.4 Hz, 1 H), 7.98 (d, J = 7.6 Hz, 1 H), 8.56 (br, 1 H).
LC/MS (M+H): 549.27.
(27-4):(E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (27-3) as the starting material, to obtain 83 mg of the title compound (yield: 76%).
HPLC purification: 36mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 1.49 (m, 2H), 1.69 (m, 2H), 2.09 (t, J = 6.8 Hz, 2H), 2.34 (q, J = 7.2 Hz, 2H), 2.80 (t, J = 6.8 Hz, 2H), 3.48 (m, 2H), 4.97 (s, 2H), 6.55 (t, J = 7.8 Hz, 1H), 6.86 (m, 2H), 6.97 (d, J 7.6 Hz, 1H), 7.14 (m, 2H), 7.45 (m, 4H), 7.79 (d, J= 7.8 Hz, 1 H), 8.10 (d, J 8.0 Hz, 1 H).
LC/MS (M+H): 465.21.
Example 28: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(tetrahydropyran-2-yl)methyl)-2-octenediamide (28-1):(E)-7-(((naphthalen-1-yloxy)methyl)-8-oxo-8-((tetrahydropyran-2-yl)methylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using tetrahydropyran-2-yl)methylamine instead of dimethylaminehydrochloride as the amine to obtain 426 mg of the title compound (yield: 87%).
'H NMR (200 MHz, CDC13) S 1.45-1.99 (m, 8H), 2.28 (m, 4H), 3.26 (m, 1H), 3.78 (m, 3H), 3.61 (s, 3H), 3.97 (m, 1H), 4.93 (s, 2H), 6.79 (m, 1H), 6.90 (m, 2H), 7.47 (m, 4H), 7.78 (m, 1H), 8.20 (m, 1H).
LC/MS (M+H): 426.22.
(28-2):(E)-7-(((naphthalen-1-yloxy)methyl)-8-oxo-8-((tetrahydropyran-2-yl)methylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (28-1) as the starting material, to obtain 370 mg of the title compound (yield: 90%).
(28-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N1-(tetrahydropyran-2-yl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (28-2) as the starting material, to obtain 323 mg of the title compound (yield: 65%).
'H NMR (200 MHz, CDC13) 8 1.42-1.95 (m, 14H), 2.08 (m, 2H), 2.25 (q, J
7.6 Hz, 2H), 3.28 (m, 1H), 3.59 (m, 3H), 3.89 (m, 2H), 4.88 (s, 2H), 4.90 (m, 1 H), 6.77 (m, 2H), 6.85 (d, J = 7.2 Hz, 1 H), 7.40 (m, 4H), 7.77 (m, 1 H), 8.14 (m, 1H), 8.68 (br, 1H).
LC/MS (M+H): 511.27.
(28-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-Nl-(tetrahydropyran-2-y1)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (28-3) as the starting material, to obtain 85 mg of the title compound (yield: 85%).
HPLC purification: 32mg (purity: 95%) 'H NMR (200 MHz, MeOH-d4) 8 1.60 (m, 6H), 1.81 (m, 2H), 2.09 (t, J = 7.2 Hz, 2H), 2.37 (q, J = 7.4 Hz, 2H), 3.35 (m, 2H), 3.68 (m, 2H), 4.00 (m, 1H), 5.02 (s, 2H), 6.65 (t, J = 7.8 Hz, 1 H), 7.01 (d, J = 6.8 Hz, 1 H), 7.44 (m, 4H), 7.78 (d, J = 8.6 Hz, 1 H), 8.15 (d, J = 9.4 Hz, 1 H).
LC/MS (M+H): 427.22.
Example 29: (E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (29-1):(E)-8-(2-cyclohexenylethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-cyclohexenylethylamine instead of dimethylaminehydrochloride as the amine to obtain 449 mg of the title compound (yield: 89%).
1H NMR (200 MHz, CDC13) S 1.25 (m, 2H), 1.30-1.71 (m, 8H), 1.79 (m, 2H), 2.09 (t, J = 7.4 Hz, 2H), 2.28 (m, 4H), 3.39 (q, J = 5.4 Hz, 2H), 3.60 (s, 3H), 4.86 (s, 2H), 5.28 (br, 1 H), 6.41 (br, 1 H), 6.89 (t, J= 7.6 Hz, 2H), 7.46 (m, 4H), 7.79 (m, 1 H), 8.14 (m, 1 H).
LC/MS (M+H): 450.26.
(29-2):(E)-8-(2-cyclohexenylethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (29-1) as the starting material, to obtain 401 mg of the title compound (yield: 95%).
(29-3):(E)-N1-(2-cyclohexenylethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-43) was repeated except for using the compound obtained in Example (29-2) as the starting material, to obtain 370 mg of the title compound (yield: 82%).
'H NMR (200 MHz, CDC13) 8 1.27 (m, 2H), 1.35-2.02 (m, 16H), 2.10 (m, 4H), 2.30 (q, J = 6.8 Hz, 2H), 3.40 (q, J = 5.8 Hz, 2H), 3.63 (m, 1H), 3.96 (m, 1 H), 4.87 (s, 2H), 4.92 (m, 1 H), 5.18 (br, 1 H), 6.44 (br, 1 H), 6.90 (t, J
= 7.6 Hz, 2H), 7.44 (m, 4H), 7.80 (m, 1 H), 8.15 (m, 1 H), 8.80 (br, 1 H).
LC/MS (M+H): 535.31.
(29-4):(E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (29-3) as the starting material, to obtain 112 mg of the title compound (yield: 91 %).
HPLC purification: 62 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) 6 1.36-1.82 (m, lOH), 1.91 (m, 2H), 2.09 (m, 4H), 2.36 (q, J = 7.4 Hz, 2H), 3.34 (m, 2H), 4.99 (s, 2H), 5.34 (br, 1H), 6.63 (t, J= 7.8 Hz, 1H), 7.01 (d, J = 6.8 Hz, 1H), 7.45 (m, 4H), 7.79 (d, J = 9.4 Hz, 1 H), 8.13 (d, J = 9.0 Hz, 1 H).
LC/MS (M+H): 451.25.
Example 30: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl)propyl)-2-octenediamide (30-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(3-(2-oxopyrrolidin-l-yl)propylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(2-oxopyrrolidin-1-yl)propylamine instead of dimethylaminehydrochloride as the amine to obtain 466 mg of the title compound (yield: 79%).
'H NMR (200 MHz, CDC13) S 1.44 (m, 2H), 1.63 (m, 4H), 1.95 (m, 2H), 2.26 (m; 6H), 3.21 (m, 6H), 3.56 (s, 3H), 4.93 (s, 2H), 6.72 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 7.23 (m, 1H), 7.39 (m, 1H), 7.74 (m,. 1H), 8.12 (m, 1 H).
LC/MS (M+H): 467.25.
(30-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(3-(2-oxopyrrolidin-l-yl)propylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (30-1) as the starting material, to obtain 370 mg of the title compound (yield: 88%).
(30-3):(E)-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl) propyl)-N8-(tetrahyd ro-2H-pyran-2-yloxy)-2-octenediam ide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (30-2) as the starting material, to obtain 316 mg of the title compound (yield: 80%).
'H NMR (200 MHz, CDC13) S 1.42-1.90 (m, 12H), 2.04 (m, 4H), 2.39 (m, 4H), 3.27 (m, 6H), 3.59 (m, 1H), 3.95 (m, 1H), 4.94 (m, 1H), 4.99 (s, 2H), 6.73 (t, J 7.6 Hz, 1 H), 6.91 (d, J = 7.4 Hz, 1 H), 7.25 (br, 4H), 7.45 (m, 4H), 7.78 (d, J 7.8 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 9.25 (br, 1H).
LC/MS (M+H): 552.30.
(30-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-l-yl)propyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (30-3) as the starting material, to obtain 166 mg of the title compound (yield: 82%).
HPLC purification: 49 mg (purity: 97%) 'H NMR (200 MHz, MeOH-d4) 8 1.53 (m, 2H), 1.74 (m, 4H), 2.06 (m, 4H), 2.36 (m, 4H), 3.33 (m, 6H), 4.86 (s, 2H), 6.61 (t, J = 7.4 Hz, 1H), 7.00 (d, J
6.8 Hz, 1H), 7.43 (m, 4H), 7.78 (d, J = 7.4 Hz, 1 H), 8.14 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 468.24.
Example 31: (E)-N1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide (31-1):(E)-8-(furan-2-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using furan-2-ylamine instead of dimethylaminehydrochloride as the amine to obtain 421 mg of the title compound (yield: 83%).
'H NMR (200 MHz, CDC13) 8 1.48 (m, 2H), 1.60 (m, 2H), 2.27 (m, 4H), 3.61 (s, 3H), 4.51 (d, J = 5.4 Hz, 2H), 4.93 (s, 2H), 6.20 (dd, J = 10.6 Hz, 3.2 Hz, 2H), 6.90 (m, 3H), 7.45 (m, 4H), 7.78 (d, J = 7.6 Hz, 1H), 8.07 (d, J= 7.6 Hz, 1 H).
LC/MS (M+H): 408.17.
(31-2):(E)-8-(furan-2-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (31-1) as the starting material, to obtain 353 mg of the title compound (yield: 90%).
(31-3):(E)-N1-(furan-2-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the ls compound obtained in Example (31-2) as the starting material, to obtain 306 mg of the title compound (yield: 55%).
'H NMR (200 MHz, CDC13) S 1.55-1.98 (m, l OH), 2.17 (m, 2H), 2.41 (q, J
7.4 Hz, 2H), 3.66 (m, 1 H), 3.97 (m, 1 H), 4.61 (d, J = 5.4 Hz, 2H), 4.8 8(m, 1H), 4.90 (s, 2H), 6.31 (d, J = 11.2 Hz, 2H), 6.96 (m, 3H), 7.52 (m, 4H), 7.89 (d, J = 6.8 Hz, 1H), 7.17 (d, J = 6.6 Hz, 1H), 8.45 (br, 1 H).
LC/MS (M+H): 493.23 (31-4):(E)-Nl-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (31-3) as the starting material, to obtain 156 mg of the title compound (yield: 79%).
HPLC purification: 68 mg (purity: 92%) 1H NMR (200 MHz, MeOH-d4) 6 1.50 (m, 2H), 1.62 (m, 2H), 2.08 (t, J = 6.8 Hz, 2H), 2.37 (q, J = 7.4 Hz, 2H), 4.47 (s, 2H), 5.03 (s, 2H), 6.24 (dd, J
14.6 Hz, 3.0 Hz, 2H), 6.62 (t, J = 7.4 Hz, 1 H), 6.99 (d, J = 7.2 Hz, 1 H), 7.43 (m, 4H), 7.78 (d, J = 9.0 Hz, 1 H), 8.08 (d, J= 8.2 Hz, 1 H).
LC/MS (M+H): 409.17.
Example 32: (E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (32-1):(E)-8-(4-(dimethylamino)benzylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-(dimethylamino)benzylamine instead of dimethylaminehydrochloride as the amine to obtain 547 mg of the title compound (yield: 72%).
'H NMR (200 MHz, CDC13) 6 1.45-1.75 (m, 4H), 2.31 (m, 4H), 2.93 (s, 6H), 3.64 (s, 3H), 4.44 (d, J = 5.4 Hz, 2H), 4.96 (s, 2H), 6.62 (m, 3H), 6.91 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.40 (m, 4H), 7.84 (d, J = 7.4 Hz, 1 H), 8.05 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 475.
(32-2): (E)-8-(4-(dimethylamino)benzylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (32-1) as the starting material, to obtain 397 mg of the title compound (yield: 99%).
(32-3): (E)-N1-(4-dimethylamino)benzyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (32-2) as the starting material, to obtain 380 mg of the title compound (yield: 96%).
'H NMR (200 MHz, CDC13) S 1.50-1.92 (m, lOH), 2.05 (m, 2H), 2.30 (q, J=7.4Hz, 2H), 2.92 (s, 2H), 2.96 (m, 1 H), 3.57 (m, 1 H), 3.92 (m, 1 H), 4.41 (d, J = 5.2 Hz, 2H), 4.81 (m, 1H), 4.94 (s, 2H), 6.60 (m, 3H), 6.89 (m, 2H), 7.12 (d, J= 8.4 Hz, 2H), 7.41 (m, 4H), 7.78 (d, J= 8.0 Hz, 1 H), 8.02 (d, J = 8.2 Hz, 1H), 8.37 (br, 1H).
LC/MS (M+H): 560.
(32-4):(E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-l-1o yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (32-3) as the starting material, to obtain 305 mg of the title compound (yield: 92%).
HPLC purification: 287 mg (purity: 98%) 'H NMR (300 MHz, MeOH-d4) b 1.44 (m, 2H), 1.59 (m, 2H), 2.00 (t, J = 7.2 Hz, 2H), 2.28 (q, J = 7.2 Hz, 2H), 3.04 (s, 6H), 4.38 (s, 2H), 5.01 (s, 2H), 6.54 (t, J = 7.5 Hz, 1H),6.88(d,J=7.2Hz, 1H),7.17(d,J=8.4Hz,2H), 7.33 (m, 6H), 7.70 (d, J = 8.1 Hz, 1 H), 8.01 (d, J= 8.1 Hz, 1 H).
LC/MS (M+H): 476.25.
Example 33: (E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (33-1):(E)-8-(2-methoxyethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-3 0 methoxyethylamine instead of dimethylaminehydrochloride as the amine to obtain 399 mg of the title compound (yield: 85%).
'H NMR (200 MHz, CDC13) b 1.44-1.79 (m, 4H), 2.31 (m, 4H), 3.19 (s, 1H), 3.49 (m, 4H), 3.64 (s, 3H), 4.95 (s, 2H), 6.92 (m, 3H), 7.48 (m, 4H), 7.81 (m, 1 H), 7.81 (m, l H), 8.20 (m, 1 H).
LC/MS (M+H): 400.20.
(33-2):(E)-8-(2-methoxyethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (33-1) as the starting material, to obtain 339 mg of the title compound (yield: 95%).
(33-3):(E)-N1-(2-methoxyethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (33-2) as the starting material, to obtain 313 mg of the title compound (yield: 70%).
'H NMR (200 MHz, CDC13) 6 1.41-1.97 (m, lOH), 2.07 (m, 2H), 2.30 (q, J
7.4 Hz, 2H), 3.17(s, 3H), 3.46 (m, 5H), 3.92 (m, 1 H), 4.90 (m, 1 H), 4.92 (s, 2H), 6.85 (m, 3H), 7.46 (m, 4H), 7.81 (m, 1H), 8.17 (m, 1H), 8.67 (m, 1H).
LC/MS (M+H): 485.26.
(33-4):(E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (33-3) as the starting material, to obtain 87 mg of the title compound (yield: 68%).
HPLC purification: 42 mg (purity: 98%) 'H NMR (300 MHz, MeOH-d4) 6 1.44 (m, 2H), 1.57 (m, 2H), 2.02 (t, J = 7.2 Hz, 2H), 2.30 (q, J = 7.2 Hz, 2H), 3.19 (s, 3H), 3.40 (s, 4H), 4.95 (s, 2H), 6. 5 7(t, J = 7.5 Hz, 1 H), 6.96 (d, J = 6.3 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J
6.9 Hz, 1H), 8.09 (d, J = 7.2 Hz, 1 H).
LC/MS (M+H): 401.20.
Example 34: (E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide (34-1):(E)-8-(cyclohexylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using cyclohexylamine instead of dimethylaminehydrochloride as the amine to obtain 423 mg of the title compound (yield: 94%).
'H NMR (200 MHz, CDC13) b 1.13 (m, 2H), 1.33 (m, 2H), 1.42-1.79 (m, 8H), 1.88 (m, 2H), 2.29 (m, 4H), 3.62 (s, 3H), 3.82 (m, 1H), 4.92 (s, 2H), 6.34 (d, J
= 7.4 Hz, 1H), 6.84 (t, J = 7.8 Hz, 111), 6.91 (d, J = 7.2 Hz, 1H), 7.47 (m, 4H), 7.81 (m, l H), 8.15 (m, 1 H).
LC/MS (M+H): 424.24.
(34-2):(E)-8-(cyclohexylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (34-1) as the starting material, to obtain 397 mg of the title compound (yield: 67%).
(34-3):(E)-N1-cyclohexyl-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (34-2) as the starting material, to obtain 257 mg of the title compound (yield: 95%).
IH NMR (200 MHz, CDC13) 5 1.14 (m, 2H), 1.34 (m, 2H), 1.40-2.00 (m, 16H), 2.08 (m, 2H), 2.30 (q, J = 7.2 Hz, 2H), 3.62 (m, 1H), 3.90 (m, 2H), 4.72 (m, 1 H), 4.93 (s, 2H), 6.40 (d, J = 7.8 Hz, 1 H), 6.83 (t, J = 7.8 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1 H), 7.48 (m, 4H), 7.81 (m, 1 H), 8.16 (m, 1 H), 8.81 (br, 1 H).
LC/MS (M+H): 509.29.
(34-4):(E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-1.0 octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (34-3) as the starting material, to obtain 122 mg of the title compound (yield: 83%).
HPLC purification: 78 mg (purity: 93%) 'H NMR (300 MHz, MeOH-d4) 5 1.11-1.39 (m, 5H), 1.40-1.71 (m, 7H), 1.79 (m, 2H), 2.03 (t, J = 6.9 Hz, 2H), 2.29 (m, 2H), 3.69 (m, 1H), 4.96 (s, 1H), 6.47 (t, J = 7.2 Hz, 1 H), 6.93 (d, J = 7.2 Hz, 1 H), 7.37 (m, 4H), 7.75 (d, J
7.5 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 425.24.
Example 35: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide (35-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(thiophen-2-ylmethylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using thiophen-2-ylmethylamine instead of dimethylaminehydrochloride as the amine to obtain 438 mg of the title compound (yield: 100%).
'H NMR (200 MHz, CDC13) b 1.43-1.75 (m, 4H), 2.29 (m, 4H), 3.62 (s, 3H), 4.68 (d, J = 5.8 Hz, 2H), 4.90 (s, 2H), 6.93 (m, 5H), 7.18 (d, J = 4.8 Hz, 1H), 7.46 (m, 4H), 7.78 (d, J = 8.0 Hz, 1 H), 8.04 (d, J = 8.0 Hz, 1 H).
LC/MS (M+H): 438.17.
(35-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(thiophen-2-ylmethylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (35-1) as the starting material, to obtain 438 mg of the title compound (yield: 92%).
(35-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N-1-(thiophen-2-ylmethyl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (35-2) as the starting material, to obtain 390 mg of the title compound (yield: 66%).
'H NMR (200 MHz, CDC13) b 1.46-1.94 (m, lOH), 2.10 (m, 2H), 2.32 (q, J
7.0 Hz, 2H), 3.64 (m, 1 H), 3.93 (m, 1 H), 4.70 (d, J = 5.2 Hz, 2H), 4.90 (m, 5H), 4.95 (s, 1H), 6.91 (m, 5H), 7.19 (d, J = 4.8 Hz, 1H), 7.47 (m, 4H), 7.80 (d, J = 8.8 Hz, 1 H), 8.09 (d, J = 10.0 Hz, 1 H), 8.41 (br, 1 H).
LC/MS (M+H): 523.22.
(35-4): (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (35-3) as the starting material, to obtain 168 mg of the title compound (yield: 87%).
HPLC purification: 55 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) 5 1.34 (m, 2H), 1.58 (m, 2H), 2.10 (m, 2H), 2.32 (m, 2H), 4.58 (s, 2H), 4.96 (s, 2H), 6.55 (m, 1H), 6.86 (m, 3H), 7.19 (d, J
= 4.8 Hz, 1 H), 7.3 6 (m, 4H), 7.71 (d, J= 7.8 Hz, 1 H), 8.01 (d, J = 7.8 Hz, 1 H).
LC/MS (M+H): 439.16.
Example 36: (E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (36-1): (E)-8-(4-methoxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methoxyphenetylamine instead of dimethylaminehydrochloride as the amine to obtain 476 mg of the title compound (yield: 100%).
'H NMR (200 MHz, CDC13) 5 1.45-1.73 (m, 4H), 2.30 (m, 4H), 2.75 (t, J
6.4 Hz, 2H), 3.56 (q, J= 6.6 Hz, 2H), 3.63 (s, 3H), 3.66 (s, 3H), 4.84 (s, 2H), 6.46 (m, 1H), 6.56 (d, J = 8.6 Hz, 2H), 6.88 (m, 2H), 6.95 (d, J = 8.6 Hz, 2H), 7.50 (m, 4H), 7.82 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H).
LC/MS (M+H): 476.24.
(36-2):(E)-8-(4-methoxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (36-1) as the starting material, to obtain 476 mg of the title compound (yield: 90%).
(36-3): (E)-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (36-2) as the starting material, to obtain 121 mg of the title compound (yield: 93%).
'H NMR (200 MHz, CDC13) b 1.50-1.90 (m, lOH), 2.19 (m, 2H), 2.30 (m, 2H), 2.86 (m, 2H), 3.67 (m, 3H), 3.81 (s, 3H), 3.92 (m, 1H), 4.85 (s, 2H), 4.92 (m, 1H), 6.61 (m, 1H), 6.87 (m, 2H), 7.15 (m, 4H), 7.46 (m, 4H), 7.82 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.39 (br, 1H).
LC/MS (M+H): 561.29.
(36-4):(E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (36-3) as the starting material, to obtain 155 mg of the title compound (yield: 84%).
HPLC purification: 50 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.44 (m, 2H), 1.57 (m, 2H), 2.03 (t, J = 6.9 Hz, 2H), 2.28 (q, J = 6.9 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 3.4 1(t, J = 7.2 Hz, 2H), 3.61 (s, 3H), 4.91 (s, 2H), 6.50 (t, J = 7.2 Hz, 1H), 6.61 (d, J = 8.1 Hz, 2H), 6.92 (d, J = 7.2 Hz, 1H), 6.98 (d, J = 8.1 Hz, 2H), 7.39 (m, 4H), 7.74 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 478.23.
Example 37: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(4-(trifluoromethoxy)benzyl)-2-octenediamide (37-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(4-trifluoromethoxy) benzylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-3 0 (trifluoromethoxy)benzylamine instead of dimethylaminehydrochloride as the amine to obtain 515 mg of the title compound (yield: 57%).
'H NMR (200 MHz, CDC13) 6 1.52-1.71 (m, 6H), 2.32 (m, 4H), 3.62 (s, 3H), 4.52 (d, J = 5.6 Hz, 2H), 4.96 (s, 2H), 6.82 (br, 1 H), 6.94 (m, 2H), 7.10 (d, J =
8.2 Hz, 2H), 7.3 8 (m, 2H), 7.48 (m, 2H), 7.82 (d, J = 8.2 Hz, 1 H), 8.02 (d, J =
8.2 Hz, 1 H).
LC/MS (M+H): 516.19.
(37-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(4-trifluoromethoxy)benzylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (37-1) as the starting material, to obtain 293 mg of the title compound (yield: 95%).
(37-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N-1-(4-(trifluoromethoxy)benzyl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (37-2) as the starting material, to obtain 291 mg of the title compound (yield: 60%).
'H NMR (200 MHz, CDC13) 6 0.86 (m, 2H), 1.28 (m, 2H), 1.44-1.79 (m, 8H), 2.34 (m, 2H), 3.64 (br, 1H), 3.92 (br, 1H), 4.52 (d, J = 5.8 Hz, 2H), 4.90 (m, 1H), 4.98 (s, 2H), 6.92 (m, 3H), 7.10 (m, 2H), 7.32 (m, 2H), 7.42 (m, 2H), 7.82 (d, J = 8.2 Hz, 111), 8.02 (d, J= 8.2 Hz, 1H), 8.29 (br, 1 H).
LC/MS (M+H): 601.24.
(37-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-Nl-(4-(trifluoromethoxy)benzyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (37-3) as the starting material, to obtain 74 mg of the title compound (yield: 52%).
HPLC purification: 15 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) 5 1.30 (m, 2H), 1.57 (m, 2H), 1.63 (m, 2H), 2.07 (t, J= 8.2 Hz, 2H), 2.3 8(q, J = 7.4 Hz, 2H), 4.46 (s, 2H), 5.05 (s, 2H), 5.47 (s, 2H), 6.61 (t, J = 7.6 Hz, 1H),6.97(d,J=7.4Hz, 1H),7.06(d,J=8.6 Hz, 1 H), 7.3 8 (m, 6H), 7.77 (d, J = 8.0 Hz, 1 H), 8.07 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 517.19.
Example 38: (E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (38-1):(E)-8-(1-(cyclohexylmethyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-(cyclohexylmethyl)pyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 506 mg of the title compound (yield: 26%).
1H NMR (200 MHz, CDC13) S 0.86 (m, 4H), 1.05-1.33 (m, 8H), 1.42-1.87 (m, 4H), 2.09 (m, 2H), 2.17-2.34 (m, 4H), 2.57 (m, 2H), 2.84 (m, 1 H), 3.62 (s, 3H), 4.53 (br, 1H), 4.93 (s, 2H), 5.30 (s, 2H), 6.84 (m, 2H), 7.47 (m, 4H), 7.78 (m, 1 H), 8.15 (m, 1 H).
LC/MS (M+H): 507.31.
(38-2): (E)-8-(1-(cyclohexylm ethyl)pyrrolidin-3-ylam ino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (38-1) as the starting material, to obtain 135 mg of the title compound (yield: 89%).
(38-3):(E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (38-2) as the starting material, to obtain 117 mg of the title compound (yield: 53%).
'H NMR (200 MHz, CDC13) 5 0.83 (m, 4H), 1.07 (m, 2H), 1.28 (m, 4H), 1.42 (m, 1 H), 1.57-1.78 (m, 12H), 2.17 (m, 2H), 2.31 (m, 6H), 2.61-2.89 (m, 311), 3.60 (m, 1 H), 3.92 (m, 1 H), 4.5 7(m, 1 H), 4.93 (s, 2H), 6.82 (t, J =
7.4 Hz, 1 H), 6.91 (d, J = 7.2 Hz, 1 H), 7.46 (m, 4H), 7.78 (d, J = 7.2 Hz, 1 H), 8.16 (d, J = 7.4 Hz, 1 H), 8.43 (br, 1 H).
LC/MS (M+H): 592.37.
(38-4):(E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (38-3) as the starting material, to obtain 58 mg of the title compound (yield: 77%).
PHLC purification: 24 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.92 (m, 2H), 1.15 (m, 4H), 1.46 (m, 2H), 1.50-1.70 (m, 8H), 2.04 (m, 3H), 2.36 (q, J = 7.2 Hz, 2H), 2.50 (m, 1 H), 2.96 (m, 3H), 3.56 (m, 1H), 3.79 (m, 1H), 4.34 (br, 1H), 4.97 (s, 214), 6.53 (t, J
=
7.0 Hz, 1 H), 6.94 (d, J = 7.2 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J = 7.6 Hz, 1 H), 8.06 (d, J = 7.6 Hz, 1H).
LC/MS (M+H): 508.31.
Example 39: (E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (39-1):(E)-8-(1-cyclopentylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopentylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 492 mg of the title compound (yield: 55%).
'H NMR (200 MHz, CDC13) 5 0.83-1.04 (m, 4H), 1.28 (m, 6H), 1.42-1.70 (m, 8H), 1.92-2.59 (m, 6H), 2.85 (m, 1H), 3.62 (s, 3H), 3.94 (m, 1H), 4.92 (s, 2H), 6.39 (d, J = 7.8 Hz, 1H), 6.84 (m, 2H), 7.48 (m, 4H), 7.79 (m, 1H), 8.17 (m, 1 H).
LC/MS (M+H): 493.30.
(39-2):(E)-8-(1-cyclopentylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (39-1) as the starting material, to obtain 274 mg of the title compound (yield: 96%).
(39-3):(E)-N1-(1-cyclopentylpiperidin-4-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (39-2) as the starting material, to obtain 257 mg of the title compound (yield: 48%).
1H NMR (200 MHz, CDC13) b 0.82 (m, 2H), 1.25-1.77 (m, 22H), 1.93-2.37 (m, 6H), 2.49 (m, 1 H), 2.90 (m, 2H), 3.61 (br, 1 H), 3.91 (br, 1 H), 4.91 (s, 2H), 6.52 (br, 1 H), 6.89 (m, 2H), 7.50 (m, 4H), 7.79 (m, 1 H), 8.16 (m, 1 H), 8.52 (br, 1H).
LC/MS (M+H): 578.35.
(39-4):(E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (39-3) as the starting material, to obtain 122 mg of the title compound (yield: 70%).
HPLC purification: 42 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.46 (m, 2H), 1.54-1.78 (m, 12H), 1.99-2.11 (m, 6H), 2.32 (q, J = 7.4 Hz, 2H), 2.98 (t, J = 12.6 Hz, 2H), 3.39 (m, 1H), 3.57 (d, J = 12.4 Hz, 2H), 3.94 (m, 1 H), 4.96 (s, 2H), 6.47 (t, J = 7.2 Hz, 1 H), 6.92 (d, J= 7.2 Hz, 1H), 7.34 (m, 4H), 7.74 (d, J= 8.0 Hz, 1H), 7.82 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 494.29.
Example 40: (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen -1-yloxy)methyl)-2-octenediamide (40-1):(E)-8-(1-benzylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-2 0 benzylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 501 mg of the title compound (yield: 70%).
'H NMR (200 MHz, CDC13) 6 0.84 (m, 2H), 1.29 (m, 2H), 1.62 (m, 4H), 2.30 (m, 6H), 2.55 (m, 2H), 3.48 (m,3H), 3.63 (s, 3H), 4.94 (s, 2H), 6.86 (m, 2H), 7.14 (m, 2H), 7.18 (m, 2H), 7.46 (m, 4H), 7.81 (d, J 7.8 Hz, 111), 8.19 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 501.27.
(40-2):(E)-8-(1-benzylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (40-1) as the starting material, to obtain 352 mg of the title compound (yield: 55%).
(40-3): (E)-N1-(1-benzylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (40-2) as the starting material, to obtain 188 mg of the title compound (yield: 67%).
'H NMR (200 MHz, CDC13) b 0.86 (m,2H), 1.28 (m, 2H), 1.42-1.77 (m, 8H), 2.08-2.37 (m, 6H), 2.54 (m, 2H), 2.75 (m, 1 H), 3.48 (m, 3H), 3.91 (br, 1 H), 4.53 (br, 1H), 4.85 (m, 1H), 4.92 (s, 2H), 6.94 (m, 3H), 7.16 (m, 4H), 7.40 (m, 4H), 7.84 (d, J = 7.0 Hz, 1 H), 8.21 (d, J = 9.6 Hz, 1 H), 8.60 (br, 1 H).
LC/MS (M+H): 586.32.
(40-4): (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (40-3) as the starting material, to obtain 64 mg of the title compound (yield: 68%).
HPLC purification: 23 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.30 (m, 2H), 1.52 (m, 2H), 1.64 (m, 2H), 2.07 (t, J = 7.0 Hz, 2H), 2.39 (q, J = 7.2 Hz, 2H), 4.32 (m, 3H), 4.94 (m, 3H), 5.47 (s, 2H), 6.57 (t, J = 7.4 Hz, 1H), 7.0 2(d, J = 7.2 Hz, 1H), 7.36-7.44 (m, 8H), 7.77 (d, J = 8.4 Hz, 1 H), 7.86 (m, 1 H), 8.08 (d, J = 6.4 Hz, 1 H), 8.75 (br, 1 H).
LC/MS (M+H): 502.26.
Example 41: (E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (41-1):(E)-8-(1-isopropylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-isopropylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 452 mg of the title compound (yield: 41%).
'H NMR (200 MHz, CDC13) b 0.84 (m, 2H), 1.0 2(m, 4H), 1.26 (m, 3H), 1.61 (m, 4H), 2.18 (m, 2H), 2.30 (m, 5H), 2.70(t, J = 6.6 Hz, 2H), 3.63 (s, 3H), 4.95 (s, 2H), 6.86 (m, 3H), 7.46 (m, 4H), 7.79 (d, J = 8.2 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H).
LC/MS (M+H): 453.27.
(41-2):(E)-8-(1-isopropylpyrrolidin-3-ylamino)-7-((naphthalen-l-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (41-1) as the starting material, to obtain 184 mg of the title compound (yield: 83%).
(41-3):(E)-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (41-2) as the starting material, to obtain 122 mg of the title compound (yield: 69%).
'H NMR (200 MHz, CDC13) b 0.83 (m, 4H), 1.05 (m, 6H), 1.25 (m, 4H), 1.59 (m, 6H), 2.09 (m, 2H), 2.34 (m, 4H), 2.76 (d, J = 5.4 Hz, 2H), 3.62 (m, 1H), 3.92 (m, 1 H), 4.94 (s, 2H), 6.79 (t, J = 7.8 Hz, 1 H), 6.94 (d, J = 7.4 Hz, 1 H), 7.14 (m, 1 H), 7.44 (m, 4H), 7.77 (m, 1 H), 8.16 (m, 1 H).
LC/MS (M+H): 538.32.
(41-4):(E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (41-3) as the starting material, to obtain 101 mg of the title compound (yield: 82%).
HPLC purification: 39 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.26 (m, 6H), 1.47 (q, J=7.2Hz, 2H), 1.62 (q, J=7.2Hz, 2H), 2.04 (t, J = 7.0 Hz, 3H), 2.34 (q, J = 7.2 Hz, 3H), 3.25-3.53 (m, 4H), 3.69 (m, 1H), 4.43 (m, 1H), 4.97 (m, 2H), 6.58 (m, IH), 6.95 (d, J
7.2 Hz, 1 H), 7.34 (m, 4H), 7.74 (d, J = 7.6 Hz, 1 H), 8.06 (d, J = 8.0 Hz, 1 H).
LC/MS (M+H): 454.26.
Example 42: (E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (42-1):(E)-8-(1-(cyclohexanecarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-(cyclohexanecarbonyl)pyrrol i din- 3 -ylamine instead of dimethylaminehydrochloride as the amine to obtain 520 mg of the title compound (yield: 66%).
'H NMR (200 MHz, CDC13) 5 1.17-1.76 (m, 14H), 2.16-2.35 (m, 7H), 3.46 (m, 2H), 3.62 (s, 3H), 3.83 (m, 2H), 4.54 (m, 1 H), 4.93 (s, 2H), 6.60 (m, 1 H), 6.88 (m, 1H), 7.47 (m, 4H), 7.80 (d, J = 7.2 Hz, 1H), 8.12 (d, J = 6.8 Hz, 1H).
LC/MS (M+H): 521.29.
(42-2):(E)-8-(1-(cyclohexanecarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (42-1) as the starting material, to obtain 342 mg of the title compound (yield: 78%).
(42-3):(E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (42-2) as the starting material, to obtain 262 mg of the title compound (yield: 40%).
'H NMR (300 MHz, CDC13) 6 1.20 (m, 4H), 1.42-1.77 (m, 16H), 2.11 (m, 4H), 2.32 (m, 3H), 3.37 (m, 2H), 3.44 (m, 1H), 3.60 (m, 2H), 3.86 (m, 1H), 4.53 (q, J = 5.6 Hz, 1H), 4.93 (s, 2H), 6.89 (m, 3H), 7.45 (m, 4H), 7.80 (d, J
7.4 Hz, 1 H), 8.10 (d, J= 7.6 Hz, 1 H), 8.41 (br, 1 H).
LC/MS (M+H): 606.35.
(42-4):(E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (42-3) as the starting material, to obtain 154 mg of the title compound (yield: 80%).
HPLC purification: 67 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.18-1.69 (m, 14H), 2.03 (m, 4H), 2.32 (q, J = 7.0 Hz, 3H), 3.49 (m, 2H), 3.80 (m, 1H), 3.93 (s, 1H), 4.40 (m, 1H), 4.98 (s, 2H), 6.48 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 5.4 Hz, 1H), 7.37 (m, 4H), 7.73 (d, J = 7.8 Hz, 1 H), 8.08 (d, J = 8.8 Hz, 1 H).
LC/MS (M+H): 522.29.
Example 43 : (E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester (43-1):(E)-3-(8-methoxy-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (1-1) was repeated except for using 3-aminopyrrolidin-l-carboxylic acid t-butylester instead of dimethylaminehydrochloride as the amine to obtain 510 mg of the title compound (yield: 83%).
'H NMR (300 MHz, CDC13) 5 1.33 (m, 2H), 1.39 (s, 9H), 1.60 (m, 2H), 2.15 (m, 2H), 2.31 (m, 4H), 3.36 (m, 4H), 3.62 (s, 3H), 4.93 (s, 2H), 6.66 (br, 1H), 6.90 (m, 2H), 7.3 8 (t, J = 7.8 Hz, 2H), 7.49 (m, 2H), 7.80 (m, 1 H), 8.10 (m, 1 H).
LC/MS (M+H): 511.27.
(43-2):(E)-8-(1-(t-butoxycarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (43-1) as the starting material, to obtain 423 mg of the title compound (yield: 77%).
(43-3):(E)-3-(2-((naphthalen-1-yloxy)methyl)-8-oxo-8-(tetrahydro-2H-pyran-2-yloxyamino)-2-octeneamido)pyrrolidin-l-carboxylic acid t-2 5 butylester The procedure of Example (4-3) was repeated except for using the compound obtained in Example (43-2) as the starting material, to obtain 320 mg of the title compound (yield: 72%).
1H NMR (300 MHz, CDC13) 5 1.25 (m, 2H), 1.39 (s, 9H), 1.45 (m, 2H), 1.50-1.77 (m, 6H), 1.92 (m, 1H), 2.04 (m, 4H), 2.30 (q, J = 7.2 Hz, 2H), 3.36 (m, 4H), 3.60 (br, 1 H), 3.92 (br, 1 H), 4.92 (s, 2H), 6.74 (br, 1 H), 6.83 (t, J
= 7.6 Hz, 1 H), 6.92 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.10 (m, 1 H), 8.71 (br, 1 H).
LC/MS (M+H): 596.33.
(43-4):(E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-4) was repeated except for using the compound obtained in Example (43-3) as the starting material, to obtain 255 mg of the title compound (yield: 95%).
HPLC purification: 5 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.29 (m, 2H), 1.42 (s, 9H), 1.62 (m, 2H), 1.89-2.09 (m, 4H), 2.33 (m, 2H), 3.20 (m, 2H), 3.57 (m, 2H), 4.41 (t, J = 5.4 Hz, 1H), 5.48 (s, 2H), 6.52 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.2 Hz, 2H), 7.40 (m, 4H), 7.79 (d, J = 8.4 Hz, 1 H), 8.10 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 512.27.
Example 44: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-2 0 (pyrrolidin-3-yl)2-octenediamide (44-1):(E)-3-(8-methoxy-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (1-1) was repeated except for using 3-aminopyrrolidin-l-carboxylic acid t-butylester instead of dimethylaminehydrochloride as the amine to obtain 510 mg of the title compound (yield: 83%).
'H NMR (300 MHz, CDC13) 6 1.33 (m, 2H), 1.39 (s, 9H), 1.60 (m, 2H), 2.15 (m, 2H), 2.31 (m, 4H), 3.36 (m, 4H), 3.62 (s, 3H), 4.93 (s, 2H), 6.66 (br, 1H), 6.90 (m, 2H), 7.3 8 (t, J = 7.8 Hz, 2H), 7.49 (m, 2H), 7.80 (m, 1 H), 8.10 (m, 1 H).
LC/MS (M+H): 511.27.
(44-2):(E)-8-(1-(t-butoxycarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (44-1) as the starting material, to obtain 423 mg of the title compound (yield: 77%).
(44-3):(E)-3-(2-((naphthalen-1-yloxy)methyl)-8-oxo-8-(tetrahydro-2H-pyran-2-yloxyamino)-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-3) was repeated except for using the compound obtained in Example (44-2) as the starting material, to obtain 320 mg of the title compound (yield: 72%).
'H NMR (300 MHz, CDC13) 5 1.25 (m, 2H), 1.39 (s, 9H), 1.45 (m, 2H), 1.50-1.77 (m, 6H), 1.92 (m, 1H), 2.04 (m, 4H), 2.30 (q, J = 7.2 Hz, 2H), 3.36 (m, 4H), 3.60 (br, 1 H), 3.92 (br, 1 H), 4.92 (s, 2H), 6.74 (br, 1 H), 6.83 (t, J
= 7.6 Hz, 1 H), 6.92 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.10 (m, 1 H), 8.71 (br, 1 H).
LC/MS (M+H): 596.33.
(44-4):(E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-4) was repeated except for using the compound obtained in Example (44-3) as the starting material, to obtain 255 mg of the title compound (yield: 95%).
HPLC purification: 5 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) 5 1.29 (m, 2H), 1.42 (s, 9H), 1.62 (m, 2H), 1.89-2.09 (m, 4H), 2.33 (m, 2H), 3.20 (m, 2H), 3.57 (m, 2H), 4.41 (t, J = 5.4 Hz, 1H), 5.48 (s, 2H), 6.52 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.2 Hz, 2H), 7.40 (m, 4H), 7.79 (d, J= 8.4 Hz, 1 H), 8.10 (d, J= 7.4 Hz, 1 H).
LC/MS (M+H): 512.27.
(44-5):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(pyrrolidin-3-yl)2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (44-4) as the starting material, to obtain 172 mg of the title compound (yield: 92%).
HPLC purification: 58 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.46 (m, 2H), 1.58 (m, 2H), 2.04 (t, J= 7.0 Hz, 2H), 2.34 (m, 4H), 3.22 (m, 2H), 3.44 (m, 2H), 4.43 (m, 1 H), 4.97 (s, 2H), 6.55 (m, 1 H), 6.95 (d, J = 6.8 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J = 7.4 Hz, 1 H), 8.0 8 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 412.22.
Example 45: (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide (45-1):(E)-8-(1-cyclohexylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclohexylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 492 mg of the title compound (yield: 54%).
'H NMR (200 MHz, CDC13) 5 1.08-1.42 (m, 4H), 1.51-1.78 (m, lOH), 1.94 (m, 2H), 2.29 (m, 6H), 2.64 (d, J = 5. 4Hz, 2H), 2.82 (m, 1H), 3.63 (s, 3H), 4.53 (m, 1H), 4.93 (s, 2H), 6.90 (m, 2H), 7.48 (m, 4H), 7.78 (m, 1H), 8.17 (d, J = 7.2 Hz, 1H).
LC/MS (M+H): 493.30.
(45-2):(E)-8-(1-cyclohexylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (45-1) as the starting material, to obtain 269 mg of the title compound (yield: 100%).
(45-3):(E)-N1-(1-cyclohexylpyrrolidin-3-yl)-2-((naphthalen-2-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (45-2) as the starting material, to obtain 269 mg of the title compound (yield: 43%).
'H NMR (200 MHz, CDC13) b 0.83 (m 4H), 1.13-1.42 (m, 6H), 1.56-1.89 (m, 12H), 2.16 (m, 6H), 2.32 (m, 2H), 2.77 (m, 1 H), 3.62 (br, 1 H), 3.94 (br, 1 H), 4.61 (m, 1 H), 4.80 (m, 1H), 4.94 (s, 2H), 6.82 (t, J = 7.8 Hz, 1 H), 6.91 (d, J
7.6 Hz, 2H), 7.44 (m, 4H), 7.82 (m, 1H), 8.16 (m, 1 H).
LC/MS (M+H): 578.35.
(45-4):(E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (45-3) as the starting material, to obtain 140 mg of the title compound (yield: 88%).
HPLC purification: 16 mg (purity: 97%) 'H NMR (300 MHz, MeOH-d4) b 1.24-1.34 (m, 8H), 1.47-1.65 (m, 6H), 1.77 (m, 1H), 1.98 (m, 2H), 2.05 (t, J = 7.2 Hz, 2H), 2.11 (s, 2H), 2.34 (m, 2H), 2.76 (br, 1H), 4.41 (m, 1H), 4.99 (s, 2H), 6.59 (t, J = 7.4 Hz, 2H), 6.98 (d, J
7.0 Hz, 1 H), 7.3 9 (m, 414), 7.74 (d, J = 7.6 Hz, 1 H), 8.07 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 494.29.
Example 46: (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (46-1):(E)-8-(1-cyclopropylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopropylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 450 mg of the title compound (yield: 78%).
'H NMR (200 MHz, CDC13) b 0.15 (m, 214), 0.28 (m, 2H), 1.28-1.93 (m, 8H), 2.29 (m, 6H), 2.80 (m, 2H), 3.62 (s, 3H), 4.92 (s, 2H), 6.69 (d, J = 7.8 Hz, 1 H), 6.82 (m, 1 H), 7.47 (m, 4H), 7.82 (m, 1 H), 8.15 (m, 1 H).
LC/MS (M+H): 451.25.
(46-2):(E)-8-(1-cyclopropylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (46-1) as the starting material, to obtain 355 mg of the title compound (yield: 98%).
(46-3):(E)-N1-(1-cyclopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (46-2) as the starting material, to obtain 334 mg of the title compound (yield: 61%).
'H NMR (200 MHz, CDC13) b 0.16 (m, 2H), 0.31 (m, 2H), 1.47-1.83 (m, 12H), 2.15 (m, 2H), 2.17 (s, 2H), 2.30 (m, 2H), 2.37 (m, 2H), 2.81 (m, 2H), 3.62 (br, 1 H), 3.91 (br, 1 H), 4.90 (m, 1 H), 4.92 (s, 2H), 6.80 (t, J = 7.8 Hz, 1 H), 6.90 (d, J = 7.6 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.14 (m, 1 H), 8.44 (br, 1H).
LC/MS (M+H): 536.30.
(46-4): (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-NB-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (46-3) as the starting material, to obtain 154 mg of the title compound (yield: 89%).
HPLC purification: 65 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.42 (m, 4H), 1.44 (q, J = 7.4 Hz, 2H), 1.59 (m, 3H), 1.82 (br, 1 H), 2.02 (t, J = 7.2 Hz, 1 H), 2.09 (s, 1 H), 2.27 (m, 1 H), 2.32 (q, J = 7.2 Hz, 2H), 2.71 (m, 2H), 3.01 (m, 2H), 4.94 (s, 2H), 6.53 (t, J=
7.4 Hz, 1 H), 6.92 (d, J = 7.2 Hz, 1 H), 7.3 6 (m, 4H), 7.74 (d, J = 7.8 Hz, 1 H), 7.81 (s, 1 H), 8.08 (d, J= 7.8 Hz, 1 H).
Example 47: (E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (47-1):(E)-8-(1-cyclopropylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopropylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 464 mg of the title compound (yield: 47%).
'H NMR (200 MHz, CDC13) b 0.33-0.40 (m, 4H), 1.24-1.73 (m, 9H), 1.88 (m, 2H), 2.17 (m, 1 H), 2.29 (m, 6H), 3.62 (s, 3H), 3.92 (m, 1 H), 4.91 (s, 2H), 6.35 (d, J = 8.0 Hz, 1H), 6.90 (m, 2H), 7.48 (m, 4H), 7.80 (m, 1H), 8.12 (m, 1 H).
LC/MS (M+H): 465.27.
(47-2): (E)-8-(1-cyclopropylpiperidin-4-ylamin o)-7-((naphtha len-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (47-1) as the starting material, to obtain 221 mg of the title compound (yield: 100%).
(47-3):(E)-N1-(1-cyclopropylpiperidin-4-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (47-2) as the starting material, to obtain 221 mg of the title compound (yield: 51 %).
'H NMR (200 MHz, CDC13) b 0.38 (m, 4H), 1.28-1.94 (m, 18H), 2.10 (m, 2H), 2.32 (m, 4H), 3.64 (m, 1H), 3.95 (m, 1H), 4.88 (m, 1H), 4.92 (s, 2H), 6.40 (d, J = 8.2 Hz, 1 H), 6.92 (m, 2H), 7.48 (m, 4H), 7.84 (m, 1 H), 8.14 (m, 1H), 8.42 (br, 1 H).
LC/MS (M+H): 550.32.
(47-4):(E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-2 5 1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (47-3) as the starting material, to obtain 150 mg of the title compound (yield: 90%).
HPLC purification: 107 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.89 (m, 4H), 1.25 (m, 4H), 1.46 (m, 2H), 1.62 (m, 2H), 2.04 (t, J = 7.2 Hz, 2H), 2.10 (m, 2H), 2.33 (q, J = 7.4, 2H), 2.73 (m, 1 H), 3.59 (m, 2H), 3.99 (m, 1 H), 4.98 (s, 2H), 6.49 (m, 1 H), 6.94 (d, J = 7.2 Hz, 1H), 7.3 6(m, 4H), 7.73 (d, J= 7. 8Hz, 1 H), 8.06 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 466.26.
Example 48: (E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (48-1):(E)-8-(1-ethylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-ethylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 452 mg of the title compound (yield: 62%).
'H NMR (200 MHz, CDC13) 5 1.02 (t, J = 7.4, 3H), 1.26-1.74 (m, 8H), 1.92-2.17 (m, 4H), 2.32 (m, 4H), 2.72 (m, 2H), 3.63 (s, 3H), 4.92 (s, 2H), 6.38 (d, J
= 8.0 Hz, 1 H), 6.80 (t, J = 7.8 Hz, 1 H), 6.90 (d, J= 7.6 Hz, 1 H), 7.48 (m, 4H), 7.82 (m, 1 H), 8.14 (m, 1 H).
LC/MS (M+H): 453.27.
(48-2):(E)-8-(1-ethylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (48-1) as the starting material, to obtain 279 mg of the title compound (yield: 100%).
(48-3):(E)-N1-(1-ethylpiperidin-4-yl)-2-((naphthalen-1-yloxy)methyl)-N8-3 0 (tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (48-2) as the starting material, to obtain 279 mg of the title compound (yield: 80%).
'H NMR (200 MHz, CDC13) b 0.84 (m, 2H), 1.05 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.44-1.79 (m, 10H), 1.94-2.26 (m, 4H), 2.35 (m, 4H), 2.90 (m, 2H), 3.62 (m, 1 H), 3.93 (m, 1 H), 4.94 (s, 2H), 4.97 (m, 1 H), 6.46 (d, J= 7.8 Hz, 1 H), 6.84 (t, J = 7.8 Hz, 1 H), 6.92 (d, J = 7.0 Hz, 1 H), 7.4 8(m, 4H), 7.82 (m, 1 H), 8.14 (m, 111), 8.43 (br, 1 H).
LC/MS (M+H): 538.32.
(48-4):(E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (48-3) as the starting material, to obtain 146 mg of the title compound (yield: 94%).
HPLC purification: 114 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.24 (t, J = 7.2 Hz, 3H), 1.45-1.81 (m, 7H), 1.93-2.10 (m, 5H), 2.32 (q, J = 7.2 Hz, 2H), 2.98 (m, 2H), 3.09 (q, J = 7.2 Hz, 2H), 3.51 (m, 1 H), 4.97 (s, 2H), 6.46 (t, J = 7.6 Hz, 1 H), 6.94 (d, J= 7.0 Hz, 1 H), 7.3 8 (m, 4H), 7.72 (d, J = 7.6 Hz, 1 H), 8.05 (d, J = 7.8 Hz, 1 H).
LC/MS (M+H): 454.26.
Example 49: (E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2 5 1-yloxy)methyl)-2-octenediamide (49-1):(E)-8-(1-ethylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-ethylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 438 mg of the title compound (yield: 52%).
'H NMR (200 MHz, CDC13) b 0.99 (t, J= 7.2 Hz, 3H), 1.26-1.73 (m, 6H), 2.16-2.47 (m, 8H), 2.60 (m, 2H), 2.80 (m, 1H), 3.63 (s, 3H), 4.95 (s, 2H), 6.81 (t, J = 7.6 Hz, 1 H), 6.90 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.79 (m, 1 H), 8.16 (m, 1H).
LC/MS (M+H): 469.30.
(49-2):(E)-8-(1-ethylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (49-1) as the starting material, to obtain 224 mg of the title compound (yield: 100%).
(49-3):(E)-N1-(1-ethylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (49-2) as the starting material, to obtain 224 mg of the title compound (yield: 69%).
'H NMR (200 MHz, CDC13) b 0.82 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H), 1.24 (m, 4H), 1.41-2.20 (m, 8H), 2.31 (m, 4H), 2.51 (m, 3H), 2.57 (m, 1H), 2.62 (m, 1 H), 3.61 (br, 1 H), 3.92 (br, 1 H), 4.91 (m, 1 H), 4.94 (s, 2H), 6.79 (t, J
= 7.8 Hz, 1 H), 6.94 (d, J = 7.0 Hz, 1 H), 7.44 (m, 4H), 7.82 (m, 1 H), 8.20 (m, 1 H).
LC/MS (M+H): 524.30.
(49-4):(E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (49-3) as the starting material, to obtain 184 mg of the title compound (yield: 91 %).
HPLC purification: 128 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.22 (m, 4H), 1.46-1.62 (m, 6H), 1.79 (m, 1 H), 2.03 (m, 3H), 2.3 3(m, 6H), 4.97 (s, 2H), 6.54 (m, 1 H), 6.94 (d, J =
6.4 Hz, 1 H), 7.3 8 (m, 4H), 7.73 (d, J = 7.8 Hz, 1 H), 8.04 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 440.25.
It should be understood that Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usage and conditions.
Test example 1 HDAC activity was analyzed using BIOMOL QuantizymeTM Assay system which comprised two steps of 1) enzyme reaction between HDAC and a substrate and 2) determination of the level of HDAC inhibitory activity. In step 1), 42 ,u,e of a buffer solution (25 mM Tris-HCl [pH 8.0], 137 mM
NaCl, 2.7 mM KCI, 1 mM MgCl2) and 50 of 250 M Fluor de LysTM
substrate were added to each well of a 96-well plate, to which 2.5 /a of a test compound (compounds of Example 1 to 49) was added. 0.5 0 of HeLa nuclear extract(10 M) (a source of HDAC enzymes) was then added thereto to a final concentration of 100 nM. The enzyme reaction was carried out for 1 hr. Subsequently, in step 2), 2 M tricostatin A was added to 50 ,ut of Flour de LysTM developer, followed by allowing the mixture to react at room temperature for 15 minutes. The light excited at 355 nm and emitted at 460 nm from the fluorophore was measured with a fluorometric plate reader. The intensity of the fluorescence increases as the enzyme activity is higher. The HDAC inhibitory activity of each of the test compounds was determined and compared with that of the control. And suberoylanilide hydroxamic acid (SAHA) (Biomol) was used at the same level with the test compounds as a comparative control.
The HDAC inhibitory concentrations (IC50) of the compounds according to the present invention are shown in Table 1.
Table 1 compound IC50 compound IC50 compound IC50 (PM/ml) (PM/ml) (PM/ml) Example Example Example 2 0.015 26 0.005 39 0.013 Example Example Example 4 0.014 27 0.020 40 0.007 Example Example Example 6 0.014 28 0.014 41 0.012 Example Example Example 7 0.012 29 0.027 42 0.022 Example Example Example 8 0.025 30 0.016 44 0.012 Example Example Example 0.020 0.006 0.010 Example Example Example 13 0.015 32 0.006 46 0.011 Example Example Example 21 0.023 33 0.024 47 0.016 Example Example Example 22 0.009 35 0.008 48 0.013 Example Example Example 23 0.021 36 0.017 49 0.010 Example Example 0.009 0.007 SAHA 0.100 Example 0.017 Example 0.010 As shown in Table l, each of the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) has a markedly higher inhibitory activity against HDAC than SAHA which is known as a HDAC inhibitor.
Test Example 2 Inhibitory activities of the compounds synthesized in Examples against proliferation of cancer cells were examined by SRB (Sulforhodamine B) analysis using cervix adenocarcinoma Hela (Korean Cell Line Bank, KCLB 10002) and colon cancer cells HCT116 (Korean Cell Line Bank, KCLB 10247) as followed:
Cancer cells were inoculated into a 96-well microplate at a concentration of 1 x 103-3 x 103 cells/well and incubated under the condition of 37 C, 5% CO2 for 24 hrs. After the incubation was completed, 0.2, 1, 5, 25, or 100 pM of each of the compounds of Examples was added to the plate, and then the reactant was incubated again. After the substrate was stained, the anti-cancer activity was determined by comparing the amount of protein in the cells treated with compound of Examples with that of protein in non-treated cells.
Specificially, after the incubation was completed, the culture medium was removed from each well, and the cells were washed 3 times with PBS
(pH7.4). Then, a solution of 50% trichloroacetic acid (TCA) was added to each well in an amount of 50 ,ul/well at 4 C for 1 hr to fix them. Then, the microplate was washed 5 times with distilled water and dried at room temperature.
50 ,ut of a staining solution prepared by dissolving 0.4% SRB in 1%
acetic acid was added to the wells, and the microplate was kept at room temperature for 1 hr. The well plate was then washed 5 times with 1%
acetic acid to remove unbound SRB and dried at room temperature.
The stained cells were treated with 150 ,ut/well of 10 mM Tris-HCl solution (pH 10.5) to elute SRB from the cells, and the absorbance of each well at 520 nm was measured.
The ED50 value representing inhibition of the cancer cell growth by the extent of 50% was calculated from the measured absorbance, and the results are shown in Table 2.
When cancer cells were treated with a HDAC inhibitor, histone deacetylation would be inhibited, leading to an increase in the amount of acetyl-histone. In this test, the increased amount of acetyl-histone in the cancer cells was determined by using Western blotting, after the treatment with each of the compounds of Examples.
Hela cells were inoculated into a 6-well microplate at a concentration of 1.5 x 108 cells/well and incubated overnight under the condition of 371C, 5% CO2.
10 pM of each compound of Examples, and suberoylanilide hydroxamic acid (SAHA) as a control was added to the plate and the plate was incubated again for 24 hrs.
The cells were harvested in the presence of the test compound and were subjected to fractionation to separate the nuclei from the cells. The cells were allowed to swell in a hypotonic solution, lysed by several rounds of freezing-thawing cycles, and then centrifuged of 1,300 rpm for 5 min to collect the nuclei. The nuclei was lysed in a lysis buffer solution (20 mM
HEPES (pH 7.9), 25% glycerol, 420 mM KCI, 1.5 mM MgCl2, 0.2 mM
EDTA) to obtain a protein extract.
The resulting protein extract was subjected to SDS-PAGE to separate the proteins by the size and transferred onto the nitrocellulose membrane according to the conventional method.
The amount of acetylated histon H4 was measured using anti-acetyl histone H4 antibody (Upstate, USA) and evaluated the HDAC inhibitory activity of the inventive compounds by comparing the degree of increase of acetylated histone H4 relative to the control (SAHA).
The results are shown in Table 2.
Table 2 Inhibitory conc.
against the cancer cell Effect on increase of acetylated growth (EC50 PM) histon H4 compared with SAHA
Example 1 1.0 ++
Example 2 0.3 ++
Example 4 0.4 ++
Example 5 0.6 ++
Example 6 0.4 ++
Example 7 0.2 ++
Example 8 0.6 +
Example 13 1.3 ++
Example 24 1.1 +
Example 25 1.3 +
Example 26 0.8 +
Example 27 1.2 +
Example 28 0.7 +
Example 31 0.6 +
Example 32 0.5 +
Example 33 0.6 +
Example 34 0.8 +
Example 35 0.4 +
Example 36 0.7 +
Example 39 0.8 +
Example 40 0.9 +
Example 41 1.0 +
Example 45 0.5 +
Example 46 < 0.2 +
Example 47 0.32 +
Example 48 1.2 +
Example 49 0.9 +
SAHA 1.6 +
As shown in Table 2, the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) has a markedly enhanced inhibitory activity against HDAC, which leads to effective suppression of the cancer cell proliferation.
(2-2): (E)-8-(2-(dimethylamino)ethylamino)-7-((naphthalen=l-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (2-1) as the starting material, to obtain 335 mg of the title compound (yield: 81 %).
'H NMR (300 MHz, MeOH-d4) 6 1.52 (m, 2H, CH2), 1.64 (m, 2H, CH2), 2.20 (m, 2H, CH2), 2.27 (s, 6H, N(CH3)2), 2.38 (m, 2H, CH2), 2.55 (m, 2H, CH2), 3.42 (m, 2H, CH2), 4.97 (s, 2H, CH2), 6.67 (s, 1 H, CH), 6.99 (t, 1 H, J =
7.0, 1.8 Hz, ArH), 7.41 (m, 4H, ArH), 7.77 (d, 1 H, J = 7.0, 1.8 Hz, ArH), 8.14 (d, 1 H, J = 7.2 Hz, ArH).
(2-3):(E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (2-2) as the starting material, to obtain 134 mg of the title compound (yield: 88%).
~H NMR (200 MHz, MeOH-d4) S 1.58 (m, 4H, CH2CH2), 2.40 (m, 2H, CH2), 2.82 (s, 6H, N(CH3)2), 3.30 (m, 4H, CH2CH2), 3.62 (m, 2H, CH2), 5.01 (s, 2H, CHZ), 6.70 (t, 1 H, J = 15.2, 7.4 Hz, CH), 7.04 (d, 1 H, J = 1.2 Hz, ArH), 7.44 (m, 4H, ArH), 7.81 (m, 1 H, ArH), 8.19 (m, ArH).
Example 3: (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (3-1):(E)-8-((2-(dimethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (2-(dimethylamino)ethyl)(methyl)amine instead of dimethylaminehydrochloride as the amine to obtain 351 mg of the title compound (yield: 77%).
'H NMR (200 MHz, CDC13) S 1.6 (m, 4H, CH2CH2), 2.2 (m, 8H, CH2CH2CH2CH2), 3.05 (s, 3H, NCH3), 3.55 (m, 2H, CH2), 3.70 (s, 3H, OCH3), 5.00 (s, 2H, Ph CH2), 5.80 (s, 1 H, CH), 6.89 (d, 1 H, J = 1.4 Hz, ArH), 7.48 (m, 4H, ArH), 7.80 (dd, 1H, J = 6.0, 2.0 Hz, ArH), 8.20 (m, 1H, ArH).
(3-2): (E)- 8-((2-(dimethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (3-1) as the starting material, to obtain 224 mg of the title compound (yield: 92%).
'H NMR (200 MHz, MeOH-d4) 8 1.6 (m, 4H, CH2CH2), 2.4 (m, 6H, CH2CH2CH2), 2.50 (m, 4H, CH2CH2), 2.80 (m, 2H, CH2), 3.01 (s, 3H, NCH3), 3.29 (m, 1 H, CH), 3.65 (m, 1 H, CH), 4.95 (s, 2H, PhCH2), 6.00 (m, 1 H, CH), 7.00 (t, 1 H, J= 16.6, 9.4 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (m, 1 H, ArH), 8.18 (m, 1 H, ArH).
(3-3): (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (3-2) as the starting material, to obtain 155 mg of the title compound (yield: 68%).
1 H NMR (200 MHz, MeOH-d4) S 1.48 (m, 2H, CHZ), 1.58 (m, 2H, CHZ), 2.4 (m, 6H, CH2CH2CH2), 2.49 (m, 4H, CH2CH2), 2.81 (m, 2H, CH2), 3.02 (s, 3H, NCH3), 3.28 (m, 1H, CH), 3.64 (m, 1H, CH), 4.95 (s, 2H, PhCH2), 6.02 (m, 1 H, CH), 7.00 (d, 1 H, J = 8.2 Hz, ArH), 7.44 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.17 (m, 1 H, ArH).
Example 4: (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-2 0 1-yloxy)methyl)octenediamide (4-1):(E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(diethylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 164 mg of the title compound (yield: 37%).
'H NMR (200 MHz, CDC13) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.14 (t, 2H, J = 14,2, 7.4 Hz, CHZ), 2.40 (m, 2H, CH2), 3.14 (rim, 6H, CH2CH2CH2CH2), 3.50 (s, 2H, CH2), 3.86 (s, 3H, OCH3), 5.02 (s, 2H, CH2), 6.73 (t, 1 H, J = 14.6, 7.2 Hz, CH), 7.01 (d, 1 H, J = 7.4 Hz, ArH), 7.40 (m, 4H, ArH), 7.76 (d, 1 H, J = 7.4 Hz, ArH), 8.18 (dd, 1 H, J = 7.4, 2.8 Hz, ArH).
(4-2):(E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (4-1) as the starting material, to obtain 130 mg of the title compound (yield: 81 %).
'H NMR (200 MHz, MeOH-d4) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.12 (m, 2H, JCHZ), 2.36 (m, 2H, CH2), 3.14 (m, 6H, CH2CH2CH2), 3.50 (s, 2H, CH2), 5.01 (s, 2H, CH2), 6.72 (d, 1H, J = 7.4 Hz, CH), 7.02 (d, 1 H, J = 7.4 Hz, ArH), 7.40 (m, 4H, ArH), 7.80 (dd, 1 H, J = 7.6, 1.8 Hz, ArH), 8.16 (d, 1 H, J = 7.2 Hz, ArH).
(4-3): (E)-N1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide (E)-8-(2-(diethylamino)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid (311 mg, 0.71 mM) obtained in Example (4-2) was dissolved in dimethylformamide (3 ml), whereto triethylamine (150 0, 1.07 mM) was added, followed by cooling to 0 C . N-hydroxy-6-trifluoro-6-trifluorobenzotriazole (159 mg, 0.78 mM), 1-(3-diethylaminopropyl)-3-ethylcarbodiimidhydrochloride (177 mg, 0.92 mM) and tetrahydropyranyl oxyamine (125 mg, 1.07 mM) were added thereto, and the mixture was stirred at room temperature for 18 hrs. After the completion of the reaction, ice water was poured thereinto and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate and salt water in order, dried over anhydrous magnesium sulfate, and concentrated under a reduced pressure. The resulting residue was subjected to silica gel column chromatography, to obtain 320 mg of the title compound (yield: 87%).
'H NMR (200 MHz, MeOH-d4) S 0.80 (m, 6H, CH2CH2CH2), 1.80 (m, 12H, CH2CH2CH2CH2), 2.10 (s, 1H, CH2), 2.35 (m, 6H, CH3CH3), 2.58 (m, 2H, CH2), 3.40 (m, 2H, CH2), 3.60 (m, 1 H, CH), 3.94 (m, 1 H, CH), 4.96 (s, 2H, CH2), 6.80 (d, 1H, J = 7.4 Hz, CH), 6.98 (d, 1H, J = 6.8 Hz, ArH), 7.42 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.21 (dd, 1 H, J = 12.6, 6.4 Hz, ArH).
(4-4):(E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide (E)-N 1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide (320 mg, 0.62 mM) obtained in Example (4-4) was dissolved in dichloromethane (10 ml), whereto trifluoroacetic acid (0.46 ml, 6.20 mM) was added slowly at 0 C, followed by reacting at room temperature for 18 hrs. After the completion of the reaction, the solvent was then removed under a reduced pressure at room temperature. The resulting residue was subjected to silica gel column chromatography (methylalcohol/dichloromethane= 1/9) to obtain 261 mg of the title compound (yield: 95%).
'H NMR (200 MHz, MeOH-d4) S 1.24 (m, 6H, CH2CH2CH2), 1.60 (m, 4H, CH2CH2), 2.14 (t, 2H, J = 13,8, 7.0 Hz, CHZ), 2.40 (q, 2H, J = 14.4, 7.0 Hz, CH2), 3.12 (m, 6H, CHZCH2CH2), 3.51 (s, 2H, CHZ), 5.02 (s, 2H, CHZ), 6.73 (t, 1 H, J = 14.8, 7.4 Hz, CH), 7.02 (d, 1 H, J = 6.4 Hz, ArH), 7.41 (m, 4H, ArH), 7.80 (dd, 1 H, J = 5.6, 2.0 Hz, ArH), 8.18 (dd, 1 H, J = 7.0, 3.8 Hz, ArH).
Example 5: (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (5-1):(E)-8-((2-(diethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (2-(diethylamino)ethyl)(methyl)amine instead of dimethylaminehydrochloride as the amine to obtain 483 mg of the title compound (yield: 71 %).
'H NMR (300 MHz, CDC13) S 1.11 (m, 6H, CH2CH2CH2), 1.40 (m, 2H, CH2), 1.65 (m, 2H, CHz), 2.28 (m, 8H, CH2 CH2CH3CH3), 2.90 (s, 2H, CH2), 3.00 (s, 3H, NCH3), 3.57 (s, 2H, CH2), 3.66 (s, 3H, OCH3), 4.93 (s, 2H, CHZ), 6.85 (d, 1 H, J= 7.8 Hz, CH), 6.99 (m, 1 H, ArH), 7.41 (m, 4H, ArH), 7.75 (m, 1 H, ArH), 8.14 (m, 1 H, NH), 8.17 (m, 1 H, ArH).
(5-2): (E)-8-((2-(diethylamino)ethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (5-1) as the starting material, to obtain 300 mg of the title compound (yield: 65%).
'H NMR (300 MHz, MeOH-d4) S 1.05 (m, 6H, CH2CHZCH2), 1.38 (m, 2H, CH2), 1.50 (m, 2H, CH2), 2.17 (m, 4H, CH2CH2), 2.99 (m, 6H, CH3CH3), 3.16 (s, 3H, NCH3), 3.60 (m, 2H, CH2), 4.87 (s, 2H, CH2), 5.86 (d, 1H, J =
7.4 Hz, CH), 6.82 (d, 1H, J = 7.4 Hz, ArH), 7.28 (m, 4H, ArH), 7.64 (t, 1 H, J
= 9.4, 6.1 Hz, ArH), 7.92 (d, 1 H, J= 9.7 Hz, ArH).
(5-3): (E)-N1-(2-(diethylamino)ethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (5-2) as the starting material, to obtain 320 mg of the title compound (yield: 87%).
'H NMR (300 MHz, MeOH-d4) 8 1.00 (m, 6H, CH2CH2CH2), 1.54 (m, 4H, CH2CH2), 1.73 (m, 8H, CH2CH2CH2CH2), 2.14 (d, 2H, J = 7.0 Hz, CH2), 2.36 (d, 2H, J = 7.4 Hz, CH2), 2.58 (d, 2H, J = 6.8 Hz, CH2), 3.07 (m, 6H, CH3CH3), 3.32 (s, 3H, NCH3), 3.55 (m, 2H, CH2)03.98 (m, 1H, CH), 5.05 (s, 2H, CH2), 5.94 (m, 1 H, CH), 7.01 (d, 1 H, J = 7.4 Hz, ArH), 7.48 (m, 4H, ArH), 7.82 (t, 1H, J = 9.1, 2.0 Hz, ArH), 8.11 (dd, 1H, J = 7.4, 2.3 Hz, ArH).
(5-4): (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediam ide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (5-3) as the starting material, to obtain 285 mg of the title compound (yield: 93%).
1H NMR (300 MHz, MeOH-d4) S 1.10 (m, 6H, CHZCH2CH2), 1.13 (m, 2H, CH2), 1.58 (m, 2H, CHZ), 2.02 (t, 2H, J = 14.1, 7.0 Hz, CHZ), 2.28 (d, 2H, J =
7.2 Hz, CH2), 3.07 (m, 6H, CH3CH3), 3.21 (s, 3H, NCH3), 3.64 (m, 2H, CHZ), 4.96 (s, 2H, CH2), 5.93 (s, 1 H, CH), 6.90 (d, 1 H, J= 7.2 Hz, ArH), 7.36 (m, 4H, ArH), 7.71 (dd, 1 H, J = 8.0, 3.7 Hz, ArH), 7.98 (d, 1 H, J = 9.4 Hz, ArH);
MS (LC, 70 eV) m/z 456 (M+1), 382.
Example 6: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide (6-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(pyrrolidin-l-yl) thylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(pyrrolidin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 74 mg of the title compound (yield: 29%).
1H NMR (200 MHz, CDC13) 8 1.50 (d, 2H, J = 7.4 Hz, CHZ), 1.62 (d, 2H, J
7.4 Hz, CHZ), 1.89 (m, 4H, CH2), 2.09 (m, 2H, CH2), 2.35 (m, 2H, CH2), 3.13 (m, 5H, CHCH2CH2), 3.32 (s, 1H, CH), 3.58 (t, 2H, J = 12.1, 6.1 Hz, CH2), 3.96 (s, 3H, OCH3), 4.96 (s, 2H, CHZ), 6.80 (d, 1H, J = 7.4 Hz, CH), 6.98 (d, 1 H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.21 (m, 1 H, ArH).
(6-2): (E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(pyrrolidin-1-yl) thylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (6-1) as the starting material, to obtain 69 mg of the title compound (yield: 96%).
'H NMR (200 MHz, MeOH-d4) 8 1.50 (d, 2H, J= 7.2 Hz, CH2), 1.60 (d, 2H, J = 7.2 Hz, CH2), 1.88 (m, 4H, CH2), 2.08 (m, 2H, CH2), 2.34 (m, 2H, CH2), 3.14 (m, 5H, CHCH2CH2), 3.34 (s, 1H, CH), 3.58 (t, 2H, J = 12.1, 6.1 Hz, CH2), 4.96 (s, 2H, CH2), 6.80 (d, 1 H, J = 7.0 Hz, CH), 6.98 (d, 1 H, J = 7.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.21 (m, 1H, ArH).
(6-3):(E)-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (6-2) was repeated except for using the compound obtained in Example (4-3) as the starting material, to obtain 87 mg of the title compound (yield: 85%).
'H NMR (200 MHz, MeOH-d4) 8 1.50 (m, 8H, CH2CH2CH2CH2), 1.80 (m, 4H, CH2CH2), 2.01 (m, 2H, CH2), 2.40 (m, 4H, CH2CH2), 2.59 (m, 5H, CHCH2CH2), 2.78 (m, 2H, CH2), 3.50 (m, 3H, CHCH2), 3.90 (s, 1H, CH), 4.96 (s, 2H, CHZ), 6.80 (d, 1H, J = 7.2 Hz, CH), 6.98 (d, 1H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.21 (m, 1 H, ArH).
(6-4): (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (6-3) as the starting material, to obtain 72 mg of the title compound (yield: 84%).
'H NMR (300 MHz, MeOH-d4) S 1.51 (d, 2H, J = 7.0 Hz, CH2), 1.62 (d, 2H, J= 7.9 Hz, CH2), 1.89 (m, 4H, CH2CH2), 2.09 (m, 2H, CH2), 2.35 (m, 2H, CH2), 3.13 (m, 5H, CHCH2CH2), 3.32 (s, 1H, CH), 3.58 (t, 2H, J= 12.1, 6.1 Hz, CH2), 5.01 (s, 2H, CH2), 6.70 (s, 1 H, CH), 7.00 (d, 1 H, J = 7.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (t, 1H, J = 8.4, 1.8 Hz, ArH), 8.12 (t, 1H, J = 9.4, 7.5 Hz, ArH); MS (LC, 70 eV) m/z 440 (M+1), 425, 328, 313, 242, 210, 192.
Example 7: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide (7-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(piperidin-l-yl) thylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(piperidin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 290 mg of the title compound (yield: 94%).
'H NMR (200 MHz, CDC13) 8 1.10 (m, 2H, CH2), 1.21 (m, 2H, CHZ), 1.60 (m, 4H, CHZ), 2.01 (m, 2H, CH2), 2.21 (m, 5H, CHCH2CH2), 2.38 (m, 5H, CHCH2CH2), 3.41 (t, 2H, J= 11.4, 5.8 Hz, CH), 3.65 (s, 3H, OCH2), 4.95 (s, 2H, CHZ), 6.81 (d, 1 H, J = 7.8 Hz, CH), 6.95 (d, 1 H, J = 7.0 Hz, ArH), 7.10 (brs, 1H, NH), 7.45 (m, 4H, ArH), 7.80 (q, 1H, J = 5.8, 2.4 Hz, ArH), 8.21 (dd, 1H, J= 7.0, 3.4 Hz, ArH).
(7-2): (E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(2-(piperidin-1-yl) thylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (7-1) as the starting material, to obtain 256 mg of the title compound (yield: 94%).
'H NMR (300 MHz, MeOH-d4) 8 1.44 (m, 4H, CH2CH2), 1.64 (m, 2H, CH2), 2.12 (m, 2H, CHZ), 2.26 (m, 2H, CH2)03.08 (m, IOH, CH2CH2CH2CH2CH2), 3.51 (d, 2H, J = 6.0 Hz, CH), 4.91 (s, 2H, CH2), 6.61 (s, 1 H, CH), 6.91 (d, 1 H, J = 6.2 Hz, ArH), 7.31 (m, 4H, ArH), 7.68 (dd, 1H, J = 6.8, 3.4 Hz, ArH), 8.00 (dd, 1H, J = 7.0, 3.4 Hz, ArH).
(7-3): (E)-2-((naphthalen-1-yloxy)methyl)-Nl-(2-(piperidin-1-yl)ethyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (7-2) as the starting material, to obtain 288 mg of the title compound (yield: 91 %).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 2H, CH2), 1.45 (m, 4H, CH2CH2), 1.60 (m, 8H, CH2CH2CH2CH2), 2.09 (s, 2H, CH2), 2.29 (m, lOH, CH2CH2CH2CH2CH2), 3.21 (m, 2H, CHZ), 3.47 (m, 2H, CHZ), 3.89 (t, 1 H, J=
7.2 Hz, CH), 4.90 (s, 2H, CH2), 6.50 (s, 1 H, CH), 6.90 (d, 1 H, J= 7.2 Hz, ArH), 7.33 (m, 4H, ArH), 7.70 (t, 1H, J = 9.0, 1.4 Hz, ArH), 8.02 (d, 1H, J
8.2 Hz, ArH).
(7-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (7-3) as the starting material, to obtain 213 mg of the title compound (yield: 94%).
'H NMR (300 MHz, MeOH-d4) S 1.41 (m, 4H, CH2CH2), 1.65 (m, 4H, CH2CH2), 2.10 (t, 2H, J = 14.3, 7.0 Hz, CH2), 2.41 (d, 2H, J = 7.2 Hz, CHz), 2.89 (m, 2H, CH2), 3.22 (t, 2H, J = 11.8, 5.9 Hz, CH), 3.32 (m, 2H, CH2), 3.52 (d, 2H, J = 11.8 Hz, CH2), 3.65 (t, J 11.8, 5.8 Hz, 2H, CHZ), 5.04 (s, 2H, CH2), 6.70 (s, 1H, CH), 7.05 (t, 1H, J 7.3, 1.0 Hz, ArH), 7.45 (m, 4H, ArH), 7.83 (d, 1 H, J = 7.2 Hz, ArH), 8.13 (d, 1 H, J = 7.2 Hz, ArH).
Example 8: (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-l-yloxy)methyl)octenediamide (8-1):(E)-8-(2-morpholinoethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-morpholinoethylamine instead of dimethylaminehydrochloride as the amine to obtain 266 mg of the title compound (yield: 91 %).
'H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CHZ), 1.64 (m, 2H, CH2), 2.20 (m, 4H, CH2CH2), 2.25 (m, 4H, CH2CH2), 2.40 (m, 2H, CH2), 3.07 (t, 2H, J =
8.6, 4.2 Hz, CH), 3.42 (t, 2H, J = 10.6, 5.4 Hz, CH2), 3.61 (s, 3H, OCH3), 4.89 (s, 2H, CH2), 6.90 (s, 1H, CH), 6.94 (d, 1H, J = 7.8 Hz, ArH), 7.45 (m, 4H, ArH), 7.82 (dd, 1H, J = 7.8, 2.4 Hz, ArH), 8.19 (dd, 1H, J = 7.8, 2.8 Hz, ArH).
(8-2): (E)-8-(2-morpholinoethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (8-1) as the starting material, to obtain 250 mg of the title compound (yield: 96%).
1 H NMR (300 MHz, MeOH-d4) S 1.50 (m, 2H, CH2), 1.62 (m, 2H, CHZ), 2.24 (m, 4H, CH2CH2), 2.38 (m, 4H, CH2CH2), 2.58 (m, 2H, CH2), 3.32 (q, 2H, J
= 3.1, 1.5 Hz, CH), 3.43 (m, 4H, CH2CH2), 4.96 (s, 2H, CHZ), 6.71 (s, 1H, CH), 7.01 (d, 1 H, J = 7.3 Hz, ArH), 7.43 (m, 4H, ArH), 7.80 (t, 1 H, J= 7.1, 5.5 Hz, ArH), 8.19 (d, 1H, J = 7.6 Hz, ArH); MS (LC, 70 eV) m/z 416 (M+1), 403, 346, 313, 298, 204, 102.
(8-3): (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-1-yloxy) ethyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (8-2) as the starting material, to obtain 155 mg of the title compound (yield: 90%).
'H NMR (300 MHz, MeOH-d4) 8 1.48 (m, 2H, CHZ), 1.59 (m, 2H, CH2), 2.25 (m, 4H, CH2CH2), 2.38 (m, 4H, CH2CH2), 2.56 (m, 2H, CHZ), 3.30 (d, 2H, J
= 7.5 Hz, CH), 3.42 (m, 4H, CH2CH2), 5.01 (s, 2H, CH2), 6.78 (s, 1H, CH), 7.00 (d, 1 H, J = 7.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.78 (d, 1 H, J= 7.4 Hz, ArH), 8.14 (d, 1H, J = 7.6 Hz, ArH); MS (LC, 70 eV) m/z 416 (M+1), 403, 346, 313, 298, 204, 102.
Example 9: (E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide (9-1): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methylpiperazin-1-ylamine instead of dimethylaminehydrochloride as the amine to obtain 175 mg of the title compound (yield: 41 %).
'H NMR (300 MHz, CDC13) 6 1.46 (m, 2H, CH2), 1.53 (m, 2H, CH2), 2.17 (m, 4H, CH2CH2), 2.34 (m, 8H, CH2CH2CH2CH2CH2CH2), 3.64 (s, 3H, NCH3), 3.75 (s, 3H, OCH3), 4.98 (s, 2H, CH2), 5.78 (t, 1H, J = 15.0, 7.5 Hz, CH), 6.84 (d, 1 H, J = 7.5 Hz, ArH), 7.44 (m, 4H, ArH), 7.79 (t, 1 H, J = 8.7, 1.2 Hz, ArH), 8.13 (d, 1 H, J= 7.8 Hz, ArH).
(9-2): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (9-1) as the starting material, to obtain 168 mg of the title compound (yield: 100%).
'H NMR (300 MHz, MeOH-d4) 6 1.55 (m, 2H, CH2), 1.68 (m, 2H, CHZ), 2.32 (m, 11H, CHCH2CH2CH2CH2CH2CH2), 3.31 (m, 1H, CH), 3.66 (s, 3H, NCH3), 5.09 (s, 2H, CH2), 5.92 (s, 1 H, CH), 6.97 (dd, 1 H, J = 6.5, 6.5 Hz, ArH), 7.46 (m, 4H, ArH), 7.81 (d, 1 H, J = 7.8 Hz, ArH), 8.16 (d, 1 H, J = 7.8 Hz, ArH).
(9-3): (E)-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy)methyl)-8-oxo-N-(tetrahydro-2H-pyran-2-yloxy)-6-octeneamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (9-2) as the starting material, to obtain 317 mg of the title compound (yield: 83%).
'H NMR (300 MHz, MeOH-d4) 8 1.54 (m, 4H, CH2CH2), 1.72 (m, 4H, CH2CH2), 2.17 (m, 8H, CH2CH2CH2CH2), 2.37 (m, 6H, CH2CH2CH2), 3.32 (q, 2H, J = 3.2, 1.6 Hz, CH2), 3.57 (s, 3H, NCH3), 3,92 (m, 1 H, CH), 5.08 (s, 2H, CH2), 5.86 (s, 1 H, CH), 6.96 (d, 1 H, J = 7.3 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (d, 1 H, J = 7.3 Hz, ArH), 8.14 (d, 1 H, J = 7.3 Hz, ArH). .
(9-4):(E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy) methyl)-8-oxoocteneamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (9-3) as the starting material, to obtain 287 mg of the title compound (yield: 92%).
'H NMR (300 MHz, MeOH-d4) 6 1.52 (m, 2H, CH2), 1.57 (m, 2H, CHZ), 2.13 (t, 2H, J = 14.3, 7.1 Hz, CH2), 2.37 (q, 2H, J = 14.4, 7.1 Hz, CH2), 2.61 (m, 4H, CH2CH2), 3.32 (m, 2H, CH2), 3.76 (m, 2H, CH2), 3.80 (s, 3H, NCH3), 5.10 (s, 2H, CH2), 5.96 (s, 1 H, CH), 6.97 (d, 1 H, J = 7.3 Hz, ArH), 7.47 (m, 4H, ArH), 7.83 (t, 1 H, J = 9.1, 4.0 Hz, ArH), 8.13 (t, 1 H, J= 9.2, 5.1 Hz, ArH); MS (LC, 70 eV) m/z 426 (M+1), 407, 325, 293, 281, 265, 149, 102.
Example 10: (E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy)methyl)octenediamide (10-1): (E)-8-(2-(4-methylpiperazin-l-yl)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(4-methylpiperazin-1-yl)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 225 mg of the title compound (yield: 48%).
'H NMR (300 MHz, CDC13) 6 1.53 (m, 2H, CH2), 1.66 (m, 4H, CH2CH2), 1.92 (m, 4H, CH2CH2), 2.31 (m, 8H, CH2CH2CH2CH2), 2.42 (s, 3H, NCH3), 3.40 (q, 2H, J = 10.5, 5.4 Hz, CHZ), 3.63 (s, 3H, OCH3), 4.87 (s, 2H, CH2), 6.95 (dd, 1 H, J = 15.6, 7.8 Hz, CH), 7.05 (s, 1 H, ArH), 7.45 (m, 4H, ArH), 7.80 (dd, 1 H, J= 6.9, 1.8 Hz, ArH), 8.19 (t, 1 H, J = 9.6, 7.8 Hz, ArH).
(10-2):(E)-8-(2-(4-methylpiperazin-1-yl)ethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (10-1) as the starting material, to obtain 157 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) S 1.24 (s, 1H, CH), 1.54 (m, 4H, CHZCH2), 2.20 (m, 4H, CH2CH2), 2.29 (m, 4H, CH2CH2), 2.51 (m, 4H, CH2CH2), 3.05 (m, 1H, CH), 3.24 (s, 3H, NCH3), 3.34 (m, 2H, CH2), 4.94 (s, 2H, CH2), 6.69 (s, 1 H, CH), 7.01 (dd, 1 H, J = 7.2, 1.0 Hz, ArH), 7.42 (m, 4H, ArH), 7.75 (d, 1H, J = 7.2 Hz, ArH), 8.08 (d, 1H, J = 1.7 Hz, ArH).
(10-3):(E)-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (10-2) as the starting material, to obtain 137 mg of the title compound (yield: 54%).
1H NMR (300 MHz, MeOH-d4) S 1.54 (m, 4H, CH2CH2), 1.64 (m, 6H, CHCH2CH2), 2.11 (m, 5H, CHCH2CH2), 2.41 (m, 8H, CH2CH2CH2CH2), 3.27 (s, 3H, NCH3), 3.34 (m, 3H, CHCH2), 3.50 (m, 2H, CH2), 3.85 (t, 1H, J
= 7.2, 1.8 Hz, CH), 4.96 (s, 2H, CHz), 6.70 (s, 1 H, CH), 7.01 (d, 1 H, J =
7.2 Hz, ArH), 7.43 (m, 4H, ArH), 7.79 (dd, 1 H, J = 6.6, 1.7 Hz, ArH), 8.10 (t, 1 H, J= 8.9, 7.2 Hz, ArH).
(10-4):(E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (10-3) as the starting material, to obtain 118 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) S 1.53 (d, 2H, J = 7.7 Hz, CHZ), 1.65 (d, 2H, J = 7.0 Hz, CH2), 2.10 (t, 2H, J = 14.3, 7.0 Hz, CH2), 2.39 (t, 2H, J = 14.2, 7.3 Hz, CHZ), 2.72 (d, 2H, J = 8.2 Hz, CHZ), 2.95 (d, 2H, J = 5.4 Hz, CHZ), 3.12 (m, 6H, CH2CH2CH2), 3.32 (s, 3H, NCH3), 3.56 (t, 2H, J = 11.2, 5.6 Hz, CH2), 5.02 (s, 2H, CH2), 6.75 (t, 1 H, J = 15.0, 7.2 Hz, CH), 7.05 (d, 1 H, J
=
7.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (d, 1 H, J = 7.5 Hz, ArH), 8.14 (d, 1 H, J = 8.5 Hz, ArH).
Example 11: (E)-N1-(cyanomethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (11-1):(E)-8-((cyanomethyl)(cyanomethyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using cyanomethylamineas instead of dimethylaminehydrochloride the amine to obtain 299 mg of the title compound (yield: 76%).
'H NMR (200 MHz, CDC13) S 1.35 (m, 2H, CH2), 1.60 (m, 2H, CH2), 2.31 (m, 4H, CH2CH2), 3.11 (s, 3H, NCH3), 3.67 (s, 3H, OCH3), 4.38 (s, 2H, CH2), 4.97 (s, 2H, CHZ), 5.98 (s, 1 H, CH), 6.85 (d, 1 H, J = 4.6 Hz, ArH), 7.37 (t, 1H, J = 10.6, 5.2 Hz, ArH), 7.47 (m, 3H, ArH), 7.79 (dd, 1H, J = 6.2, 1.4 Hz, ArH), 8.06 (d, 1 H, J = 4.6 Hz, ArH).
(11-2):(E)-8-((cyanomethyl)(cyanomethyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (11-1) as the starting material, to obtain 250 mg of the title compound (yield: 84%).
1H NMR (300 MHz, MeOH-d4) S 1.37 (m, 2H, CH2), 1.61 (m, 2H, CHZ), 2.31 (m, 4H, CH2CH2), 3.31 (s, 3H, NCH3), 4.16 (d, 2H, J = 8.5 Hz, CH2), 5.01 (s, 2H, CH2), 6.21 (m, 1 H, CH), 6.98 (d, 1H, J = 7.0 Hz, ArH), 7.44 (m, 4H, ArH), 7.81 (t, 1 H, J = 8.8, 2.8 Hz, ArH), 8.13 (d, 1 H, J = 13.6 Hz, ArH).
(11-3):(E)-N1-(cyanomethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (11-2) as the starting material, to obtain 222 mg of the title compound (yield: 64%).
'H NMR (300 MHz, MeOH-d4) S 1.48 (m, 4H, CH2CH2), 1.71 (m, 4H, CH2CH2), 1.92 (m, 4H, CH2CH2), 2.32 (m, 4H, CH2CH2), 3.21 (s, 3H, NCH3), 3.73 (t, 1H, J = 7.2 Hz, CH2), 4.39 (s, 2H, CH2), 5.06 (s, 2H, CH2), 6.18 (m, 1 H, CH), 7.20 (d, 1 H, J = 7.0 Hz, ArH), 7.64 (m, 4H, ArH), 8.09 (dd, 1 H, J
14.8, 7.2 Hz, ArH), 8.13 (m, 1H, ArH).
(11-4):(E)-N1-(cyanomethyl)-N8-hydroxy-Nl-methyl-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (11-3) as the starting material, to obtain 170 mg of the title compound (yield: 75%).
'H NMR (300 MHz, MeOH-d4) S 1.34 (d, 2H, J = 7.7 Hz, CHZ), 1.50 (d, 2H, J = 6.7 Hz, CH2), 1.89 (d, 2H, J = 7.2 Hz, CH2), 2.25 (q, 2H, J = 16.2, 7.9 Hz, CH2), 3.20 (s, 3H, NCH3), 3.91 (d, 2H, J = 7.6 Hz, CH2), 4.98 (s, 2H, CH2), 5.98 (d, 1 H, J = 14.7 Hz, CH), 6.86 (d, 1 H, J= 6.7 Hz, ArH), 7.3 5(m, 4H, ArH), 7. 5 6(t, 1 H, J = 9.1, 3.4 Hz, ArH), 7.9 8(m, 1 H, ArH).
Example 12: (E)-N8-hydroxy-N1-(2-hydroxyethyl)-Nl-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide (12-1):(E)-8-((2-hydroxyethyl)(methyl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-2 0 hydroxyethylamine instead of dimethylaminehydrochloride as the amine to obtain 366 mg of the title compound (yield: 93%).
'H NMR (300 MHz, CDC13) S 1.51 (m, 2H, CH2), 1.68 (m, 2H, CH2), 2.29 (m, 4H, CH2CH2), 3.08 (s, 3H, NCH3), 3.66 (m, 4H, CH2CH2), 3.81 (S, 3H, OCH3), 4.96 (s, 2H, CH2), 6.86 (d, 1 H, J = 7.0 Hz, CH), 7.26 (s, 1 H, ArH), 7.44 (m, 4H, ArH), 7.77 (d, 1 H, J = 7.2 Hz, ArH), 8.15 (d, 1 H, J = 7.2 Hz, ArH).
(12-2): (E)-8-((2-hydroxyethyl)(methyl)amino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (12-1) as the starting material, to obtain 320 mg of the title compound (yield: 88%).
'H NMR (300- MHz, MeOH-d4) S 1.30 (m, 4H, CH2CH2), 2.08 (m, 4H, CH2CH2), 3.07 (s, 3H, NCH3), 3.09 (m, 4H, CH2CH2), 4.74 (s, 2H, CHZ), 6.77 (t, 1H, J = 7.2, 1.2 Hz, CH), 6.95 (s, 1H, ArH), 7.20 (m, 4H, ArH), 7.56 (t, 1 H, J = 7.0, 1.9 Hz, ArH), 7.90 (d, 1 H, J = 7.2 Hz, ArH).
(12-3):(E)-N8-hydroxy-N1-(2-hydroxyethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (12-2) as the starting material, to obtain 262 mg of the title compound (yield: 90%).
ls 'H NMR (300 MHz, MeOH-d4) 8 1.32 (m, 4H, CH2CH2), 2.06 (m, 4H, CH2CH2), 3.08 (s, 3H, NCH3), 3.13 (m, 4H, CH2CH2), 4.92 (s, 2H, CH2), 6.78 (t, 1H, J= 7.4, 1.8 Hz, CH), 6.92 (s, 1H, ArH), 7.28 (m, 4H, ArH), 7.56 (d, 1H, J = 7.4 Hz, ArH), 7.88 (d, 1H, J = 7.4 Hz, ArH); MS (LC, 70 eV) m/z 448 (M+l), 305, 204.
Example 13: (E)-N8-hydroxy-Nl-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (13-1):(E)-8-(methyl(1-methylpyrrolidin-3-yl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-methylpyrrolidin-3-ylamine instead of dimethylaminehydrochlori.de as the amine to obtain 355 mg of the title compound (yield: 91%).
'H NMR (200 MHz, CDC13) S 1.42 (m, 4H, CHZCHZ), 1.80 (m, 4H, CHZCH2), 2.20 (m, 4H, CH2CH2), 2.98 (s, 3H, NCH3), 3.61 (s, 3H, NCH3), 3.80 (s, 3H, OCH3), 4.82 (s, 2H, CH2), 4.96 (s, 2H, CH2), 5.81 (m, 1H, CH), 6.82 (m, 1H, ArH), 7.45 (m, 4H, ArH), 7.80 (m, 1H, ArH), 8.15 (m, 1H, ArH).
(13-2):(E)-8-(methyl(1-methylpyrrolidin-3-yl)amino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (13-1) as the starting material, to obtain 320 mg of the title compound (yield: 86%).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 4H, CH2CH2), 1.76 (m, 4H, CH2CH2), 2.22 (m, 4H, CH2CH2), 2.88 (s, 3H, NCH3), 3.58 (s, 3H, NCH3), 4.80 (s, 2H, CHZ), 4.99 (s, 2H, CH2), 5.84 (m, 1 H, CH), 6.80 (m, 1 H, ArH), 7.44 (m, 4H, ArH), 7.80 (m, 1 H, ArH), 8.12 (m, 1 H, ArH).
(13-3):(E)-N8-hydroxy-Nl-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (13-2) as the starting material, to obtain 188 mg of the title compound (yield: 41 %).
'H NMR (300 MHz, MeOH-d4) S 1.42 (m, 4H, CHZCH2), 1.80 (m, 4H, CH2CH2), 2.20 (m, 4H, CH2CH2), 2.98 (s, 3H, NCH3), 3.60 (s, 3H, NCH3), 3.80 (s, 3H, OCH2), 5.00 (s, 2H, CH2), 4.96 (s, 2H, CH2), 5.82 (m, 1 H, CH), 6.84 (m, 1 H, ArH), 7.44 (m, 4H, ArH), 7.78 (m, 1 H, ArH), 8.14 (m, 1H, ArH).
Example 14: (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (14-1):(E)-7-(3-(dimethylamino)propylcarbamoyl)-8-(naphthalen-l-yloxy)octane acid methylester The procedure of Example (1-1) was repeated except for using 3-(dimethylamino)propylamine instead of dimethylaminehydrochloride as the amine to obtain 467 mg of the title compound (yield: 73%).
'H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CH2), 1.64 (m, 4H, CH2CH2), 2.01 (s, 6H, N(CH3)2), 2.25 (m, 6H, CH2CH2CH2), 3.40 (m, 2H, CH2), 3.60 (s, 3H, OCH3), 4.96 (s, 2H, CH2), 6.81 (t, 1H, J = 15.4, 7.8 Hz, CH), 6.94 (t, 1H, J = 7.4, 6.2 Hz, ArH), 7.43 (m, 4H, ArH), 7.79 (m, 1 H, ArH), 8.19 (dd, 1 H, J
= 6.8, 3.6 Hz, ArH).
(14-2):(E)-7-(3-(dimethylamino)propylcarbamoyl)-8-(naphthalen-l-yloxy)octane acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (14-1) as the starting material, to obtain 154 mg of the title compound (yield: 83%).
'H NMR (300 MHz, MeOH-d4) S 1.30 (m, 2H, CHZ), 1.64 (d, 2H, J = 6.9 Hz, CH2), 1.94 (m, 2H, CH2), 2.27 (t, 2H, J = 14.2, 7.0 Hz, CHZ), 2.39 (d, 2H, J=
7.2 Hz, CH2), 2.74 (s, 6H, N(CH3)2), 3.03 (t, 2H, J = 15.0, 7.2 Hz, CH2), 3.33 (m, 2H, CH2), 5.05 (s, 2H, CH2), 6.66 (s, 1 H, CH), 7.03 (dd, 1 H, J = 7.2, 1.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.80 (d, 1 H, J = 6.9 Hz, ArH), 8.14 (d, 1 H, J
7.0 Hz, ArH).
(14-3):(E)-N1-(3-(dimethylamino)propyl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (14-2) as the starting material, to obtain 160 mg of the title compound (yield: 89%).
'H NMR (200 MHz, MeOH-d4) S 1.59 (m, 13H, CH2CH2CH2CH2CH2CH2CH2), 1.90 (s, 6H, N(CH3)2), 2.23 (m, 6H, CH2CHZCH2), 3.41 (q, 2H, J = 11.8, 6.2 Hz, CH2), 3.61 (m, 1 H, CH), 3.91 (m, 1 H, CH), 4.87 (s, 2H, CH2), 6.82 (d, 1 H, J = 7.4 Hz, CH), 6.89 (d, 1 H, J =
6.8 Hz, ArH), 7.44 (m, 4H, ArH), 7.79 (dd, 1 H, J = 5.2, 3.2 Hz, ArH), 8.16 (t, 1 H, J= 9.4, 6.4 Hz, ArH).
(14-4):(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (14-3) as the starting material, to obtain 142 mg of the title compound (yield: 92%).
1 H NMR (300 MHz, MeOH-d4) 6 1.52 (t, 2H, J = 7.5, 4.1 Hz, CH2), 1.64 (d, 2H, J = 7.1 Hz, CHZ), 1.92 (t, 2H, J= 13.8, 7.5 Hz, CH2), 2.10 (t, 1 H, J=
14.2, 7.0 Hz, CH2), 2.37 (d, 2H, J = 7.2 Hz, CH2), 2.72 (s, 6H, N(CH3)2), 3.01 (t, 2H, J = 14.8, 7.3 Hz, CHz), 3.35 (m, 3H, CHCHZ), 5.03 (s, 2H, CH2), 6.62 (t, 1 H, J = 15.0, 7.5 Hz, CH), 7.02 (d, 1 H, J = 7.1 Hz, ArH), 7.46 (m, 4H, ArH), 7.80 (dd, 1 H, J= 6.2, 1.9 Hz, ArH), 8.14 (t, 1 H, J = 8.9, 6.9 Hz, ArH); MS
(LC, 70 eV) m/z 429 (M+1), 413, 301, 256, 224.
Example 15: (E)-N-hydroxy-8-morpholino-7-((naphthalen-l-yloxy)methyl)-8-oxoocteneamide (15-1): (E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctene acid methylester The procedure of Example (1-1) was repeated except for using morpholinoamine instead of dimethylaminehydrochloride as the amine to obtain 416 mg of the title compound (yield: 67%).
1H NMR (200 MHz, CDC13) S 1.45 (m, 2H, CHZ), 1.63 (m, 2H, CH2), 2.25 (m, 4H, CH2CH2), 3.60 (m, 8H, CH2CH2CH2CH2), 3.71 (s, 3H, OCH3), 5.01 (s, 2H, CH2), 5.82 (t, 1 H, J= 15.0, 7.8 Hz, CH), 6.84 (dd, 1 H, J 7.2, 1.2 Hz, ArH), 7.46 (m, 4H, ArH), 7.79 (m, 1 H, ArH), 8.13 (dd, 1 H, J= 4.0, 3.2 Hz, ArH).
(15-2): (E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (15-1) as the starting material, to obtain 85 mg of the title compound (yield: 89%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H, CH2), 1.63 (m, 2H, CH2), 2.24 (m, 4H, CH2CH2), 3.58 (m, 8H, CH2CH2CH2CH2), 5.02 (s, 2H, CHZ), 5.86 (t, 1 H, J = 15.2, 7.6 Hz, CH), 6.82 (dd, 1 H, J = 7.4, 1.2 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (d, 1 H, J= 7.4 Hz, ArH), 8.13 (t, 1 H, J = 7.4, 3.4 Hz, ArH).
(15-3):(E)-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxo-N-(tetrahydro-2H-pyran-2-yloxy)octeneamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (15-2) as the starting material, to obtain 92 mg of the title compound (yield: 88%).
'H NMR (200 MHz, MeOH-d4) 6 1.54 (m, 5H, CH CH2CH2), 1.68 (m, 4H, CH2CH2), 2.18 (m, 2H, CH2), 2.40 (m, 2H, CH2), 3.25 (m, 5H, CHCH2CH2), 3.59 (m, 6H, CH2CH2CH2), 3.99 (m, 1H, CH), 5.08 (s, 2H, CHZ), 5.90 (t, 1H, J= 15.0, 7.6 Hz, CH), 6.97 (t, 1 H, J= 7.0, 5.8 Hz, ArH), 7.48 (m, 4H, ArH), 7.91 (dd, 1 H, J = 12.6, 3.0 Hz, ArH), 8.13 (t, 1 H, J = 7.0, 4.0 Hz, ArH).
(15-4): (E)-N-hydroxy-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxooctenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (15-3) as the starting material, to obtain 64 mg of the title compound (yield: 72%).
1 H NMR (300 MHz, MeOH-d4) 6 1.53 (s, 2H, CH2), 1.68 (m, 2H, CHZ), 2.13 (t, 2H, J = 14.1, 7.0 Hz, CHZ), 2.35 (q, 2H, J = 14.6, 7.3 Hz, CHZ), 3.33 (m, 2H, CH2), 3.53 (m, 6H, CH2CH2CH2), 5.06 (s, 2H, ArH), 5.86 (t, 1H, J = 14.9, 7.4 Hz, CH), 6.97 (t, 1 H, J = 7.2, 2.4 Hz, ArH), 7.45 (m, 4H, ArH), 7.80 (dd, 1 H, J = 5.6, 2.6 Hz, ArH), 8.13 (dd, 1 H, J = 6.2, 2.6 Hz, ArH); MS (LC, 70 eV) m/z 413 (M+1), 380, 309, 293, 265, 236, 149, 121.
Example 16: (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3-1o yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (16-1): (E)-8-(6-(4-methylpiperazin-1-yl)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(4-methylpiperazin-1-yl)pyridin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 216 mg of the title compound (yield: 37%).
'H NMR (300 MHz, MeOH-d4) 8 1.47 (m, 2H), 1.67 (, 2H), 1.88 (m, 2H), 2.37 (t, 2H), 2.93 (s, 3H), 3.34 (m, 4H), 3.61 (s, 3H), 3.79 (br, 4H), 4.34 (t, 1 H), 4.5 8(d, 1 H), 6.91 (d, 1 H), 7.42 (m, 3H), 7.51 (d, 1 H), 7. 8 6(m, 1 H), 7.91 (m, 2H), 8.06 (s, 1 H), 8.11 (m, 1 H), 8.39 (s, 1 H); MS (LC, 70 eV) m/z 517 (M+1).
(16-2):(E)-8-(6-(4-methylpiperazin-1-yl)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (16-1) as the starting material, to obtain 249 mg of the title compound (yield: 94%).
1H NMR (300 MHz, MeOH-d4) 6 1.45 (m, 2H), 1,67 (m, 2H), 2.30 (t, 2H), 2.94 (s, 3H), 3.33 (m, 4H), 3.83 (br, 4H), 4.45 (t, 1H), 4.56 (d) 1H), 7.03 (d, 1 H), 7.41 (m, 4H), 7.76 (m, 2H), 7.92 (d, 1 H), 8.12 (m, 2H), 8.49 (s, 1 H);
MS
(LC, 70 eV) m/z 503 (M+l).
(16-3): (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (16-2) as the starting material, to obtain 132 mg of the title compound (yield: 72%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H), 1,67 (m, 2H), 2.11 (t, 2H), 2.94 (s, 3H), 3.33 (m, 4H), 3.83 (br, 4H), 4.45 (t, 1H), 4.56 (d, 1H), 7.03 (d, 1H), 7.41 (m, 4H), 7.76 (m, 2H), 7.92 (d, 1 H), 8.12 (m, 2H), 8.49 (s, 1 H);
MS
(LC, 70 eV) m/z 518 (M+1).
Example 17: (E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (17-1):(E)-7-(6-(2-morpholinoethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(2-morpholinoethylamino)pyridin-3-yl instead of dimethylaminehydrochloride amine as the amine to obtain 350 mg of the title compound (yield: 64%).
'H NMR (300 MHz, MeOH-d4) 6 1.45 (m, 2H), 1.63 (m, 2H), 1.91 (m, 2H), 2.29 (t, 2H), 2.88 (m, 6H), 3.52 (t, 2H), 3.69 (s, 3H), 3.81 (m, 4H), 4.34 (t, 1 H), 4.78 (d, 1 H), 6.60 (d, 1 H), 7.42 (m, 6H), 7.66 (d, 1 H), 7.74 (m, 1 H), 8.12 (m, 1H), 8.24 (s, 1 H); MS (LC, 70 eV) m/z 547 (M+1).
(17-2):(E)-7-(6-(2-morpholinoethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (17-1) as the starting material, to obtain 207 mg of the title compound (yield: 87%).
'H NMR (300 MHz, MeOH-d4) S 1.45 (m, 2H), 1.63 (m, 2H), 1.91 (m, 2H), 2.29 (t, 2H), 2.88 (m, 6H), 3.52 (t, 2H), 3.81 (m, 4H), 4.34 (t, 1H), 4.78 (d, 1 H), 6.60 (d, 1 H), 7.42 (m, 6H), 7.66 (d, 1 H), 7.74 (m, 1 H), 8.12 (m, 1 H), 8.24 (s, 1H); MS (LC, 70 eV) m/z 533 (M+1).
(17-3):(E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (17-2) as the starting material, to obtain 171 mg of the title compound (yield: 48%).
'H NMR (300 MHz, DMSO-d6) 8 1.39 (m, 2H), 1.54 (m, 2H), 1.78 (m, 2H), 1.96 (t, 2H), 3.35 (m, 6H), 3.69 (m, 2H), 3.85 (m, 4H), 4.38 (t,1H), 4.52 (d, 1 H), 6.87 (d, 1 H), 7.45 (m, 6H), 7.82 (m, 2H), 8.03 (m, 1 H), 8.3 8(s, 1 H), 10.07 (s, 1H), 10.39 (s, 1H); MS (LC, 70 eV) m/z 548 (M+l ).
Example 18: (E)-N1-(6-(dimethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (18-1):(E)-7-(6-(dimethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-l-yloxy)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using not dimethylaminehydrochloride but 6-(dimethylamino)pyridin-3-ylamine as the amine to obtain 256 mg of the title compound (yield: 63%).
'H NMR (300 MHz, CDC13) S 1.64 (m, 4H), 2.36 (m, 4H), 3.07 (s, 6H), 3.68 (s, 3H), 5.06 (s, 2H), 6.52 (d, 1H), 6.98 (m, 2H), 7.44 (t, 1H), 7.53 (m, 3H), 7.87 (m, 2H), 8.11 (d, 1H), 8.27 (m, 1H); MS (LC, 70 eV) m/z 462 (M+1).
(18-2):(E)-7-(6-(dimethylamino)pyridin-3-ylcarbamoyl)-8-(naphthalen-1-yloxy)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (18-1) as the starting material, to obtain 190 mg of the title compound (yield: 76%).
'H NMR (300 MHz, MeOH-d4) 8 1.61 (m, 4H), 2.28 (t, 2H), 2.44 (q, 2H), 3.08 (s, 6H), 5.12 (s, 2H), 6.71 (m, 2H), 7.05 (d, 1H), 7.44 (m, 4H), 7.79 (m, 2H), 8.23 (m, 2H); MS (LC, 70 eV) m/z 448 (M+1).
(18-3):(E)-Nl-(6-(dimethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (18-2) as the starting material, to obtain 90 mg of the title compound (yield: 46%).
'H NMR (300 MHz, MeOH-d4) S 1.66 (m, 4H), 2.11 (t, 2H), 2.43 (q, 2H), 3.06 (s, 6H), 5.10 (s, 2H), 6.68 (m, 2H), 7.07 (d, 1H), 7.44 (m, 4H), 7.78 (m, 2H), 8.20 (m, 2H); MS (LC, 70 eV) m/z 463 (M+1).
Example 19: (E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (19-1):(E)-8-(6-(2-(dimethylamino)ethylamino)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 6-(2-(dimethylamino)ethylamino)pyridin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 307 mg of the title compound (yield: 31 %).
'H NMR (300 MHz, CDC13) 8 1.65 (m, 4H), 2.08 (m, 2H), 2.31 (s, 6H), 2.38 (m, 2H), 2.59 (t, 2H), 3.35 (q, 2H), 3.67 (s, 3H), 5.06 (s, 2H), 6.44 (d, 1H), 7.03 (m, 2H), 7.45 (t, 1 H), 7.53 (m, 3H), 7.75 (dd, IH), 7.85 (dd, 1H), 8.06 (d, 1H), 8.24 (m, 2H); MS (LC, 70 eV) m/z 505 (M+1).
(19-2):(E)-8-(6-(2-(dimethylamino)ethylamino)pyridin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (19-1) as the starting material, to obtain 226 mg of the title compound (yield: 75%).
'H NMR (300 MHz, MeOH-d4) S 1.64 (m, 4H), 2.27 (t, 2H), 2.47 (m, 2H), 2.91 (s, 6H), 3.28 (q, 2H), 3.65 (t, 2H), 5.11 (s, 2H), 6.66 (d, 1 H), 6.72 (t, 1 H), 7.08 (d, 1 H), 7.44 (m, 4H), 7.67 (dd, 1 H), 7.78 (dd, 1 H), 8.15 (dd, 1 H), 8.29 (m, 1H); MS (LC, 70 eV) m/z 491 (M+1).
(19-3):(E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (19-2) as the starting material, to obtain 11 mg of the title compound (yield: 5%).
'H NMR (300 MHz, MeOH-d4) 8 1.64 (m, 4H), 2.11 (t, 2H), 2.50 (s, 6H), 2.52 (m, 2H), 2.83 (t, 2H), 4.11 (t, 2H), 5.13 (s, 2H), 6.78 (m, 1H), 7.06 (d, 1 H), 7.45 (m, 4H), 7.5 8(dd, 1 H), 7.78 (dd, 1 H), 8.06 (dd, 1 H), 8.13 (d, 1 H), 8.74 (d, 1 H); MS (LC, 70 eV) m/z 506 (M+1).
Example 20: (E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide (20-1):7-(6-methoxy-pyridin-3-ylcarbamoyl)-8-(naphthalen-1-ylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using (6-methoxypyridin-3-yl)amine instead of dimethylaminehydrochloride as the amine to obtain 1.67 mg of the title compound (yield: 42%).
1H NMR (300 MHz, CDC13) S 1.54-1.73 (m, 4H), 2.29-2.37 (m, 4H), 3.63 (S, 3H), 3.85 (S, 3H), 6.65 (m, 1H), 6.82-6.98 (m, 2H), 7.39-7.52 (m, 4H), 7.81-7.91 (m, 3H), 8.10 (m, 1H), 9.29 (S, 1H).
(20-2):7-(6-methoxy-pyridin-3-ylcarbamoyl)-8-(naphthalen-1-ylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (20-1) as the starting material, to obtain 670 mg of the title compound (yield: 40%).
(20-3):(E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (1-3) was repeated except for using the compound obtained in Example (20-2) as the starting material, to obtain 482 mg of the title compound (yield: 69%).
1H NMR (300 MHz, MeOH-d4) S 1.45-1.59 (m, 4H), 1.97 (m, 2H), 2.40 (m, 2H), 3.80 (S, 3H), 4.17 (S, 2H), 6.15 (S, 1H), 6.55 (m, 2H), 6.78 (d, J = 9.0 Hz, 1 H), 7.13 (d, J = 7.7 Hz, 1 H), 7.24-7.41 (m, 3 H), 7.74 (d, J = 8.8 Hz, 1 H), 7.91 (m, 1H), 8.10 (S, 1H), 8.38 (S, 1H), 9.84 (S, 1H), 10.37 (S, 1H).
Example 21: (E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yl)methyl)octenediamide (21-1):(E)-8-(3-(1H-imidazol-1-yl)propylamino)-7-((naphthalen-l-yl)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(1 H-imidazol-1-yl)propylamine instead of dimethylaminehydrochloride as the amine to obtain 449 mg of the title compound (yield: 77%).
'H NMR (300 MHz, CDC13) 6 1.53-1.84 (m, 4H), 2.05 (m, 2H), 2.39 (m, 4H), 3.42 (q, J = 6.3Hz, 2H), 3.72 (s, 3H), 3.98 (t, J=7.OHz, 2H), 5.02 (s, 2H), 6.72 (t, J = 6.0 Hz, 1H), 6.88-7.07 (m, 4H), 7.36-7.65(m, 4H), 7.90(d, J = 6.7 Hz, 1 H), 8.22 (d, J = 7.3 Hz, 1 H).
LC/MS (M+H): 450.23.
(21-2):(E)-8-(3-(1H-imidazol-1-yl)propylamino)-7-((naphthalen-l-yl)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (21-1) as the starting material, to obtain 350 mg of the title compound (yield: 85%).
(21-3):(E)-N1-(3-(1H-imidazol-l-yl)propyl)-2-((naphthalen-l-yl)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (21-2) as the starting material, to obtain 220 mg of the title compound (yield: 63%).
'H NMR (200 MHz, CDC13) 6 1.40-1.75 (m, 11H), 1.81 (t, J= 6.4 Hz, 2H), 1.96 (m, 2H), 2.15 (m, 2H), 3.19 (q, J = 6.1 Hz, 2H), 3.38 (d, J = 11.8 Hz, 1 H), 3.76 (t, J = 6.9 Hz, 3H), 4.74 (s, 2H), 6.46 (m, 1 H), 6.67 (m, 2H), 6.83 (m, 2H) 7.32 (m, 5H), 7.65 (d, J = 6.5 Hz, 1H), 7.96 (d, J= 7.7 Hz, 1H), 9.33 (br, 1H).
LC/MS (M+H): 535.28.
(21-4):(E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (21-3) as the starting material, to obtain 63 mg of the title compound (yield: 37%).
HPLC purification: 46mg (purity : 97%) 'H NMR (300 MHz, MeOH-d4) S 1.52 (m, 2H), 1.68 (m, 2H), 2.03 (t, J
6.6Hz, 2H), 2.11 (t, J = 6.6 Hz, 2H), 2.3 5(q, J = 7.2Hz, 2H), 5.04 (s, 2H), 6.57 (t, J = 6.3 Hz, 2H), 7.01 (d, J = 7.2 Hz, 1 H), 7.18 (s, 1 H), 7.26 (s, 1 H), 7.43 (m, 4H), 7.78 (d, J = 7.8Hz, 1 H), 8.09 (s, 1 H), 8.13 (d, J =5.1 Hz, 1 H).
LC/MS (M+H): 451.23.
Example 22: (E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (22-1):(E)-8-(4-hydroxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-2 0 8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-hydroxyphenetylamine instead of dimethylaminehydrochloride as the amine to obtain 461 mg of the title compound (yield: 95%).
'H NMR (300 MHz, CDC13) S 1.50-1.80 (m, 4H), 2.38 (m, 4H), 2.82 (t, J
6.9Hz, 2H), 3.63 (m, 2H), 3.72 (s, 3H), 4.92 (s, 2H), 6.44 (br, 1H), 6.53-6.59 (t, J 5.4 Hz, 1H), 6.66 (d, J 8.4 Hz, 2H), 6.95 (m, 4H), 7.37 (m, 4H), 7.90 (d, J 9.1 Hz, 1 H), 8.12 (d, J 9.7 Hz, 1 H).
LC/MS (M+H): 412.20.
(22-2):(E)-8-(4-hydroxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (22-1) as the starting material, to obtain 439 mg of the title compound (yield: 92%).
'H NMR (300 MHz, MeOH-d4) 8 1.52 (m, 2H, CH2), 1.64 (m, 2H, CH2), 2.20 (m, 2H, CH2), 2.27 (s, 6H, N(CH3)2), 2.38 (m, 2H, CH2), 2.55 (m, 2H, CH2), 3.42 (m, 2H, CH2), 4.97 (s, 2H, CH2), 6.67 (s, 1 H, CH), 6.99 (t, 1 H, J= 7.0, 1.8 Hz, ArH), 7.41 (m, 4H, ArH), 7.77 (d, 1 H, J= 7.0, 1.8 Hz, ArH), 8.14 (d, 1 H, J = 7.2 Hz, ArH).
(22-3):(E)-N1-(4-hydroxyphenetyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (22-2) as the starting material, to obtain 394 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 1.42-1.85 (m, 12H), 2.04 (m, 2H), 2.22 (m, 2H), 2.71 (t, J = 6.4 Hz, 2H), 3.50 (m, 3H), 3.92 (m, 1H), 4.79 (s, 2H), 4.92 (m, 1 H), 6.3 8(t, J = 5.4 Hz, 1 H), 6.67 (m, 3H), 6.86 (m, 3H) 7.18 (br, 1 H), 7.44 (m, 4H), 7.77 (m, 1 H), 8.00 (m, 1 H), 8.93 (br, 1 H).
LC/MS (M+H): 497.26.
(22-4):(E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (22-3) as the starting material, to obtain 121 mg of the title compound (yield: 78%).
HPLC purification: 61mg (purity: 95%) 'H NMR (200 MHz, MeOH-d4) S 1.48-1.72 (m, 4H), 2.08 (t, J = 7.2Hz, 2H), 2.34 (q, J = 6.8 Hz, 2H), 2.73 (t, J = 7.2Hz, 2H), 3.45 (t, 7.0 Hz, 2H), 4.98 (s, 2H), 6.53 (t, J = 7.4 Hz, 1H), 6.63 (d, J = 7.8 Hz, 211), 6.97 (d, J = 8. 2Hz, 3H), 7.43 (m, 4H), 7.78 (d, J = 7.0 Hz, 1H), 8.10 (d, J = 9.2 Hz, 1H).
LC/MS (M+H): 413.20.
Example 23: (E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (23-1):(E)-8-(3-(dimethylamino)-2,2-dimethylpropylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(dimethylamino)-2,2-dimethylpropylamine instead of dimethylaminehydrochloride as the amine to obtain 454 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 0.87 (s, 6H), 1.45-1.73 (m, 4H), 1.85 (s, 6H), 2.11 (s, 2H), 2.27 (m, 2H), 3.25 (d, J = 4.4 Hz, 2H), 3.60 (s, 3H), 4.87 (s, 2H), 6.92 (m, 2H), 7.42 (m, 4H), 7.72 (d, J = 7.4 Hz, 1 H), 8.19 (d, J = 9.0 Hz, 1 H).
LC/MS (M+H): 405.27.
(23-2):(E)-8-(3-(dimethylamino)-2,2-dimethylpropylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (23-1) as the starting material, to obtain 339 mg of the title compound (yield: 93%).
'H NMR (200 MHz, MeOH-d4) S 1.6 (m, 4H, CH2CH2), 2.4 (m, 6H, CH2CH2CH2), 2.50 (m, 414, CH2CH2), 2.80 (m, 2H, CH2), 3.01 (s, 3H, NCH3), 3.29 (m, IH, CH), 3.65 (m, 1 H, CH), 4.95 (s, 2H, PhCH2), 6.00 (m, 1 H, CH), 7.00 (t, 1 H, J= 16.6, 9.4 Hz, ArH), 7.46 (m, 4H, ArH), 7.82 (m, 1 H, ArH), 8.18 (m, 1 H, ArH).
(23-3):(E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (23-2) as the starting material, to obtain 304 mg of the title compound (yield: 52%).
'H NMR (200 MHz, CDC13) 6 0.88 (s, 6H), 1.49-1.82 (m, 10H), 1.86 (s, 6H), 2.02 (m, 2H), 2.13 (s, 2H), 2.31 (q, J = 7.4 Hz, 2H), 3.27 (d, J = 4.6 Hz, 2H), 3.58 (m, 1H), 3.93 (m, 1H), 4.88 (s, 2H), 4.90 (m, 1H), 6.95 (t, J= 7.4 Hz, 2H), 7.45 (m, 4H), 7.78 (d, J= 6.0 Hz, 1H), 8.21 (d, J = 7.0 Hz, 1H), 8.48 (br, 1 H), 8.62 (br, 1 H).
LC/MS (M+H): 490.32.
(23-4):(E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (23-3) as the starting material, to obtain 144 mg of the title compound (yield: 74%).
HPLC purification: 101 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 0.98(s, 6H), 1.54 (m, 2H), 1.6 6(m, 2H), 2.12 (t, J= 7.4 Hz, 2H), 2.40 (s, 6H), 2.46 (m, 4H), 3.26 (s, 2H), 5.04 (s, 2H), 6.71 (t, J = 8.2 Hz, 1 H), 7.04 (m, 1 H), 7.45 (m, 4H), 7.80 (d, J = 7.8 Hz, 1 H), 8.13 (d, J = 8.6 Hz, 1H.
LC/MS (M+H): 406.26.
Example 24: (E)-Nl-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide (24-1):(E)-8-(2-(diisopropylamino)ethylamino)-8-oxo-7-((naphthalen-l-yloxy)methyl)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-(diisopropylamino)ethylamine instead of dimethylaminehydrochloride as the amine to obtain 420 mg of the title compound (yield: 89%).
'H NMR (200 MHz, CDC13) 8 0.87 (d, J = 7.0 Hz, 12H), 1.51 (m, 2H), 1.64 (m, 2H), 2.26 (m, 4H), 2.57 (t, J = 6.0 Hz, 2H), 2.86 (m, 2H), 3.31 (q, J =
5.6 Hz, 2H), 3.61 (s, 3H), 4.90 (s, 1H), 6.90 (m, 3H), 7.44 (m, 4H), 7.77 (d, J
7.2 Hz, 1 H), 8.17 (d, J= 7.0 Hz, 1 H).
LC/MS (M+H): 419.28.
(24-2):(E)-8-(2-(diisopropylamino)ethylamino)-8-oxo-7-((naphthalen-l-yloxy)methyl)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (24-1) as the starting material, to obtain 420 mg of the title compound (yield: 78%).
(24-3):(E)-N1-(2-(diisopropylamino)ethyl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (24-2) as the starting material, to obtain 319 mg of the title compound (yield: 50%).
'H NMR (200 MHz, CDC13) 8 0.95 (br, 9H), 1.50-1.95 (m, lOH), 2.10 (m, 2H), 2.31 (q, J = 6.8 Hz, 2H), 2.67 (m, 2H), 2.96 (s, 2H), 3.46 (m, 2H), 3.57 (m, 2H), 3.97 (m, 1 H), 4.93 (s, 2H), 4.94 (m, 1 H), 6.87 (m, 3H), 7.49 (m, 4H), 7.78 (d, J= 6.8 Hz, 1H), 8.15 (d, J= 8.6 Hz, 1H).
LC/MS (M+H): 504.34.
(24-4):(E)-N1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (24-3) as the starting material, to obtain 145 mg of the title compound (yield: 85%).
HPLC purification: 59 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 1.32 (t, J = 6.2 Hz, 9H), 1.46-1.78 (m, 4H), 2.10 (t, J 7.0 Hz, 2H), 2.41 (q, J 6.8 Hz, 2H), 3.23 (t, J 6.2 Hz, 2H), 3.63 (t, J 7.0 Hz, 1 H), 3.74 (m, 2H), 5.05 (s, 2H), 6.76 (t, J 6.6 Hz, 1 H), 7.02 (d, J 7.0 Hz, 1 H), 7.45 (m, 4H), 7.80 (d, J = 7.6 Hz, 1 H), 8.12 (d, J
7.8 Hz, 1 H).
LC/MS (M+H): 420.28.
Example 25: (E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (25-1):(E)-8-(1-methoxypropan-2-ylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-methoxypropan-2-ylamine instead of dimethylaminehydrochloride as the amine to obtain 413 mg of the title compound (yield: 83%).
'H NMR (200 MHz, CDC13) 8 1.15 (d, J = 6.8 Hz, 3H), 1.50 (m, 2H), 1.63 (m, 2H), 2.29 (m, 4H), 3.15 (s, 3H), 3.31 (d, J = 4.0 Hz, 2H), 3.62 (s, 3H), 4.24 (m, 1 H), 4.93 (s, 2H), 6.64 (d, J = 7.8 Hz, 1 H), 6.84 (t, J= 7.8 Hz, 1 H), 6.91 (d, J = 7.2 Hz, 1 H), 7.46 (m, 4H), 7.83 (m, 1H), 8.19 (m, 1 H).
LC/MS (M+H): 414.22.
(25-2):(E)-8-(1-methoxypropan-2-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (25-1) as the starting material, to obtain 346 mg of the title compound (yield: 81 %).
(25-3):(E)-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (25-2) as the starting material, to obtain 289 mg of the title compound (yield: 75%).
'H NMR (200 MHz, CDC13) S 1.17 (d, J = 6.8 Hz, 3H), 1.41-1.89 (m, lOH), 2.09 (m, 2H), 2.31 (q, J = 7.0 Hz, 2H), 3.17 (s, 3H), 3.57 (m, 1H), 3.93 (m, 1 H), 4.24 (m, 1 H), 4.93 (m, 1 H), 6.69 (d, J = 7.8 Hz, 1 H), 6.84 (t, J =
6.6 Hz, 1 H), 6.91 (d, J = 7.8 Hz, 1 H), 7.41 (m, 4H), 7.8 0(d, J = 7.8 Hz, 1 H), 8.19 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 499.27.
(25-4):(E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-l-2 0 yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (25-3) as the starting material, to obtain 125 mg of the title compound (yield: 88%).
HPLC purification: 63mg (purity: 97%) 'H NMR (200 MHz, DMSO-d4) 6 1.07 (d, J = 7.0 Hz, 3H), 1.45 (m, 2H), 1.51 (m, 2H), 1.96 (t, J = 7.0 Hz, 2H), 2.29 (m, 2H), 3.24 (s, 3H), 3.36 (s, 2H), 4.09 (m, 1 H), 4.96 (s, 2H), 6.51 (t, J = 7.8 Hz, 1 H), 7.07 (d, J = 6.8 Hz, 1H), 7.47 (m, 4H), 7.86 (m, 2H), 8.06 (d, J = 9.0 Hz, 1H), 8.70 (br, 4H), 10.35 (br, 1 H).
LC/MS (M+H): 415.22.
Example 26: (E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (26-1):(E)-8-(4-methoxybenzylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methoxybenzylamine instead of dimethylaminehydrochloride as the amine to obtain 461 mg of the title compound (yield: 98%).
'H NMR (200 MHz, CDC13) S 1.49 (m, 2H), 1.59 (m, 2H), 2.29 (m, 4H), 3.62 (s, 3H), 3.77 (s, 3H), 4.44 (d, J = 5.8 Hz, 2H), 4.94 (s, 2H), 6.75 (m, 3H), 6.88 (d, J= 7.4 Hz, 2H), 7.15 (d, J= 8.6 Hz, 2H), 7.44 (m, 4H), 7.78 (d, J= 7.4 Hz, 1 H), 7.99 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 462.22.
(26-2):(E)-8-(4-methoxybenzylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (26-1) as the starting material, to obtain 454 mg of the title compound (yield: 86%).
(26-3):(E)-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy)methyl)-N8-2 5 (tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (26-2) as the starting material, to obtain 378 mg of the title compound (yield: 85%).
'H NMR (200 MHz, CDC13) S 1.52-1.95 (m, 10H), 2.07 (m, 2H), 2.29 (q, J
7.2 Hz, 2H), 3.75 (s, 3H), 3.91 (m, 1H), 4.43 (d, J = 5.8 Hz, 2H), 4.90 (m, 1H), 4.92 (s, 2H), 6.79 (m, 3H), 6.87 (d, J= 7.6 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.47 (m, 4H), 7.77 (d, J = 8.0 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 8.65 (br, 1H).
LC/MS (M+H): 547.27.
(26-4):(E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (26-3) as the starting material, to obtain 142 mg of the title compound (yield: 80%).
HPLC purification: 81mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) 8 1.52 (m, 2H), 1.58 (m, 2H), 2.08 (t, J = 7.4 Hz, 2H), 2.34 (q, J = 7.6 Hz, 2H), 3.37 (s, 3H), 3.74 (s, 1H), 5.03 (s, 2H), 6.59 (t, J = 7.4 Hz, 1H), 6.74 (d, J = 8.2 Hz, 2H), 6.96 (d, J = 6.6 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 7.42 (m, 4H), 7.77 (d, J = 7.8 Hz, 1H),8.06(d,J=
7.4 Hz, 1 H).
LC/MS (M+H): 463.22.
Example 27: (E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (27-1):(E)-8-(4-fluorophenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-fluorophenetylamine instead of dimethylaminehydrochloride as the amine to obtain 463 mg of the title compound (yield: 93%).
'H NMR (200 MHz, CDC13) S 1.52 (m, 2H), 1.62 (m, 2H), 2.28 (m, 4H), 2.76 (t, J= 6.8 Hz, 2H), 3.54 (q, J = 5.6 Hz, 2H), 3.61 (s, 3H), 4.82 (s, 2H), 6.66 (br, 1H), 6.70 (m, 2H), 6.86 (m, 2H), 6.96 (m, 2H), 7.48 (m, 4H), 7.80 (d, J
7.4 Hz, 1H), 7.99 (d, J = 7.0 Hz, 1 H).
LC/MS (M+H): 464.21.
(27-2):(E)-8-(4-fluorophenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (27-1) as the starting material, to obtain 434 mg of the title compound (yield: 86%).
(27-3):(E)-N1-(4-fluorophenetylamino)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (27-2) as the starting material, to obtain 362 mg of the title compound (yield: 651 %).
'H NMR (200 MHz, CDC13) 6 1.48-1.89 (m, 10H), 2.16 (m, 2H), 2.28 (q, J
7.2 Hz, 2H), 2.75 (t, J = 6.8 Hz, 2H), 3.53 (q, J= 5.8 Hz, 2H), 3.60 (m, 1H), 3.91 (m, 1 H), 4.81 (s, 2H), 4.90 (m, 1 H), 6.49 (m, 1 H), 6.70 (m, 2H), 6.85 (m, 2H), 6.96 (m, 2H), 7.42 (m, 4H), 7.81 (d, J = 7.4 Hz, 1 H), 7.98 (d, J = 7.6 Hz, 1 H), 8.56 (br, 1 H).
LC/MS (M+H): 549.27.
(27-4):(E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (27-3) as the starting material, to obtain 83 mg of the title compound (yield: 76%).
HPLC purification: 36mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) S 1.49 (m, 2H), 1.69 (m, 2H), 2.09 (t, J = 6.8 Hz, 2H), 2.34 (q, J = 7.2 Hz, 2H), 2.80 (t, J = 6.8 Hz, 2H), 3.48 (m, 2H), 4.97 (s, 2H), 6.55 (t, J = 7.8 Hz, 1H), 6.86 (m, 2H), 6.97 (d, J 7.6 Hz, 1H), 7.14 (m, 2H), 7.45 (m, 4H), 7.79 (d, J= 7.8 Hz, 1 H), 8.10 (d, J 8.0 Hz, 1 H).
LC/MS (M+H): 465.21.
Example 28: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(tetrahydropyran-2-yl)methyl)-2-octenediamide (28-1):(E)-7-(((naphthalen-1-yloxy)methyl)-8-oxo-8-((tetrahydropyran-2-yl)methylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using tetrahydropyran-2-yl)methylamine instead of dimethylaminehydrochloride as the amine to obtain 426 mg of the title compound (yield: 87%).
'H NMR (200 MHz, CDC13) S 1.45-1.99 (m, 8H), 2.28 (m, 4H), 3.26 (m, 1H), 3.78 (m, 3H), 3.61 (s, 3H), 3.97 (m, 1H), 4.93 (s, 2H), 6.79 (m, 1H), 6.90 (m, 2H), 7.47 (m, 4H), 7.78 (m, 1H), 8.20 (m, 1H).
LC/MS (M+H): 426.22.
(28-2):(E)-7-(((naphthalen-1-yloxy)methyl)-8-oxo-8-((tetrahydropyran-2-yl)methylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (28-1) as the starting material, to obtain 370 mg of the title compound (yield: 90%).
(28-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N1-(tetrahydropyran-2-yl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (28-2) as the starting material, to obtain 323 mg of the title compound (yield: 65%).
'H NMR (200 MHz, CDC13) 8 1.42-1.95 (m, 14H), 2.08 (m, 2H), 2.25 (q, J
7.6 Hz, 2H), 3.28 (m, 1H), 3.59 (m, 3H), 3.89 (m, 2H), 4.88 (s, 2H), 4.90 (m, 1 H), 6.77 (m, 2H), 6.85 (d, J = 7.2 Hz, 1 H), 7.40 (m, 4H), 7.77 (m, 1 H), 8.14 (m, 1H), 8.68 (br, 1H).
LC/MS (M+H): 511.27.
(28-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-Nl-(tetrahydropyran-2-y1)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (28-3) as the starting material, to obtain 85 mg of the title compound (yield: 85%).
HPLC purification: 32mg (purity: 95%) 'H NMR (200 MHz, MeOH-d4) 8 1.60 (m, 6H), 1.81 (m, 2H), 2.09 (t, J = 7.2 Hz, 2H), 2.37 (q, J = 7.4 Hz, 2H), 3.35 (m, 2H), 3.68 (m, 2H), 4.00 (m, 1H), 5.02 (s, 2H), 6.65 (t, J = 7.8 Hz, 1 H), 7.01 (d, J = 6.8 Hz, 1 H), 7.44 (m, 4H), 7.78 (d, J = 8.6 Hz, 1 H), 8.15 (d, J = 9.4 Hz, 1 H).
LC/MS (M+H): 427.22.
Example 29: (E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (29-1):(E)-8-(2-cyclohexenylethylamino)-7-((naphthalen-l-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-cyclohexenylethylamine instead of dimethylaminehydrochloride as the amine to obtain 449 mg of the title compound (yield: 89%).
1H NMR (200 MHz, CDC13) S 1.25 (m, 2H), 1.30-1.71 (m, 8H), 1.79 (m, 2H), 2.09 (t, J = 7.4 Hz, 2H), 2.28 (m, 4H), 3.39 (q, J = 5.4 Hz, 2H), 3.60 (s, 3H), 4.86 (s, 2H), 5.28 (br, 1 H), 6.41 (br, 1 H), 6.89 (t, J= 7.6 Hz, 2H), 7.46 (m, 4H), 7.79 (m, 1 H), 8.14 (m, 1 H).
LC/MS (M+H): 450.26.
(29-2):(E)-8-(2-cyclohexenylethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (29-1) as the starting material, to obtain 401 mg of the title compound (yield: 95%).
(29-3):(E)-N1-(2-cyclohexenylethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-43) was repeated except for using the compound obtained in Example (29-2) as the starting material, to obtain 370 mg of the title compound (yield: 82%).
'H NMR (200 MHz, CDC13) 8 1.27 (m, 2H), 1.35-2.02 (m, 16H), 2.10 (m, 4H), 2.30 (q, J = 6.8 Hz, 2H), 3.40 (q, J = 5.8 Hz, 2H), 3.63 (m, 1H), 3.96 (m, 1 H), 4.87 (s, 2H), 4.92 (m, 1 H), 5.18 (br, 1 H), 6.44 (br, 1 H), 6.90 (t, J
= 7.6 Hz, 2H), 7.44 (m, 4H), 7.80 (m, 1 H), 8.15 (m, 1 H), 8.80 (br, 1 H).
LC/MS (M+H): 535.31.
(29-4):(E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (29-3) as the starting material, to obtain 112 mg of the title compound (yield: 91 %).
HPLC purification: 62 mg (purity: 92%) 'H NMR (200 MHz, MeOH-d4) 6 1.36-1.82 (m, lOH), 1.91 (m, 2H), 2.09 (m, 4H), 2.36 (q, J = 7.4 Hz, 2H), 3.34 (m, 2H), 4.99 (s, 2H), 5.34 (br, 1H), 6.63 (t, J= 7.8 Hz, 1H), 7.01 (d, J = 6.8 Hz, 1H), 7.45 (m, 4H), 7.79 (d, J = 9.4 Hz, 1 H), 8.13 (d, J = 9.0 Hz, 1 H).
LC/MS (M+H): 451.25.
Example 30: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl)propyl)-2-octenediamide (30-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(3-(2-oxopyrrolidin-l-yl)propylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 3-(2-oxopyrrolidin-1-yl)propylamine instead of dimethylaminehydrochloride as the amine to obtain 466 mg of the title compound (yield: 79%).
'H NMR (200 MHz, CDC13) S 1.44 (m, 2H), 1.63 (m, 4H), 1.95 (m, 2H), 2.26 (m; 6H), 3.21 (m, 6H), 3.56 (s, 3H), 4.93 (s, 2H), 6.72 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 7.23 (m, 1H), 7.39 (m, 1H), 7.74 (m,. 1H), 8.12 (m, 1 H).
LC/MS (M+H): 467.25.
(30-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(3-(2-oxopyrrolidin-l-yl)propylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (30-1) as the starting material, to obtain 370 mg of the title compound (yield: 88%).
(30-3):(E)-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl) propyl)-N8-(tetrahyd ro-2H-pyran-2-yloxy)-2-octenediam ide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (30-2) as the starting material, to obtain 316 mg of the title compound (yield: 80%).
'H NMR (200 MHz, CDC13) S 1.42-1.90 (m, 12H), 2.04 (m, 4H), 2.39 (m, 4H), 3.27 (m, 6H), 3.59 (m, 1H), 3.95 (m, 1H), 4.94 (m, 1H), 4.99 (s, 2H), 6.73 (t, J 7.6 Hz, 1 H), 6.91 (d, J = 7.4 Hz, 1 H), 7.25 (br, 4H), 7.45 (m, 4H), 7.78 (d, J 7.8 Hz, 1H), 8.13 (d, J = 7.8 Hz, 1H), 9.25 (br, 1H).
LC/MS (M+H): 552.30.
(30-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-l-yl)propyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (30-3) as the starting material, to obtain 166 mg of the title compound (yield: 82%).
HPLC purification: 49 mg (purity: 97%) 'H NMR (200 MHz, MeOH-d4) 8 1.53 (m, 2H), 1.74 (m, 4H), 2.06 (m, 4H), 2.36 (m, 4H), 3.33 (m, 6H), 4.86 (s, 2H), 6.61 (t, J = 7.4 Hz, 1H), 7.00 (d, J
6.8 Hz, 1H), 7.43 (m, 4H), 7.78 (d, J = 7.4 Hz, 1 H), 8.14 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 468.24.
Example 31: (E)-N1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide (31-1):(E)-8-(furan-2-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using furan-2-ylamine instead of dimethylaminehydrochloride as the amine to obtain 421 mg of the title compound (yield: 83%).
'H NMR (200 MHz, CDC13) 8 1.48 (m, 2H), 1.60 (m, 2H), 2.27 (m, 4H), 3.61 (s, 3H), 4.51 (d, J = 5.4 Hz, 2H), 4.93 (s, 2H), 6.20 (dd, J = 10.6 Hz, 3.2 Hz, 2H), 6.90 (m, 3H), 7.45 (m, 4H), 7.78 (d, J = 7.6 Hz, 1H), 8.07 (d, J= 7.6 Hz, 1 H).
LC/MS (M+H): 408.17.
(31-2):(E)-8-(furan-2-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (31-1) as the starting material, to obtain 353 mg of the title compound (yield: 90%).
(31-3):(E)-N1-(furan-2-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the ls compound obtained in Example (31-2) as the starting material, to obtain 306 mg of the title compound (yield: 55%).
'H NMR (200 MHz, CDC13) S 1.55-1.98 (m, l OH), 2.17 (m, 2H), 2.41 (q, J
7.4 Hz, 2H), 3.66 (m, 1 H), 3.97 (m, 1 H), 4.61 (d, J = 5.4 Hz, 2H), 4.8 8(m, 1H), 4.90 (s, 2H), 6.31 (d, J = 11.2 Hz, 2H), 6.96 (m, 3H), 7.52 (m, 4H), 7.89 (d, J = 6.8 Hz, 1H), 7.17 (d, J = 6.6 Hz, 1H), 8.45 (br, 1 H).
LC/MS (M+H): 493.23 (31-4):(E)-Nl-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (31-3) as the starting material, to obtain 156 mg of the title compound (yield: 79%).
HPLC purification: 68 mg (purity: 92%) 1H NMR (200 MHz, MeOH-d4) 6 1.50 (m, 2H), 1.62 (m, 2H), 2.08 (t, J = 6.8 Hz, 2H), 2.37 (q, J = 7.4 Hz, 2H), 4.47 (s, 2H), 5.03 (s, 2H), 6.24 (dd, J
14.6 Hz, 3.0 Hz, 2H), 6.62 (t, J = 7.4 Hz, 1 H), 6.99 (d, J = 7.2 Hz, 1 H), 7.43 (m, 4H), 7.78 (d, J = 9.0 Hz, 1 H), 8.08 (d, J= 8.2 Hz, 1 H).
LC/MS (M+H): 409.17.
Example 32: (E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (32-1):(E)-8-(4-(dimethylamino)benzylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-(dimethylamino)benzylamine instead of dimethylaminehydrochloride as the amine to obtain 547 mg of the title compound (yield: 72%).
'H NMR (200 MHz, CDC13) 6 1.45-1.75 (m, 4H), 2.31 (m, 4H), 2.93 (s, 6H), 3.64 (s, 3H), 4.44 (d, J = 5.4 Hz, 2H), 4.96 (s, 2H), 6.62 (m, 3H), 6.91 (m, 2H), 7.14 (d, J = 8.4 Hz, 2H), 7.40 (m, 4H), 7.84 (d, J = 7.4 Hz, 1 H), 8.05 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 475.
(32-2): (E)-8-(4-(dimethylamino)benzylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (32-1) as the starting material, to obtain 397 mg of the title compound (yield: 99%).
(32-3): (E)-N1-(4-dimethylamino)benzyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (32-2) as the starting material, to obtain 380 mg of the title compound (yield: 96%).
'H NMR (200 MHz, CDC13) S 1.50-1.92 (m, lOH), 2.05 (m, 2H), 2.30 (q, J=7.4Hz, 2H), 2.92 (s, 2H), 2.96 (m, 1 H), 3.57 (m, 1 H), 3.92 (m, 1 H), 4.41 (d, J = 5.2 Hz, 2H), 4.81 (m, 1H), 4.94 (s, 2H), 6.60 (m, 3H), 6.89 (m, 2H), 7.12 (d, J= 8.4 Hz, 2H), 7.41 (m, 4H), 7.78 (d, J= 8.0 Hz, 1 H), 8.02 (d, J = 8.2 Hz, 1H), 8.37 (br, 1H).
LC/MS (M+H): 560.
(32-4):(E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-l-1o yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (32-3) as the starting material, to obtain 305 mg of the title compound (yield: 92%).
HPLC purification: 287 mg (purity: 98%) 'H NMR (300 MHz, MeOH-d4) b 1.44 (m, 2H), 1.59 (m, 2H), 2.00 (t, J = 7.2 Hz, 2H), 2.28 (q, J = 7.2 Hz, 2H), 3.04 (s, 6H), 4.38 (s, 2H), 5.01 (s, 2H), 6.54 (t, J = 7.5 Hz, 1H),6.88(d,J=7.2Hz, 1H),7.17(d,J=8.4Hz,2H), 7.33 (m, 6H), 7.70 (d, J = 8.1 Hz, 1 H), 8.01 (d, J= 8.1 Hz, 1 H).
LC/MS (M+H): 476.25.
Example 33: (E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (33-1):(E)-8-(2-methoxyethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 2-3 0 methoxyethylamine instead of dimethylaminehydrochloride as the amine to obtain 399 mg of the title compound (yield: 85%).
'H NMR (200 MHz, CDC13) b 1.44-1.79 (m, 4H), 2.31 (m, 4H), 3.19 (s, 1H), 3.49 (m, 4H), 3.64 (s, 3H), 4.95 (s, 2H), 6.92 (m, 3H), 7.48 (m, 4H), 7.81 (m, 1 H), 7.81 (m, l H), 8.20 (m, 1 H).
LC/MS (M+H): 400.20.
(33-2):(E)-8-(2-methoxyethylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (33-1) as the starting material, to obtain 339 mg of the title compound (yield: 95%).
(33-3):(E)-N1-(2-methoxyethyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (33-2) as the starting material, to obtain 313 mg of the title compound (yield: 70%).
'H NMR (200 MHz, CDC13) 6 1.41-1.97 (m, lOH), 2.07 (m, 2H), 2.30 (q, J
7.4 Hz, 2H), 3.17(s, 3H), 3.46 (m, 5H), 3.92 (m, 1 H), 4.90 (m, 1 H), 4.92 (s, 2H), 6.85 (m, 3H), 7.46 (m, 4H), 7.81 (m, 1H), 8.17 (m, 1H), 8.67 (m, 1H).
LC/MS (M+H): 485.26.
(33-4):(E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (33-3) as the starting material, to obtain 87 mg of the title compound (yield: 68%).
HPLC purification: 42 mg (purity: 98%) 'H NMR (300 MHz, MeOH-d4) 6 1.44 (m, 2H), 1.57 (m, 2H), 2.02 (t, J = 7.2 Hz, 2H), 2.30 (q, J = 7.2 Hz, 2H), 3.19 (s, 3H), 3.40 (s, 4H), 4.95 (s, 2H), 6. 5 7(t, J = 7.5 Hz, 1 H), 6.96 (d, J = 6.3 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J
6.9 Hz, 1H), 8.09 (d, J = 7.2 Hz, 1 H).
LC/MS (M+H): 401.20.
Example 34: (E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide (34-1):(E)-8-(cyclohexylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using cyclohexylamine instead of dimethylaminehydrochloride as the amine to obtain 423 mg of the title compound (yield: 94%).
'H NMR (200 MHz, CDC13) b 1.13 (m, 2H), 1.33 (m, 2H), 1.42-1.79 (m, 8H), 1.88 (m, 2H), 2.29 (m, 4H), 3.62 (s, 3H), 3.82 (m, 1H), 4.92 (s, 2H), 6.34 (d, J
= 7.4 Hz, 1H), 6.84 (t, J = 7.8 Hz, 111), 6.91 (d, J = 7.2 Hz, 1H), 7.47 (m, 4H), 7.81 (m, l H), 8.15 (m, 1 H).
LC/MS (M+H): 424.24.
(34-2):(E)-8-(cyclohexylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (34-1) as the starting material, to obtain 397 mg of the title compound (yield: 67%).
(34-3):(E)-N1-cyclohexyl-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (34-2) as the starting material, to obtain 257 mg of the title compound (yield: 95%).
IH NMR (200 MHz, CDC13) 5 1.14 (m, 2H), 1.34 (m, 2H), 1.40-2.00 (m, 16H), 2.08 (m, 2H), 2.30 (q, J = 7.2 Hz, 2H), 3.62 (m, 1H), 3.90 (m, 2H), 4.72 (m, 1 H), 4.93 (s, 2H), 6.40 (d, J = 7.8 Hz, 1 H), 6.83 (t, J = 7.8 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1 H), 7.48 (m, 4H), 7.81 (m, 1 H), 8.16 (m, 1 H), 8.81 (br, 1 H).
LC/MS (M+H): 509.29.
(34-4):(E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-1.0 octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (34-3) as the starting material, to obtain 122 mg of the title compound (yield: 83%).
HPLC purification: 78 mg (purity: 93%) 'H NMR (300 MHz, MeOH-d4) 5 1.11-1.39 (m, 5H), 1.40-1.71 (m, 7H), 1.79 (m, 2H), 2.03 (t, J = 6.9 Hz, 2H), 2.29 (m, 2H), 3.69 (m, 1H), 4.96 (s, 1H), 6.47 (t, J = 7.2 Hz, 1 H), 6.93 (d, J = 7.2 Hz, 1 H), 7.37 (m, 4H), 7.75 (d, J
7.5 Hz, 1H), 8.08 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 425.24.
Example 35: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide (35-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(thiophen-2-ylmethylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using thiophen-2-ylmethylamine instead of dimethylaminehydrochloride as the amine to obtain 438 mg of the title compound (yield: 100%).
'H NMR (200 MHz, CDC13) b 1.43-1.75 (m, 4H), 2.29 (m, 4H), 3.62 (s, 3H), 4.68 (d, J = 5.8 Hz, 2H), 4.90 (s, 2H), 6.93 (m, 5H), 7.18 (d, J = 4.8 Hz, 1H), 7.46 (m, 4H), 7.78 (d, J = 8.0 Hz, 1 H), 8.04 (d, J = 8.0 Hz, 1 H).
LC/MS (M+H): 438.17.
(35-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(thiophen-2-ylmethylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (35-1) as the starting material, to obtain 438 mg of the title compound (yield: 92%).
(35-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N-1-(thiophen-2-ylmethyl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (35-2) as the starting material, to obtain 390 mg of the title compound (yield: 66%).
'H NMR (200 MHz, CDC13) b 1.46-1.94 (m, lOH), 2.10 (m, 2H), 2.32 (q, J
7.0 Hz, 2H), 3.64 (m, 1 H), 3.93 (m, 1 H), 4.70 (d, J = 5.2 Hz, 2H), 4.90 (m, 5H), 4.95 (s, 1H), 6.91 (m, 5H), 7.19 (d, J = 4.8 Hz, 1H), 7.47 (m, 4H), 7.80 (d, J = 8.8 Hz, 1 H), 8.09 (d, J = 10.0 Hz, 1 H), 8.41 (br, 1 H).
LC/MS (M+H): 523.22.
(35-4): (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (35-3) as the starting material, to obtain 168 mg of the title compound (yield: 87%).
HPLC purification: 55 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) 5 1.34 (m, 2H), 1.58 (m, 2H), 2.10 (m, 2H), 2.32 (m, 2H), 4.58 (s, 2H), 4.96 (s, 2H), 6.55 (m, 1H), 6.86 (m, 3H), 7.19 (d, J
= 4.8 Hz, 1 H), 7.3 6 (m, 4H), 7.71 (d, J= 7.8 Hz, 1 H), 8.01 (d, J = 7.8 Hz, 1 H).
LC/MS (M+H): 439.16.
Example 36: (E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide (36-1): (E)-8-(4-methoxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-methoxyphenetylamine instead of dimethylaminehydrochloride as the amine to obtain 476 mg of the title compound (yield: 100%).
'H NMR (200 MHz, CDC13) 5 1.45-1.73 (m, 4H), 2.30 (m, 4H), 2.75 (t, J
6.4 Hz, 2H), 3.56 (q, J= 6.6 Hz, 2H), 3.63 (s, 3H), 3.66 (s, 3H), 4.84 (s, 2H), 6.46 (m, 1H), 6.56 (d, J = 8.6 Hz, 2H), 6.88 (m, 2H), 6.95 (d, J = 8.6 Hz, 2H), 7.50 (m, 4H), 7.82 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.1 Hz, 1H).
LC/MS (M+H): 476.24.
(36-2):(E)-8-(4-methoxyphenetylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (36-1) as the starting material, to obtain 476 mg of the title compound (yield: 90%).
(36-3): (E)-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (36-2) as the starting material, to obtain 121 mg of the title compound (yield: 93%).
'H NMR (200 MHz, CDC13) b 1.50-1.90 (m, lOH), 2.19 (m, 2H), 2.30 (m, 2H), 2.86 (m, 2H), 3.67 (m, 3H), 3.81 (s, 3H), 3.92 (m, 1H), 4.85 (s, 2H), 4.92 (m, 1H), 6.61 (m, 1H), 6.87 (m, 2H), 7.15 (m, 4H), 7.46 (m, 4H), 7.82 (d, J = 8.0 Hz, 1H), 8.09 (d, J = 8.0 Hz, 1H), 8.39 (br, 1H).
LC/MS (M+H): 561.29.
(36-4):(E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (36-3) as the starting material, to obtain 155 mg of the title compound (yield: 84%).
HPLC purification: 50 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.44 (m, 2H), 1.57 (m, 2H), 2.03 (t, J = 6.9 Hz, 2H), 2.28 (q, J = 6.9 Hz, 2H), 2.70 (t, J = 6.9 Hz, 2H), 3.4 1(t, J = 7.2 Hz, 2H), 3.61 (s, 3H), 4.91 (s, 2H), 6.50 (t, J = 7.2 Hz, 1H), 6.61 (d, J = 8.1 Hz, 2H), 6.92 (d, J = 7.2 Hz, 1H), 6.98 (d, J = 8.1 Hz, 2H), 7.39 (m, 4H), 7.74 (d, J = 7.8 Hz, 1H), 8.05 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 478.23.
Example 37: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(4-(trifluoromethoxy)benzyl)-2-octenediamide (37-1):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(4-trifluoromethoxy) benzylamino)-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 4-3 0 (trifluoromethoxy)benzylamine instead of dimethylaminehydrochloride as the amine to obtain 515 mg of the title compound (yield: 57%).
'H NMR (200 MHz, CDC13) 6 1.52-1.71 (m, 6H), 2.32 (m, 4H), 3.62 (s, 3H), 4.52 (d, J = 5.6 Hz, 2H), 4.96 (s, 2H), 6.82 (br, 1 H), 6.94 (m, 2H), 7.10 (d, J =
8.2 Hz, 2H), 7.3 8 (m, 2H), 7.48 (m, 2H), 7.82 (d, J = 8.2 Hz, 1 H), 8.02 (d, J =
8.2 Hz, 1 H).
LC/MS (M+H): 516.19.
(37-2):(E)-7-((naphthalen-1-yloxy)methyl)-8-oxo-8-(4-trifluoromethoxy)benzylamino)-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (37-1) as the starting material, to obtain 293 mg of the title compound (yield: 95%).
(37-3):(E)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-N-1-(4-(trifluoromethoxy)benzyl)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (37-2) as the starting material, to obtain 291 mg of the title compound (yield: 60%).
'H NMR (200 MHz, CDC13) 6 0.86 (m, 2H), 1.28 (m, 2H), 1.44-1.79 (m, 8H), 2.34 (m, 2H), 3.64 (br, 1H), 3.92 (br, 1H), 4.52 (d, J = 5.8 Hz, 2H), 4.90 (m, 1H), 4.98 (s, 2H), 6.92 (m, 3H), 7.10 (m, 2H), 7.32 (m, 2H), 7.42 (m, 2H), 7.82 (d, J = 8.2 Hz, 111), 8.02 (d, J= 8.2 Hz, 1H), 8.29 (br, 1 H).
LC/MS (M+H): 601.24.
(37-4):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-Nl-(4-(trifluoromethoxy)benzyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (37-3) as the starting material, to obtain 74 mg of the title compound (yield: 52%).
HPLC purification: 15 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) 5 1.30 (m, 2H), 1.57 (m, 2H), 1.63 (m, 2H), 2.07 (t, J= 8.2 Hz, 2H), 2.3 8(q, J = 7.4 Hz, 2H), 4.46 (s, 2H), 5.05 (s, 2H), 5.47 (s, 2H), 6.61 (t, J = 7.6 Hz, 1H),6.97(d,J=7.4Hz, 1H),7.06(d,J=8.6 Hz, 1 H), 7.3 8 (m, 6H), 7.77 (d, J = 8.0 Hz, 1 H), 8.07 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 517.19.
Example 38: (E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (38-1):(E)-8-(1-(cyclohexylmethyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-(cyclohexylmethyl)pyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 506 mg of the title compound (yield: 26%).
1H NMR (200 MHz, CDC13) S 0.86 (m, 4H), 1.05-1.33 (m, 8H), 1.42-1.87 (m, 4H), 2.09 (m, 2H), 2.17-2.34 (m, 4H), 2.57 (m, 2H), 2.84 (m, 1 H), 3.62 (s, 3H), 4.53 (br, 1H), 4.93 (s, 2H), 5.30 (s, 2H), 6.84 (m, 2H), 7.47 (m, 4H), 7.78 (m, 1 H), 8.15 (m, 1 H).
LC/MS (M+H): 507.31.
(38-2): (E)-8-(1-(cyclohexylm ethyl)pyrrolidin-3-ylam ino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (38-1) as the starting material, to obtain 135 mg of the title compound (yield: 89%).
(38-3):(E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (38-2) as the starting material, to obtain 117 mg of the title compound (yield: 53%).
'H NMR (200 MHz, CDC13) 5 0.83 (m, 4H), 1.07 (m, 2H), 1.28 (m, 4H), 1.42 (m, 1 H), 1.57-1.78 (m, 12H), 2.17 (m, 2H), 2.31 (m, 6H), 2.61-2.89 (m, 311), 3.60 (m, 1 H), 3.92 (m, 1 H), 4.5 7(m, 1 H), 4.93 (s, 2H), 6.82 (t, J =
7.4 Hz, 1 H), 6.91 (d, J = 7.2 Hz, 1 H), 7.46 (m, 4H), 7.78 (d, J = 7.2 Hz, 1 H), 8.16 (d, J = 7.4 Hz, 1 H), 8.43 (br, 1 H).
LC/MS (M+H): 592.37.
(38-4):(E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (38-3) as the starting material, to obtain 58 mg of the title compound (yield: 77%).
PHLC purification: 24 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.92 (m, 2H), 1.15 (m, 4H), 1.46 (m, 2H), 1.50-1.70 (m, 8H), 2.04 (m, 3H), 2.36 (q, J = 7.2 Hz, 2H), 2.50 (m, 1 H), 2.96 (m, 3H), 3.56 (m, 1H), 3.79 (m, 1H), 4.34 (br, 1H), 4.97 (s, 214), 6.53 (t, J
=
7.0 Hz, 1 H), 6.94 (d, J = 7.2 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J = 7.6 Hz, 1 H), 8.06 (d, J = 7.6 Hz, 1H).
LC/MS (M+H): 508.31.
Example 39: (E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (39-1):(E)-8-(1-cyclopentylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopentylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 492 mg of the title compound (yield: 55%).
'H NMR (200 MHz, CDC13) 5 0.83-1.04 (m, 4H), 1.28 (m, 6H), 1.42-1.70 (m, 8H), 1.92-2.59 (m, 6H), 2.85 (m, 1H), 3.62 (s, 3H), 3.94 (m, 1H), 4.92 (s, 2H), 6.39 (d, J = 7.8 Hz, 1H), 6.84 (m, 2H), 7.48 (m, 4H), 7.79 (m, 1H), 8.17 (m, 1 H).
LC/MS (M+H): 493.30.
(39-2):(E)-8-(1-cyclopentylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (39-1) as the starting material, to obtain 274 mg of the title compound (yield: 96%).
(39-3):(E)-N1-(1-cyclopentylpiperidin-4-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (39-2) as the starting material, to obtain 257 mg of the title compound (yield: 48%).
1H NMR (200 MHz, CDC13) b 0.82 (m, 2H), 1.25-1.77 (m, 22H), 1.93-2.37 (m, 6H), 2.49 (m, 1 H), 2.90 (m, 2H), 3.61 (br, 1 H), 3.91 (br, 1 H), 4.91 (s, 2H), 6.52 (br, 1 H), 6.89 (m, 2H), 7.50 (m, 4H), 7.79 (m, 1 H), 8.16 (m, 1 H), 8.52 (br, 1H).
LC/MS (M+H): 578.35.
(39-4):(E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (39-3) as the starting material, to obtain 122 mg of the title compound (yield: 70%).
HPLC purification: 42 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.46 (m, 2H), 1.54-1.78 (m, 12H), 1.99-2.11 (m, 6H), 2.32 (q, J = 7.4 Hz, 2H), 2.98 (t, J = 12.6 Hz, 2H), 3.39 (m, 1H), 3.57 (d, J = 12.4 Hz, 2H), 3.94 (m, 1 H), 4.96 (s, 2H), 6.47 (t, J = 7.2 Hz, 1 H), 6.92 (d, J= 7.2 Hz, 1H), 7.34 (m, 4H), 7.74 (d, J= 8.0 Hz, 1H), 7.82 (s, 1H), 8.07 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 494.29.
Example 40: (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen -1-yloxy)methyl)-2-octenediamide (40-1):(E)-8-(1-benzylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-2 0 benzylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 501 mg of the title compound (yield: 70%).
'H NMR (200 MHz, CDC13) 6 0.84 (m, 2H), 1.29 (m, 2H), 1.62 (m, 4H), 2.30 (m, 6H), 2.55 (m, 2H), 3.48 (m,3H), 3.63 (s, 3H), 4.94 (s, 2H), 6.86 (m, 2H), 7.14 (m, 2H), 7.18 (m, 2H), 7.46 (m, 4H), 7.81 (d, J 7.8 Hz, 111), 8.19 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 501.27.
(40-2):(E)-8-(1-benzylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (40-1) as the starting material, to obtain 352 mg of the title compound (yield: 55%).
(40-3): (E)-N1-(1-benzylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (40-2) as the starting material, to obtain 188 mg of the title compound (yield: 67%).
'H NMR (200 MHz, CDC13) b 0.86 (m,2H), 1.28 (m, 2H), 1.42-1.77 (m, 8H), 2.08-2.37 (m, 6H), 2.54 (m, 2H), 2.75 (m, 1 H), 3.48 (m, 3H), 3.91 (br, 1 H), 4.53 (br, 1H), 4.85 (m, 1H), 4.92 (s, 2H), 6.94 (m, 3H), 7.16 (m, 4H), 7.40 (m, 4H), 7.84 (d, J = 7.0 Hz, 1 H), 8.21 (d, J = 9.6 Hz, 1 H), 8.60 (br, 1 H).
LC/MS (M+H): 586.32.
(40-4): (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (40-3) as the starting material, to obtain 64 mg of the title compound (yield: 68%).
HPLC purification: 23 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.30 (m, 2H), 1.52 (m, 2H), 1.64 (m, 2H), 2.07 (t, J = 7.0 Hz, 2H), 2.39 (q, J = 7.2 Hz, 2H), 4.32 (m, 3H), 4.94 (m, 3H), 5.47 (s, 2H), 6.57 (t, J = 7.4 Hz, 1H), 7.0 2(d, J = 7.2 Hz, 1H), 7.36-7.44 (m, 8H), 7.77 (d, J = 8.4 Hz, 1 H), 7.86 (m, 1 H), 8.08 (d, J = 6.4 Hz, 1 H), 8.75 (br, 1 H).
LC/MS (M+H): 502.26.
Example 41: (E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (41-1):(E)-8-(1-isopropylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-isopropylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 452 mg of the title compound (yield: 41%).
'H NMR (200 MHz, CDC13) b 0.84 (m, 2H), 1.0 2(m, 4H), 1.26 (m, 3H), 1.61 (m, 4H), 2.18 (m, 2H), 2.30 (m, 5H), 2.70(t, J = 6.6 Hz, 2H), 3.63 (s, 3H), 4.95 (s, 2H), 6.86 (m, 3H), 7.46 (m, 4H), 7.79 (d, J = 8.2 Hz, 1H), 8.17 (d, J = 8.6 Hz, 1H).
LC/MS (M+H): 453.27.
(41-2):(E)-8-(1-isopropylpyrrolidin-3-ylamino)-7-((naphthalen-l-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (41-1) as the starting material, to obtain 184 mg of the title compound (yield: 83%).
(41-3):(E)-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (41-2) as the starting material, to obtain 122 mg of the title compound (yield: 69%).
'H NMR (200 MHz, CDC13) b 0.83 (m, 4H), 1.05 (m, 6H), 1.25 (m, 4H), 1.59 (m, 6H), 2.09 (m, 2H), 2.34 (m, 4H), 2.76 (d, J = 5.4 Hz, 2H), 3.62 (m, 1H), 3.92 (m, 1 H), 4.94 (s, 2H), 6.79 (t, J = 7.8 Hz, 1 H), 6.94 (d, J = 7.4 Hz, 1 H), 7.14 (m, 1 H), 7.44 (m, 4H), 7.77 (m, 1 H), 8.16 (m, 1 H).
LC/MS (M+H): 538.32.
(41-4):(E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (41-3) as the starting material, to obtain 101 mg of the title compound (yield: 82%).
HPLC purification: 39 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.26 (m, 6H), 1.47 (q, J=7.2Hz, 2H), 1.62 (q, J=7.2Hz, 2H), 2.04 (t, J = 7.0 Hz, 3H), 2.34 (q, J = 7.2 Hz, 3H), 3.25-3.53 (m, 4H), 3.69 (m, 1H), 4.43 (m, 1H), 4.97 (m, 2H), 6.58 (m, IH), 6.95 (d, J
7.2 Hz, 1 H), 7.34 (m, 4H), 7.74 (d, J = 7.6 Hz, 1 H), 8.06 (d, J = 8.0 Hz, 1 H).
LC/MS (M+H): 454.26.
Example 42: (E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (42-1):(E)-8-(1-(cyclohexanecarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-(cyclohexanecarbonyl)pyrrol i din- 3 -ylamine instead of dimethylaminehydrochloride as the amine to obtain 520 mg of the title compound (yield: 66%).
'H NMR (200 MHz, CDC13) 5 1.17-1.76 (m, 14H), 2.16-2.35 (m, 7H), 3.46 (m, 2H), 3.62 (s, 3H), 3.83 (m, 2H), 4.54 (m, 1 H), 4.93 (s, 2H), 6.60 (m, 1 H), 6.88 (m, 1H), 7.47 (m, 4H), 7.80 (d, J = 7.2 Hz, 1H), 8.12 (d, J = 6.8 Hz, 1H).
LC/MS (M+H): 521.29.
(42-2):(E)-8-(1-(cyclohexanecarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (42-1) as the starting material, to obtain 342 mg of the title compound (yield: 78%).
(42-3):(E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (42-2) as the starting material, to obtain 262 mg of the title compound (yield: 40%).
'H NMR (300 MHz, CDC13) 6 1.20 (m, 4H), 1.42-1.77 (m, 16H), 2.11 (m, 4H), 2.32 (m, 3H), 3.37 (m, 2H), 3.44 (m, 1H), 3.60 (m, 2H), 3.86 (m, 1H), 4.53 (q, J = 5.6 Hz, 1H), 4.93 (s, 2H), 6.89 (m, 3H), 7.45 (m, 4H), 7.80 (d, J
7.4 Hz, 1 H), 8.10 (d, J= 7.6 Hz, 1 H), 8.41 (br, 1 H).
LC/MS (M+H): 606.35.
(42-4):(E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (42-3) as the starting material, to obtain 154 mg of the title compound (yield: 80%).
HPLC purification: 67 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.18-1.69 (m, 14H), 2.03 (m, 4H), 2.32 (q, J = 7.0 Hz, 3H), 3.49 (m, 2H), 3.80 (m, 1H), 3.93 (s, 1H), 4.40 (m, 1H), 4.98 (s, 2H), 6.48 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 5.4 Hz, 1H), 7.37 (m, 4H), 7.73 (d, J = 7.8 Hz, 1 H), 8.08 (d, J = 8.8 Hz, 1 H).
LC/MS (M+H): 522.29.
Example 43 : (E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester (43-1):(E)-3-(8-methoxy-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (1-1) was repeated except for using 3-aminopyrrolidin-l-carboxylic acid t-butylester instead of dimethylaminehydrochloride as the amine to obtain 510 mg of the title compound (yield: 83%).
'H NMR (300 MHz, CDC13) 5 1.33 (m, 2H), 1.39 (s, 9H), 1.60 (m, 2H), 2.15 (m, 2H), 2.31 (m, 4H), 3.36 (m, 4H), 3.62 (s, 3H), 4.93 (s, 2H), 6.66 (br, 1H), 6.90 (m, 2H), 7.3 8 (t, J = 7.8 Hz, 2H), 7.49 (m, 2H), 7.80 (m, 1 H), 8.10 (m, 1 H).
LC/MS (M+H): 511.27.
(43-2):(E)-8-(1-(t-butoxycarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (43-1) as the starting material, to obtain 423 mg of the title compound (yield: 77%).
(43-3):(E)-3-(2-((naphthalen-1-yloxy)methyl)-8-oxo-8-(tetrahydro-2H-pyran-2-yloxyamino)-2-octeneamido)pyrrolidin-l-carboxylic acid t-2 5 butylester The procedure of Example (4-3) was repeated except for using the compound obtained in Example (43-2) as the starting material, to obtain 320 mg of the title compound (yield: 72%).
1H NMR (300 MHz, CDC13) 5 1.25 (m, 2H), 1.39 (s, 9H), 1.45 (m, 2H), 1.50-1.77 (m, 6H), 1.92 (m, 1H), 2.04 (m, 4H), 2.30 (q, J = 7.2 Hz, 2H), 3.36 (m, 4H), 3.60 (br, 1 H), 3.92 (br, 1 H), 4.92 (s, 2H), 6.74 (br, 1 H), 6.83 (t, J
= 7.6 Hz, 1 H), 6.92 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.10 (m, 1 H), 8.71 (br, 1 H).
LC/MS (M+H): 596.33.
(43-4):(E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-4) was repeated except for using the compound obtained in Example (43-3) as the starting material, to obtain 255 mg of the title compound (yield: 95%).
HPLC purification: 5 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.29 (m, 2H), 1.42 (s, 9H), 1.62 (m, 2H), 1.89-2.09 (m, 4H), 2.33 (m, 2H), 3.20 (m, 2H), 3.57 (m, 2H), 4.41 (t, J = 5.4 Hz, 1H), 5.48 (s, 2H), 6.52 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.2 Hz, 2H), 7.40 (m, 4H), 7.79 (d, J = 8.4 Hz, 1 H), 8.10 (d, J = 7.4 Hz, 1 H).
LC/MS (M+H): 512.27.
Example 44: (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-2 0 (pyrrolidin-3-yl)2-octenediamide (44-1):(E)-3-(8-methoxy-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (1-1) was repeated except for using 3-aminopyrrolidin-l-carboxylic acid t-butylester instead of dimethylaminehydrochloride as the amine to obtain 510 mg of the title compound (yield: 83%).
'H NMR (300 MHz, CDC13) 6 1.33 (m, 2H), 1.39 (s, 9H), 1.60 (m, 2H), 2.15 (m, 2H), 2.31 (m, 4H), 3.36 (m, 4H), 3.62 (s, 3H), 4.93 (s, 2H), 6.66 (br, 1H), 6.90 (m, 2H), 7.3 8 (t, J = 7.8 Hz, 2H), 7.49 (m, 2H), 7.80 (m, 1 H), 8.10 (m, 1 H).
LC/MS (M+H): 511.27.
(44-2):(E)-8-(1-(t-butoxycarbonyl)pyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy)methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (44-1) as the starting material, to obtain 423 mg of the title compound (yield: 77%).
(44-3):(E)-3-(2-((naphthalen-1-yloxy)methyl)-8-oxo-8-(tetrahydro-2H-pyran-2-yloxyamino)-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-3) was repeated except for using the compound obtained in Example (44-2) as the starting material, to obtain 320 mg of the title compound (yield: 72%).
'H NMR (300 MHz, CDC13) 5 1.25 (m, 2H), 1.39 (s, 9H), 1.45 (m, 2H), 1.50-1.77 (m, 6H), 1.92 (m, 1H), 2.04 (m, 4H), 2.30 (q, J = 7.2 Hz, 2H), 3.36 (m, 4H), 3.60 (br, 1 H), 3.92 (br, 1 H), 4.92 (s, 2H), 6.74 (br, 1 H), 6.83 (t, J
= 7.6 Hz, 1 H), 6.92 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.10 (m, 1 H), 8.71 (br, 1 H).
LC/MS (M+H): 596.33.
(44-4):(E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido)pyrrolidin-l-carboxylic acid t-butylester The procedure of Example (4-4) was repeated except for using the compound obtained in Example (44-3) as the starting material, to obtain 255 mg of the title compound (yield: 95%).
HPLC purification: 5 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) 5 1.29 (m, 2H), 1.42 (s, 9H), 1.62 (m, 2H), 1.89-2.09 (m, 4H), 2.33 (m, 2H), 3.20 (m, 2H), 3.57 (m, 2H), 4.41 (t, J = 5.4 Hz, 1H), 5.48 (s, 2H), 6.52 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.2 Hz, 2H), 7.40 (m, 4H), 7.79 (d, J= 8.4 Hz, 1 H), 8.10 (d, J= 7.4 Hz, 1 H).
LC/MS (M+H): 512.27.
(44-5):(E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(pyrrolidin-3-yl)2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (44-4) as the starting material, to obtain 172 mg of the title compound (yield: 92%).
HPLC purification: 58 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.46 (m, 2H), 1.58 (m, 2H), 2.04 (t, J= 7.0 Hz, 2H), 2.34 (m, 4H), 3.22 (m, 2H), 3.44 (m, 2H), 4.43 (m, 1 H), 4.97 (s, 2H), 6.55 (m, 1 H), 6.95 (d, J = 6.8 Hz, 1 H), 7.3 8(m, 4H), 7.73 (d, J = 7.4 Hz, 1 H), 8.0 8 (d, J = 7.8 Hz, 1H).
LC/MS (M+H): 412.22.
Example 45: (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide (45-1):(E)-8-(1-cyclohexylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclohexylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 492 mg of the title compound (yield: 54%).
'H NMR (200 MHz, CDC13) 5 1.08-1.42 (m, 4H), 1.51-1.78 (m, lOH), 1.94 (m, 2H), 2.29 (m, 6H), 2.64 (d, J = 5. 4Hz, 2H), 2.82 (m, 1H), 3.63 (s, 3H), 4.53 (m, 1H), 4.93 (s, 2H), 6.90 (m, 2H), 7.48 (m, 4H), 7.78 (m, 1H), 8.17 (d, J = 7.2 Hz, 1H).
LC/MS (M+H): 493.30.
(45-2):(E)-8-(1-cyclohexylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (45-1) as the starting material, to obtain 269 mg of the title compound (yield: 100%).
(45-3):(E)-N1-(1-cyclohexylpyrrolidin-3-yl)-2-((naphthalen-2-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (45-2) as the starting material, to obtain 269 mg of the title compound (yield: 43%).
'H NMR (200 MHz, CDC13) b 0.83 (m 4H), 1.13-1.42 (m, 6H), 1.56-1.89 (m, 12H), 2.16 (m, 6H), 2.32 (m, 2H), 2.77 (m, 1 H), 3.62 (br, 1 H), 3.94 (br, 1 H), 4.61 (m, 1 H), 4.80 (m, 1H), 4.94 (s, 2H), 6.82 (t, J = 7.8 Hz, 1 H), 6.91 (d, J
7.6 Hz, 2H), 7.44 (m, 4H), 7.82 (m, 1H), 8.16 (m, 1 H).
LC/MS (M+H): 578.35.
(45-4):(E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (45-3) as the starting material, to obtain 140 mg of the title compound (yield: 88%).
HPLC purification: 16 mg (purity: 97%) 'H NMR (300 MHz, MeOH-d4) b 1.24-1.34 (m, 8H), 1.47-1.65 (m, 6H), 1.77 (m, 1H), 1.98 (m, 2H), 2.05 (t, J = 7.2 Hz, 2H), 2.11 (s, 2H), 2.34 (m, 2H), 2.76 (br, 1H), 4.41 (m, 1H), 4.99 (s, 2H), 6.59 (t, J = 7.4 Hz, 2H), 6.98 (d, J
7.0 Hz, 1 H), 7.3 9 (m, 414), 7.74 (d, J = 7.6 Hz, 1 H), 8.07 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 494.29.
Example 46: (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (46-1):(E)-8-(1-cyclopropylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopropylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 450 mg of the title compound (yield: 78%).
'H NMR (200 MHz, CDC13) b 0.15 (m, 214), 0.28 (m, 2H), 1.28-1.93 (m, 8H), 2.29 (m, 6H), 2.80 (m, 2H), 3.62 (s, 3H), 4.92 (s, 2H), 6.69 (d, J = 7.8 Hz, 1 H), 6.82 (m, 1 H), 7.47 (m, 4H), 7.82 (m, 1 H), 8.15 (m, 1 H).
LC/MS (M+H): 451.25.
(46-2):(E)-8-(1-cyclopropylpyrrolidin-3-ylamino)-7-((naphthalen-2-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (46-1) as the starting material, to obtain 355 mg of the title compound (yield: 98%).
(46-3):(E)-N1-(1-cyclopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (46-2) as the starting material, to obtain 334 mg of the title compound (yield: 61%).
'H NMR (200 MHz, CDC13) b 0.16 (m, 2H), 0.31 (m, 2H), 1.47-1.83 (m, 12H), 2.15 (m, 2H), 2.17 (s, 2H), 2.30 (m, 2H), 2.37 (m, 2H), 2.81 (m, 2H), 3.62 (br, 1 H), 3.91 (br, 1 H), 4.90 (m, 1 H), 4.92 (s, 2H), 6.80 (t, J = 7.8 Hz, 1 H), 6.90 (d, J = 7.6 Hz, 1 H), 7.46 (m, 4H), 7.80 (m, 1 H), 8.14 (m, 1 H), 8.44 (br, 1H).
LC/MS (M+H): 536.30.
(46-4): (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-NB-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (46-3) as the starting material, to obtain 154 mg of the title compound (yield: 89%).
HPLC purification: 65 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.42 (m, 4H), 1.44 (q, J = 7.4 Hz, 2H), 1.59 (m, 3H), 1.82 (br, 1 H), 2.02 (t, J = 7.2 Hz, 1 H), 2.09 (s, 1 H), 2.27 (m, 1 H), 2.32 (q, J = 7.2 Hz, 2H), 2.71 (m, 2H), 3.01 (m, 2H), 4.94 (s, 2H), 6.53 (t, J=
7.4 Hz, 1 H), 6.92 (d, J = 7.2 Hz, 1 H), 7.3 6 (m, 4H), 7.74 (d, J = 7.8 Hz, 1 H), 7.81 (s, 1 H), 8.08 (d, J= 7.8 Hz, 1 H).
Example 47: (E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (47-1):(E)-8-(1-cyclopropylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-cyclopropylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 464 mg of the title compound (yield: 47%).
'H NMR (200 MHz, CDC13) b 0.33-0.40 (m, 4H), 1.24-1.73 (m, 9H), 1.88 (m, 2H), 2.17 (m, 1 H), 2.29 (m, 6H), 3.62 (s, 3H), 3.92 (m, 1 H), 4.91 (s, 2H), 6.35 (d, J = 8.0 Hz, 1H), 6.90 (m, 2H), 7.48 (m, 4H), 7.80 (m, 1H), 8.12 (m, 1 H).
LC/MS (M+H): 465.27.
(47-2): (E)-8-(1-cyclopropylpiperidin-4-ylamin o)-7-((naphtha len-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (47-1) as the starting material, to obtain 221 mg of the title compound (yield: 100%).
(47-3):(E)-N1-(1-cyclopropylpiperidin-4-yl)-2-((naphthalen-1-yloxy) methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (47-2) as the starting material, to obtain 221 mg of the title compound (yield: 51 %).
'H NMR (200 MHz, CDC13) b 0.38 (m, 4H), 1.28-1.94 (m, 18H), 2.10 (m, 2H), 2.32 (m, 4H), 3.64 (m, 1H), 3.95 (m, 1H), 4.88 (m, 1H), 4.92 (s, 2H), 6.40 (d, J = 8.2 Hz, 1 H), 6.92 (m, 2H), 7.48 (m, 4H), 7.84 (m, 1 H), 8.14 (m, 1H), 8.42 (br, 1 H).
LC/MS (M+H): 550.32.
(47-4):(E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-2 5 1-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (47-3) as the starting material, to obtain 150 mg of the title compound (yield: 90%).
HPLC purification: 107 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 0.89 (m, 4H), 1.25 (m, 4H), 1.46 (m, 2H), 1.62 (m, 2H), 2.04 (t, J = 7.2 Hz, 2H), 2.10 (m, 2H), 2.33 (q, J = 7.4, 2H), 2.73 (m, 1 H), 3.59 (m, 2H), 3.99 (m, 1 H), 4.98 (s, 2H), 6.49 (m, 1 H), 6.94 (d, J = 7.2 Hz, 1H), 7.3 6(m, 4H), 7.73 (d, J= 7. 8Hz, 1 H), 8.06 (d, J= 7.8 Hz, 1 H).
LC/MS (M+H): 466.26.
Example 48: (E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide (48-1):(E)-8-(1-ethylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-ethylpiperidin-4-ylamine instead of dimethylaminehydrochloride as the amine to obtain 452 mg of the title compound (yield: 62%).
'H NMR (200 MHz, CDC13) 5 1.02 (t, J = 7.4, 3H), 1.26-1.74 (m, 8H), 1.92-2.17 (m, 4H), 2.32 (m, 4H), 2.72 (m, 2H), 3.63 (s, 3H), 4.92 (s, 2H), 6.38 (d, J
= 8.0 Hz, 1 H), 6.80 (t, J = 7.8 Hz, 1 H), 6.90 (d, J= 7.6 Hz, 1 H), 7.48 (m, 4H), 7.82 (m, 1 H), 8.14 (m, 1 H).
LC/MS (M+H): 453.27.
(48-2):(E)-8-(1-ethylpiperidin-4-ylamino)-7-((naphthalen-1-yloxy)methyl) -8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (48-1) as the starting material, to obtain 279 mg of the title compound (yield: 100%).
(48-3):(E)-N1-(1-ethylpiperidin-4-yl)-2-((naphthalen-1-yloxy)methyl)-N8-3 0 (tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (48-2) as the starting material, to obtain 279 mg of the title compound (yield: 80%).
'H NMR (200 MHz, CDC13) b 0.84 (m, 2H), 1.05 (t, J = 7.4 Hz, 3H), 1.27 (m, 2H), 1.44-1.79 (m, 10H), 1.94-2.26 (m, 4H), 2.35 (m, 4H), 2.90 (m, 2H), 3.62 (m, 1 H), 3.93 (m, 1 H), 4.94 (s, 2H), 4.97 (m, 1 H), 6.46 (d, J= 7.8 Hz, 1 H), 6.84 (t, J = 7.8 Hz, 1 H), 6.92 (d, J = 7.0 Hz, 1 H), 7.4 8(m, 4H), 7.82 (m, 1 H), 8.14 (m, 111), 8.43 (br, 1 H).
LC/MS (M+H): 538.32.
(48-4):(E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (48-3) as the starting material, to obtain 146 mg of the title compound (yield: 94%).
HPLC purification: 114 mg (purity: 95%) 'H NMR (300 MHz, MeOH-d4) b 1.24 (t, J = 7.2 Hz, 3H), 1.45-1.81 (m, 7H), 1.93-2.10 (m, 5H), 2.32 (q, J = 7.2 Hz, 2H), 2.98 (m, 2H), 3.09 (q, J = 7.2 Hz, 2H), 3.51 (m, 1 H), 4.97 (s, 2H), 6.46 (t, J = 7.6 Hz, 1 H), 6.94 (d, J= 7.0 Hz, 1 H), 7.3 8 (m, 4H), 7.72 (d, J = 7.6 Hz, 1 H), 8.05 (d, J = 7.8 Hz, 1 H).
LC/MS (M+H): 454.26.
Example 49: (E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2 5 1-yloxy)methyl)-2-octenediamide (49-1):(E)-8-(1-ethylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid methylester The procedure of Example (1-1) was repeated except for using 1-ethylpyrrolidin-3-ylamine instead of dimethylaminehydrochloride as the amine to obtain 438 mg of the title compound (yield: 52%).
'H NMR (200 MHz, CDC13) b 0.99 (t, J= 7.2 Hz, 3H), 1.26-1.73 (m, 6H), 2.16-2.47 (m, 8H), 2.60 (m, 2H), 2.80 (m, 1H), 3.63 (s, 3H), 4.95 (s, 2H), 6.81 (t, J = 7.6 Hz, 1 H), 6.90 (d, J = 7.4 Hz, 1 H), 7.46 (m, 4H), 7.79 (m, 1 H), 8.16 (m, 1H).
LC/MS (M+H): 469.30.
(49-2):(E)-8-(1-ethylpyrrolidin-3-ylamino)-7-((naphthalen-1-yloxy) methyl)-8-oxo-6-octene acid The procedure of Example (1-2) was repeated except for using the compound obtained in Example (49-1) as the starting material, to obtain 224 mg of the title compound (yield: 100%).
(49-3):(E)-N1-(1-ethylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-N8-(tetrahydro-2H-pyran-2-yloxy)-2-octenediamide The procedure of Example (4-3) was repeated except for using the compound obtained in Example (49-2) as the starting material, to obtain 224 mg of the title compound (yield: 69%).
'H NMR (200 MHz, CDC13) b 0.82 (m, 2H), 1.06 (t, J = 7.4 Hz, 3H), 1.24 (m, 4H), 1.41-2.20 (m, 8H), 2.31 (m, 4H), 2.51 (m, 3H), 2.57 (m, 1H), 2.62 (m, 1 H), 3.61 (br, 1 H), 3.92 (br, 1 H), 4.91 (m, 1 H), 4.94 (s, 2H), 6.79 (t, J
= 7.8 Hz, 1 H), 6.94 (d, J = 7.0 Hz, 1 H), 7.44 (m, 4H), 7.82 (m, 1 H), 8.20 (m, 1 H).
LC/MS (M+H): 524.30.
(49-4):(E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-l-yloxy)methyl)-2-octenediamide The procedure of Example (4-4) was repeated except for using the compound obtained in Example (49-3) as the starting material, to obtain 184 mg of the title compound (yield: 91 %).
HPLC purification: 128 mg (purity: 96%) 'H NMR (300 MHz, MeOH-d4) b 1.22 (m, 4H), 1.46-1.62 (m, 6H), 1.79 (m, 1 H), 2.03 (m, 3H), 2.3 3(m, 6H), 4.97 (s, 2H), 6.54 (m, 1 H), 6.94 (d, J =
6.4 Hz, 1 H), 7.3 8 (m, 4H), 7.73 (d, J = 7.8 Hz, 1 H), 8.04 (d, J = 8.2 Hz, 1 H).
LC/MS (M+H): 440.25.
It should be understood that Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usage and conditions.
Test example 1 HDAC activity was analyzed using BIOMOL QuantizymeTM Assay system which comprised two steps of 1) enzyme reaction between HDAC and a substrate and 2) determination of the level of HDAC inhibitory activity. In step 1), 42 ,u,e of a buffer solution (25 mM Tris-HCl [pH 8.0], 137 mM
NaCl, 2.7 mM KCI, 1 mM MgCl2) and 50 of 250 M Fluor de LysTM
substrate were added to each well of a 96-well plate, to which 2.5 /a of a test compound (compounds of Example 1 to 49) was added. 0.5 0 of HeLa nuclear extract(10 M) (a source of HDAC enzymes) was then added thereto to a final concentration of 100 nM. The enzyme reaction was carried out for 1 hr. Subsequently, in step 2), 2 M tricostatin A was added to 50 ,ut of Flour de LysTM developer, followed by allowing the mixture to react at room temperature for 15 minutes. The light excited at 355 nm and emitted at 460 nm from the fluorophore was measured with a fluorometric plate reader. The intensity of the fluorescence increases as the enzyme activity is higher. The HDAC inhibitory activity of each of the test compounds was determined and compared with that of the control. And suberoylanilide hydroxamic acid (SAHA) (Biomol) was used at the same level with the test compounds as a comparative control.
The HDAC inhibitory concentrations (IC50) of the compounds according to the present invention are shown in Table 1.
Table 1 compound IC50 compound IC50 compound IC50 (PM/ml) (PM/ml) (PM/ml) Example Example Example 2 0.015 26 0.005 39 0.013 Example Example Example 4 0.014 27 0.020 40 0.007 Example Example Example 6 0.014 28 0.014 41 0.012 Example Example Example 7 0.012 29 0.027 42 0.022 Example Example Example 8 0.025 30 0.016 44 0.012 Example Example Example 0.020 0.006 0.010 Example Example Example 13 0.015 32 0.006 46 0.011 Example Example Example 21 0.023 33 0.024 47 0.016 Example Example Example 22 0.009 35 0.008 48 0.013 Example Example Example 23 0.021 36 0.017 49 0.010 Example Example 0.009 0.007 SAHA 0.100 Example 0.017 Example 0.010 As shown in Table l, each of the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) has a markedly higher inhibitory activity against HDAC than SAHA which is known as a HDAC inhibitor.
Test Example 2 Inhibitory activities of the compounds synthesized in Examples against proliferation of cancer cells were examined by SRB (Sulforhodamine B) analysis using cervix adenocarcinoma Hela (Korean Cell Line Bank, KCLB 10002) and colon cancer cells HCT116 (Korean Cell Line Bank, KCLB 10247) as followed:
Cancer cells were inoculated into a 96-well microplate at a concentration of 1 x 103-3 x 103 cells/well and incubated under the condition of 37 C, 5% CO2 for 24 hrs. After the incubation was completed, 0.2, 1, 5, 25, or 100 pM of each of the compounds of Examples was added to the plate, and then the reactant was incubated again. After the substrate was stained, the anti-cancer activity was determined by comparing the amount of protein in the cells treated with compound of Examples with that of protein in non-treated cells.
Specificially, after the incubation was completed, the culture medium was removed from each well, and the cells were washed 3 times with PBS
(pH7.4). Then, a solution of 50% trichloroacetic acid (TCA) was added to each well in an amount of 50 ,ul/well at 4 C for 1 hr to fix them. Then, the microplate was washed 5 times with distilled water and dried at room temperature.
50 ,ut of a staining solution prepared by dissolving 0.4% SRB in 1%
acetic acid was added to the wells, and the microplate was kept at room temperature for 1 hr. The well plate was then washed 5 times with 1%
acetic acid to remove unbound SRB and dried at room temperature.
The stained cells were treated with 150 ,ut/well of 10 mM Tris-HCl solution (pH 10.5) to elute SRB from the cells, and the absorbance of each well at 520 nm was measured.
The ED50 value representing inhibition of the cancer cell growth by the extent of 50% was calculated from the measured absorbance, and the results are shown in Table 2.
When cancer cells were treated with a HDAC inhibitor, histone deacetylation would be inhibited, leading to an increase in the amount of acetyl-histone. In this test, the increased amount of acetyl-histone in the cancer cells was determined by using Western blotting, after the treatment with each of the compounds of Examples.
Hela cells were inoculated into a 6-well microplate at a concentration of 1.5 x 108 cells/well and incubated overnight under the condition of 371C, 5% CO2.
10 pM of each compound of Examples, and suberoylanilide hydroxamic acid (SAHA) as a control was added to the plate and the plate was incubated again for 24 hrs.
The cells were harvested in the presence of the test compound and were subjected to fractionation to separate the nuclei from the cells. The cells were allowed to swell in a hypotonic solution, lysed by several rounds of freezing-thawing cycles, and then centrifuged of 1,300 rpm for 5 min to collect the nuclei. The nuclei was lysed in a lysis buffer solution (20 mM
HEPES (pH 7.9), 25% glycerol, 420 mM KCI, 1.5 mM MgCl2, 0.2 mM
EDTA) to obtain a protein extract.
The resulting protein extract was subjected to SDS-PAGE to separate the proteins by the size and transferred onto the nitrocellulose membrane according to the conventional method.
The amount of acetylated histon H4 was measured using anti-acetyl histone H4 antibody (Upstate, USA) and evaluated the HDAC inhibitory activity of the inventive compounds by comparing the degree of increase of acetylated histone H4 relative to the control (SAHA).
The results are shown in Table 2.
Table 2 Inhibitory conc.
against the cancer cell Effect on increase of acetylated growth (EC50 PM) histon H4 compared with SAHA
Example 1 1.0 ++
Example 2 0.3 ++
Example 4 0.4 ++
Example 5 0.6 ++
Example 6 0.4 ++
Example 7 0.2 ++
Example 8 0.6 +
Example 13 1.3 ++
Example 24 1.1 +
Example 25 1.3 +
Example 26 0.8 +
Example 27 1.2 +
Example 28 0.7 +
Example 31 0.6 +
Example 32 0.5 +
Example 33 0.6 +
Example 34 0.8 +
Example 35 0.4 +
Example 36 0.7 +
Example 39 0.8 +
Example 40 0.9 +
Example 41 1.0 +
Example 45 0.5 +
Example 46 < 0.2 +
Example 47 0.32 +
Example 48 1.2 +
Example 49 0.9 +
SAHA 1.6 +
As shown in Table 2, the inventive alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives of formula (1) has a markedly enhanced inhibitory activity against HDAC, which leads to effective suppression of the cancer cell proliferation.
Claims (15)
1. An alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1):
wherein:
R1 is hydrogen or C1-3 alkyl;
R2 is C1-6 alkyl optionally having one or more substituents selected from the group consisting of diC1-3 alkylamino, oxopyrrolidinyl, pyrrolidinyl, piperidinyl, morpholinyl, C1-3 alkylpiperazinyl, cyano, hydroxy, imidazolyl, methoxy, tetrahydrofuran, C3-8 cycloalkenyl, and thiophenyl; C1-6 alkyl substituted with hydroxyphenyl, fluorophenyl, diC1-3 alkyl amino phenyl, methoxyphenyl and trifluoromethoxyphenyl; pyrrolidine substituted with C1-3 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-3 alkyl, benzyl or C3-8 cycloalkylcarbonyl; piperidine substituted with C3-8 cycloalkyl or C1-6 alkyl;
furan; pyridine substituted with (diC1-3 alkyl amino) C1-3alkyl amino, methoxy, diC1-3 alkyl amino, morpholino C1-3 alkylamino, or C1-3 alkylpiperazinyl; or 8 cycloalkyl; or R1 and R2 may optionally form a morpholinyl, piperidinyl or piperazinyl ring together with the nitrogen atom to which they are bonded.
wherein:
R1 is hydrogen or C1-3 alkyl;
R2 is C1-6 alkyl optionally having one or more substituents selected from the group consisting of diC1-3 alkylamino, oxopyrrolidinyl, pyrrolidinyl, piperidinyl, morpholinyl, C1-3 alkylpiperazinyl, cyano, hydroxy, imidazolyl, methoxy, tetrahydrofuran, C3-8 cycloalkenyl, and thiophenyl; C1-6 alkyl substituted with hydroxyphenyl, fluorophenyl, diC1-3 alkyl amino phenyl, methoxyphenyl and trifluoromethoxyphenyl; pyrrolidine substituted with C1-3 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-3 alkyl, benzyl or C3-8 cycloalkylcarbonyl; piperidine substituted with C3-8 cycloalkyl or C1-6 alkyl;
furan; pyridine substituted with (diC1-3 alkyl amino) C1-3alkyl amino, methoxy, diC1-3 alkyl amino, morpholino C1-3 alkylamino, or C1-3 alkylpiperazinyl; or 8 cycloalkyl; or R1 and R2 may optionally form a morpholinyl, piperidinyl or piperazinyl ring together with the nitrogen atom to which they are bonded.
2. The compound of claim 1, which is selected from the group consisting of:
(E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy)methyl) octenediamide, (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-N1-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide, (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-N1-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide, (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy) methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen -1-yloxy)methyl)octenediamide, (E)-N1 -(cyanomethyl)-N8-hydroxy-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(2-hydroxyethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N-hydroxy-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3 -yl)-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(dimethylamino)pyridin-3 -yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(tetrahydrofuran -2-yl)methyl)-2-octenediamide, (E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl)propyl)-2-octenediamide, (E)-N1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-1yloxy) methyl)-2-octenediamide, (E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide, (E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(4-(trifluoromethoxy)benzyl)-2-octenediamide, (E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido) pyrrolidin-1-carboxylic acid t-butylester, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(pyrrolidin-3-yl)2-octenediamide, (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, and (E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide.
(E)-N8-hydroxy-N1,N1-dimethyl-2-((naphthalen-1-yloxy)methyl) octenediamide, (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(2-(dimethylamino)ethyl)-N8-hydroxy-N1-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide, (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N1-(2-(diethylamino)ethyl)-N8-hydroxy-N1-methyl-2-((naphthalene-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(pyrrolidin-1-yl)ethyl)octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(2-(piperidin-1-yl)ethyl)octenediamide, (E)-N8-hydroxy-N1-(2-morpholinoethyl)-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N-hydroxy-8-(4-methylpiperazin-1-yl)-7-((naphthalen-1-yloxy) methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N1-(2-(4-methylpiperazin-1-yl)ethyl)-2-((naphthalen -1-yloxy)methyl)octenediamide, (E)-N1 -(cyanomethyl)-N8-hydroxy-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(2-hydroxyethyl)-N1-methyl-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-methyl-N1-(1-methylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N-hydroxy-8-morpholino-7-((naphthalen-1-yloxy)methyl)-8-oxoocteneamide, (E)-N8-hydroxy-N1-(6-(4-methylpiperazin-1-yl)pyridin-3 -yl)-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(2-morpholinoethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(dimethylamino)pyridin-3 -yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(6-(2-(dimethylamino)ethylamino)pyridin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(6-methoxypyridin-3-yl)-2-((naphthalen-1-yloxy) methyl)octenediamide, (E)-N1-(3-(1H-imidazol-1-yl)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(4-hydroxyphenetyl)-2-((naphthalen-l-yloxy) methyl)-2-octenediamide, (E)-N1-(3-(dimethylamino)-2,2-dimethylpropyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N1-(2-(diisopropylamino)ethyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)octenediamide, (E)-N8-hydroxy-N1-(1-methoxypropan-2-yl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(4-methoxybenzyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N1-(4-fluorophenetyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(tetrahydrofuran -2-yl)methyl)-2-octenediamide, (E)-N1-(2-cyclohexenylethyl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(3-(2-oxopyrrolidin-1-yl)propyl)-2-octenediamide, (E)-N1-(furan-2-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(4-(dimethylamino)benzyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(2-methoxyethyl)-2-((naphthalen-1yloxy) methyl)-2-octenediamide, (E)-N1-cyclohexyl-N8-hydroxy-2-((naphthalen-1yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1yloxy)methyl)-N1-(thiophen-2-ylmethyl)-2-octenediamide, (E)-N8-hydroxy-N1-(4-methoxyphenetyl)-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(4-(trifluoromethoxy)benzyl)-2-octenediamide, (E)-N1-(1-(cyclohexylmethyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopentylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-benzylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N8-hydroxy-N1-(1-isopropylpyrrolidin-3-yl)-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-(cyclohexanecarbonyl)pyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-3-(8-(hydroxyamino)-2-((naphthalen-1-yloxy)methyl)-8-oxo-2-octeneamido) pyrrolidin-1-carboxylic acid t-butylester, (E)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-N1-(pyrrolidin-3-yl)2-octenediamide, (E)-N1-(1-cyclohexylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-2-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopropylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-cyclopropylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)-2-octenediamide, (E)-N1-(1-ethylpiperidin-4-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide, and (E)-N1-(1-ethylpyrrolidin-3-yl)-N8-hydroxy-2-((naphthalen-1-yloxy) methyl)-2-octenediamide.
3. A method for preparing the compound of formula (1), which comprises the steps of:
1) treating a compound of formula (2) with sulfuric acid, and then with pyridinium chlorochromate (PCC) to obtain a compound of formula (3);
2) allowing the compound of formula (3) to react with an alkyl acrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to obtain a compound of the formula (4);
3) subjecting the compound of formula (4) to a reaction with tribromophosphine (PBr3) to obtain a compound of formula (5);
1) treating a compound of formula (2) with sulfuric acid, and then with pyridinium chlorochromate (PCC) to obtain a compound of formula (3);
2) allowing the compound of formula (3) to react with an alkyl acrylate in the presence of 1,4-diazabicyclo[2.2.2]octane (DABCO) to obtain a compound of the formula (4);
3) subjecting the compound of formula (4) to a reaction with tribromophosphine (PBr3) to obtain a compound of formula (5);
4) bringing the compound of formula (5) to react with 1-naphthol to obtain a compound of formula (6);
5) hydrolyzing the compound of formula (6) in the presence of an inorganic or organic acid to obtain a compound of formula (7);
6) acylating the compound of formula (7) with an amine (R1R2NH or R2NH2) to obtain a compound of formula (8);
7) hydrolyzing the compound of formula (8) in the presence of an inorganic base to obtain a compound of formula (9);
8) acylating the compound of formula (9) with tetrahydropyranyloxyamine (NH2OTHP) to obtain a compound of formula (10); and
9) removing the tetrahydropyranyl group from the compound of formula (10) by trifluoroacetic acid (TFA) treatment.
Wherein:
R1 and R2 have the same meanings as defined in formula (1) above, and Y is C1-4 alkyl.
4. The method of claim 3, wherein the alkyl acrylate in step 2) is selected from the group consisting of ethyl acrylate, isobutyl acrylate, and t-butyl acrylate.
5. The method of claim 3, wherein the reaction step 4) is carried out in acetone or acetonitrile in the presence of potassium carbonate, sodium bicarbonate, or sodium carbonate.
6. The method of claim 3, wherein the hydrolysis step 5) is carried out in the dichloromethane, tetrahydrofuran or N,N'-dimethylformamide.
7. The method of claim 3, wherein the inorganic acid used in step 5) is selected from the group consisting of hydrochloric acid, sulfuric acid and phosphoric acid, and the organic acid is trifluoroacetic acid (TFA).
8. The method of claim 3, wherein the acylation step 6) is carried out using an acylation agent in an aprotic solvent.
9. The method of claim 8, wherein the aprotic solvent is selected from the group consisting of dimethylformamide, dimethylsulfoxide, tetrahydrofuran, and dichloromethane and the acylation agent is selected from the group consisting of N-Methanesulfonyloxy-6-trifluoromethylbenzotriazole (FMS), N-hydroxy-6-trifluorobenzotriazole (FOBT) and 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl).
Wherein:
R1 and R2 have the same meanings as defined in formula (1) above, and Y is C1-4 alkyl.
4. The method of claim 3, wherein the alkyl acrylate in step 2) is selected from the group consisting of ethyl acrylate, isobutyl acrylate, and t-butyl acrylate.
5. The method of claim 3, wherein the reaction step 4) is carried out in acetone or acetonitrile in the presence of potassium carbonate, sodium bicarbonate, or sodium carbonate.
6. The method of claim 3, wherein the hydrolysis step 5) is carried out in the dichloromethane, tetrahydrofuran or N,N'-dimethylformamide.
7. The method of claim 3, wherein the inorganic acid used in step 5) is selected from the group consisting of hydrochloric acid, sulfuric acid and phosphoric acid, and the organic acid is trifluoroacetic acid (TFA).
8. The method of claim 3, wherein the acylation step 6) is carried out using an acylation agent in an aprotic solvent.
9. The method of claim 8, wherein the aprotic solvent is selected from the group consisting of dimethylformamide, dimethylsulfoxide, tetrahydrofuran, and dichloromethane and the acylation agent is selected from the group consisting of N-Methanesulfonyloxy-6-trifluoromethylbenzotriazole (FMS), N-hydroxy-6-trifluorobenzotriazole (FOBT) and 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl).
10. The method of claim 3, wherein the hydrolysis step 7) is carried out in aqueous alcohol or tetrahydrofuran.
11. The method of claim 3, wherein the inorganic base is lithium hydroxide (LiOH.H2O) or sodium hydroxide.
12. The method of claim 3, wherein the acylation step 8) is carried out in the presence of N-hydroxy-6-trifluoro benzotriazole (FOBT) and 1-(3-diethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl).
13. The method of claim 3, wherein step 9) is carried out in methanol, ethanol, tetrahydrofuran, or dichloromethane.
14. An anti-cancer composition comprising the alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) of claim 1 as an active ingredient and a pharmaceutically acceptable carrier.
15. An inhibitor for histone deacetylase comprising the alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivative of formula (1) of claim 1 as an active ingredient and a pharmaceutically acceptable carrier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050103693A KR100696139B1 (en) | 2005-11-01 | 2005-11-01 | Alkylcarbamoyl naphthalenyloxyoctenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof |
KR10-2005-0103693 | 2005-11-01 | ||
PCT/KR2006/004482 WO2007052938A1 (en) | 2005-11-01 | 2006-10-31 | Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2628040A1 true CA2628040A1 (en) | 2007-05-10 |
Family
ID=38006052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002628040A Abandoned CA2628040A1 (en) | 2005-11-01 | 2006-10-31 | Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1945606A4 (en) |
JP (1) | JP2009513697A (en) |
KR (1) | KR100696139B1 (en) |
CN (1) | CN101300226B (en) |
BR (1) | BRPI0618131A2 (en) |
CA (1) | CA2628040A1 (en) |
WO (1) | WO2007052938A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11655207B2 (en) | 2017-06-15 | 2023-05-23 | Crystalgenomics, Inc. | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2667855C (en) * | 2006-11-03 | 2014-12-30 | Korea Research Institute Of Chemical Technology | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same |
KR100814092B1 (en) | 2006-11-03 | 2008-03-14 | 한국화학연구원 | Alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives having inhibitory activity against histone deacetylase, method for the preparation thereof, and anticancer composition comprising the same |
WO2009053808A2 (en) * | 2007-10-22 | 2009-04-30 | Orchid Research Laboratories Limited | Histone deacetylase inhibitors |
EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
KR101388596B1 (en) * | 2008-12-11 | 2014-04-24 | 대한민국 | Histone deacetylase inhibitor that reactivates hiv-1 proviruses from latently hiv-infected cells |
KR20190113639A (en) * | 2018-03-28 | 2019-10-08 | 크리스탈지노믹스(주) | Pharmaceutical composition for preventing or treating fibrosis |
KR102678356B1 (en) * | 2018-10-29 | 2024-06-26 | 씨지인바이츠 주식회사 | Alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide phosphate, alkylcarbamoyl naphthalenyloxy octenoyl hydroxyamide tartrate or combination thereof and preparing method thereof |
CN110105213B (en) * | 2019-06-06 | 2022-03-25 | 唐山师范学院 | Synthesis method of (E) -2- (naphthyl-1-oxymethyl) -2-dioctyl olefine acid-8-ester |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378450A (en) * | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | Novel class of cytodifferentiating agents and histone deactylase inhibitors, and methods of use thereof |
EP1280764B1 (en) * | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
DK1485348T3 (en) * | 2002-03-13 | 2008-09-29 | Janssen Pharmaceutica Nv | Carbonylamino derivatives as novel inhibitors of histane deacetylase |
US7501417B2 (en) * | 2002-03-13 | 2009-03-10 | Janssen Pharmaceutica, N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
AU2003219595A1 (en) * | 2002-04-11 | 2003-10-27 | In2Gen Co., Ltd. | Alpha,Beta-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS |
ITMI20030025A1 (en) * | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | HYDROXAMIC ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITY. |
JP4612621B2 (en) * | 2003-01-17 | 2011-01-12 | トポターゲット ユーケー リミテッド | Carbamate compounds containing ester or ketone linkages as HDAC inhibitors |
JP4790594B2 (en) * | 2003-02-25 | 2011-10-12 | トポターゲット ユーケー リミテッド | Hydroxamic acid compounds containing bicyclic heteroaryl groups as HDAC inhibitors |
-
2005
- 2005-11-01 KR KR1020050103693A patent/KR100696139B1/en not_active IP Right Cessation
-
2006
- 2006-10-31 WO PCT/KR2006/004482 patent/WO2007052938A1/en active Application Filing
- 2006-10-31 EP EP06812321A patent/EP1945606A4/en not_active Withdrawn
- 2006-10-31 CA CA002628040A patent/CA2628040A1/en not_active Abandoned
- 2006-10-31 CN CN2006800407666A patent/CN101300226B/en active Active
- 2006-10-31 BR BRPI0618131-7A patent/BRPI0618131A2/en not_active IP Right Cessation
- 2006-10-31 JP JP2008538811A patent/JP2009513697A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11655207B2 (en) | 2017-06-15 | 2023-05-23 | Crystalgenomics, Inc. | Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
EP1945606A1 (en) | 2008-07-23 |
KR100696139B1 (en) | 2007-03-20 |
WO2007052938A1 (en) | 2007-05-10 |
CN101300226A (en) | 2008-11-05 |
JP2009513697A (en) | 2009-04-02 |
EP1945606A4 (en) | 2010-05-05 |
BRPI0618131A2 (en) | 2011-08-16 |
CN101300226B (en) | 2012-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2628040A1 (en) | Alkylcarbamoyl naphthalenyloxy- octenoylhydroxyamide derivatives having inhibitory activity against histone deacetylase and preparation thereof | |
US5391577A (en) | N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation | |
US5756817A (en) | O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same | |
US20020045749A1 (en) | Antibacterial agents | |
KR20030059084A (en) | Carboxamide compounds and their use as antagonists of a human 11cby receptor | |
NZ548530A (en) | Aryloxyalkylcarbamate-type derivatives, preparation method thereof and use of same in therapeutics | |
CA2596613A1 (en) | Derivatives of n-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, thiourea and urea) as cannabinoid cb1 receptor antagonists | |
DE60306934T2 (en) | Use of nitrile compounds as medicaments | |
US7019003B2 (en) | Peptide deformylase inhibitors | |
US8853281B2 (en) | Cysteine protease inhibitors | |
DE69626009T2 (en) | PYRROLIDINYLHYDROXAMIC ACIDS AND METHOD FOR THE PRODUCTION THEREOF | |
EP0326106B1 (en) | Alkylene diamines | |
KR100814092B1 (en) | Alkylcarbamoyl naphthalenyloxyoctenoyl hydroxyamide derivatives having inhibitory activity against histone deacetylase, method for the preparation thereof, and anticancer composition comprising the same | |
US7375120B2 (en) | Peptide deformylase inhibitors | |
ES2346964T3 (en) | DERIVATIVES OF HYDROXAMIC ACID. | |
EP1585757A2 (en) | Peptide deformylase inhibitors | |
FR2911136A1 (en) | New N-(4-cyano-1H-pyrazol-3-yl)-methylamine derivatives, are cannabinoid CB1 receptor antagonists, useful e.g. for treating psychiatric, neurodegenerative or metabolic disorders | |
CN113121417A (en) | Novel piperidine derivative and pharmaceutical application thereof | |
EP2582660B1 (en) | New cathepsin s protease inhibitors, useful in the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | |
US6797730B2 (en) | Peptide deformylase inhibitors | |
US20040097732A1 (en) | Peptide deformylase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |